For people living with geographic atrophy (GA), even simple daily tasks can become more challenging over time.
Early action matters. Talk to an eye care professional about vision changes today.
Learn more: askaboutga.com
For U.S. audiences only.
Astellas Pharma
Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha). More on Wikipedia
-
Astellas Pharma US
@AstellasUS
-
Astellas Pharma US
@AstellasUS
Liz, a caregiver for her husband with #prostatecancer, shares advice for those on a similar journey: Be a safe space for them to share what they’re going through.
This #nationalfamilycaregiversmonth, see caregiver resources at knowyourprostateplan.com/resources-caregivers
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
For many living with untreated geographic atrophy (GA), understanding their options and having informed conversations with their eye doctor may help them make the right decision.
For U.S. Audiences Only
Learn more: askaboutga.com
#geographicatrophy -
Astellas Pharma US
@AstellasUS
Every menopause journey is unique. We're proud to be at the @MenopauseOrg 2026 Annual Meeting, where we'll share new findings on women's experiences with menopause and connect with the HCPs, researchers and advocates working to improve care.
-
Astellas Pharma US
@AstellasUS
Menopause is a natural stage of life, but conversations about it haven't always come naturally.
This #worldmenopauseday, we're recognizing the importance of dialogue and education around women's experiences during menopause. Together, we can help women feel seen and supported. -
Astellas Pharma US
@AstellasUS
Geographic atrophy (GA) may be easy to miss in its early stages, but it can worsen over time, leading to irreversible vision loss.
Discussing any changes in vision with an eye doctor is crucial to earlier diagnosis.
Learn more: askaboutga.com
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
We're at #ims2026 presenting a new preliminary analysis from a Phase 4 real-world study evaluating treatment effects of non-hormonal therapies on VMS bother and sleep outcomes.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Living with geographic atrophy (GA) often means adapting to progressive vision loss while navigating uncertainty. Recognizing the challenges people may face can help encourage understanding.
For U.S. Audiences Only
Learn more: askaboutga.com
#geographicatrophy -
Astellas Pharma US
@AstellasUS
How can AI, automation and robotics help unlock the potential of cell therapy? Our latest @NatureIndex feature explores how emerging technologies could help make #regenerativemedicine more reproducible and scalable.
Read more: go.nature.com/4hbLaEB
#astellaspioneeringscience -
Astellas Pharma US
@AstellasUS
Geographic atrophy (GA) can cause subtle shifts, like trouble reading or recognizing faces. This can be easy to overlook but is important to discuss with an eye doctor.
Visit askaboutga.com to help prepare for the next appointment.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Living with a #raredisease can make finding trusted information difficult. We're pleased to share the refreshed xlmtm.com, an educational resource for families and caregivers affected by #xlmtm.
For U.S. Audiences Only.
Learn more: Visit xlmtm.com -
Astellas Pharma US
@AstellasUS
After their #prostatecancer diagnoses, Nick and Dan learned that asking the right questions was key to being active participants in their care plans.
This #prostatecancerawarenessmonth, find education and discussion resources on knowyourprostateplan.com. -
Astellas Pharma US
@AstellasUS
Deciding to begin treatment often starts with what matters most.
For people living with geographic atrophy (GA), personal priorities can help guide care discussions.
For U.S. Audiences Only
Learn more: askaboutga.com
#geographicatrophy #ophthalmology -
Astellas Pharma US
@AstellasUS
Could tumor biology help personalize treatment and potentially avoid surgery? We’re proud to collaborate with @AACR on the ADOPT-GEA study in exploring personalized approaches for people with resectable gastroesophageal cancer.
For U.S. audiences only.
AACR
@AACR
We are pleased to announce the first clinical trial sponsored by the new AACR Center for Cancer Clinical Trials: AACR-ADOPT-GEA. This phase II trial will test whether personalized treatment approaches can help gastroesophageal cancer patients skip surgery. www.aacr.org/about-the-aacr/newsroom/news-releases/aacr-c…
-
Astellas Pharma US
@AstellasUS
Vision changes caused by geographic atrophy (GA) may be better managed over time when detected early.
Regular eye exams and early diagnosis play a critical role in identifying GA.
Learn more: askaboutga.com
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
A geographic atrophy (GA) diagnosis can affect more than vision, with many patients experiencing emotional challenges.
Patient stories can help bring perspective and a better understanding of life with GA.
For U.S. Audiences only.
Explore more: askaboutga.com -
Astellas Pharma US
@AstellasUS
Geographic atrophy (GA) can worsen over time, sometimes in ways that are easy to overlook.
Identifying GA early may help slow long-term impact on vision.
Learn more: askaboutga.com
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Our team looks forward to joining the retina community at the ASRS 2026 Annual Meeting in Montréal, to share insights in geographic atrophy (GA) treatment.
For U.S. Audiences only.
Learn more: www.prnewswire.com/news-releases/astellas-to-spotlight-ne… -
Astellas Pharma US
@AstellasUS
📣Now FDA-approved in muscle-invasive bladder cancer: a regimen for use before and after surgery for adult patients regardless of cisplatin eligibility. Read more: newsroom.astellas.com/2026-07-13-us-fda-approves-padcev-p…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Geographic atrophy (GA) can lead to irreversible vision loss, making early diagnosis and proactive management critical.
While it’s often assumed patients are hesitant to begin treatment, many recognize its value as part of their GA care.
Learn more: askaboutga.com -
Astellas Pharma US
@AstellasUS
Astellas researchers recently met with lawmakers in Washington, D.C., to share how we’re working to advance science in the fields of oncology, women’s health, and cell & gene therapy. #phrmaflyin26
-
Astellas Pharma US
@AstellasUS
Strong partnerships help achieve more for patients, sooner. Join us at #bio2026 in San Diego next week to connect with our team and hear Astellas share dealmaking insights: convention.bio.org/program/2026-program
-
Astellas Pharma US
@AstellasUS
A family history of geographic atrophy (GA) and vision changes can be warning signs of GA. Talking to a doctor is the best route to take. It may be possible to potentially preserve vision for longer on the road ahead.
Learn More: askaboutga.com
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Purposeful partnerships accelerate breakthrough science. At Astellas, we work with ambitious innovators globally to uncover opportunities that could transform the lives of patients. Connect with us: astellas.com/en/partnering #bio2026
-
Astellas Pharma US
@AstellasUS
#asco26 take-away: data alone isn’t enough. Practical application matters most. We valued the conversations connecting evidence with real-world perspectives, learning what it takes to turn innovation into impact for patients. 📍Astellas booth #15131
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
At #asco2026, we’re focused on connecting evidence to real world care — and the practical “how do we use it?” questions that follow new data.
📍 Visit the Astellas booth #15131
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Ahead of #asco26, our Head of Oncology Development shares how targeted protein degradation is reshaping our approach to KRAS-driven cancers. Read the full article in @FiercePharma: www.fiercepharma.com/sponsored/eliminating-kras-why-targe…
-
Astellas Pharma US
@AstellasUS
Bladder cancer is the sixth most common cancer in the U.S. Knowing what to look for—and when to talk to your doctor—can make a real difference in what comes next.
This #bladdercancerawarenessmonth, hear real stories about navigating this disease: www.youtube.com/@LetsTalkBladderCancer?cbrd=1&ucbcb=1 -
Astellas Pharma US
@AstellasUS
On #clinicaltrialsday, we recognize those behind every moment of progress in research. From patients and families, to investigators and study teams – thank you for making progress possible.
#researchrising #ctd2026 #astellaspioneeringscience -
Astellas Pharma US
@AstellasUS
Geographic atrophy can come on fast — like an unexpected wave. However, early detection can help brace for the impact and chart a course toward potentially preserving vision for longer.
Learn More: askaboutga.com
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
At #asco26, Astellas' focus is translating evidence into real-world cancer care and what comes next.
We’ll be listening to the questions that follow new data: implementation, decision points, and what matters most to patients. newsroom.astellas.com/2026-05-19-astellas-to-present-data…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
The eye is helping define what’s next in #regenerativemedicine.
Hear how Astellas is advancing #celltherapy in #ophthalmology—including our investigational program for geographic atrophy—in the latest RetinUp podcast episode: podcasts.apple.com/us/podcast/asp7317-for-geographic-atro…
For U.S. Audiences Only. -
Astellas Pharma US
@AstellasUS
Our Chief R&D Officer shares how we are sharpening our R&D focus to push the boundaries of pioneering science, from advancing novel modalities to strategic partnerships and the use of AI. Read more: cen.acs.org/articles/104/web/2026/04/Astellass-RampD-head…
#astellaspioneeringscience -
Astellas Pharma US
@AstellasUS
That’s a wrap on ARVO! We had a great time connecting with ophthalmology leaders and discussing new insights on geographic atrophy, reflecting our continued commitment to advancing patient care.
Explore data highlights: newsroom.astellas.com/2026-05-12-IZERVAY-R-avacincaptad-p…
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
We're gearing up for the Retina World Congress (RWC) in Fort Lauderdale, where we’ll connect with leaders across ophthalmology.
Join Laura Kovanda, Vice President, Biopharma & Ophthalmology Development, to learn about Astellas’ commitment to ophthalmology and pipeline updates. -
Astellas Pharma US
@AstellasUS
We’re at @ACOG 2026 to present new findings on patient-reported outcomes, real-world outcomes, and treatment patterns of menopausal vasomotor symptoms. We’re helping to inform care for women’s health in midlife, and we look forward to meaningful conversations. #acog26
-
Astellas Pharma US
@AstellasUS
We’re heading to ARVO, where we’ll share nine abstracts, spanning long-term outcomes from our FDA-approved therapy to early clinical progress with our investigational retinal cell therapy.
Find us at booth #11016 and read more: newsroom.astellas.com/2026-04-30-Astellas-to-Highlight-Ne…
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
For more than 8 in 10 people living with geographic atrophy (GA), fear of vision loss shapes everyday decisions.*
With early detection, patients can take a more active role in their eye health.
To learn more, visit askaboutga.com
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
The eye is providing powerful lessons for the future of #regenerativemedicine.
Learn more on how progress in #celltherapy could reshape how we approach degenerative diseases in ophthalmology and beyond in @FiercePharma: www.fiercepharma.com/sponsored/how-cell-therapy-shaping-f…
#changingtomorrow -
Astellas Pharma US
@AstellasUS
At Astellas, we’re not chasing the expected – we’re pursuing what’s never been done before. Learn more on how we’re building the capabilities to deliver the next generation of medicines, and the generation after that: www.astellas.com/en/science
-
Astellas Pharma US
@AstellasUS
The U.S. FDA has granted priority review to a supplemental Biologics License Application (sBLA) for our perioperative treatment for adults with muscle-invasive #bladdercancer, regardless of cisplatin eligibility.
Learn more: newsroom.astellas.com/2026-04-21-us-fda-grants-priority-r…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Geographic atrophy (GA) can appear with or without warning.
Just like checking the weather forecast helps prepare for rain, identifying GA early allows time to plan care that may help preserve vision for longer.
Learn More: askaboutga.com
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Today, on #internationalpompeday, we stand with the Pompe community—patients, families, caregivers, and advocates—who inspire us with their strength. At Astellas, we’re committed to advancing innovation while listening, learning, and reflecting. #pompedisease #changingtomorrow
This media couldn't be displayed. See it on the original post. -
Astellas Pharma US
@AstellasUS
When living with geographic atrophy, an advanced form of dry age-related macular degeneration, every moment matters. Staying informed, scheduling routine eye exams and having open conversations with eye care professionals can make a difference.
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Miami, let’s talk geographic atrophy (GA). Join us for a Product Symposium at Sunshine Eye and Retina 2026, focused on the latest evidence in GA and practical insights to help identify at-risk patients and support timely, informed treatment decisions.
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Breakthroughs happen faster when brilliant minds come together.
Learn more about how our #openinnovation labs are pushing the boundaries of what science can do: www.astellas.com/en/science/research-and-development/open…
#changingtomorrow -
Astellas Pharma US
@AstellasUS
Geographic atrophy (GA) is a progressive, irreversible eye disease that can cause vision loss. Family history of GA may raise your risk.
Early diagnosis is the first step to potentially slow the clock on vision loss. Learn More: askaboutga.com
For U.S. audiences. -
Astellas Pharma US
@AstellasUS
What if we could outsmart #cancer? Free people from #chronicdisease? Restore sight for those suffering from #visionloss?
At Astellas, we are pushing science to find the answers patients urgently need.
Learn more here: www.astellas.com/en/science/research-and-development
#changingtomorrow -
Astellas Pharma US
@AstellasUS
New at ASCO #gu26: strong clinical evidence from a Phase 3 trial in cisplatin-eligible patients with muscle-invasive bladder cancer in partnership with @pfizer and @Merck.
Learn about our work in redefining #bladdercancer care: newsroom.astellas.com/2026-03-02-padcev-tm-and-keytruda-r…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
This #rarediseaseday, we unite to support and celebrate those living with rare diseases. While clinical trials offer hope for groundbreaking treatments, they must focus on outcomes that matter most to patients and their families. #changingtomorrow #astellaspioneeringscience
-
Astellas Pharma US
@AstellasUS
Today at ASCO #gu26, we presented data from our Phase 3 trial in cisplatin-eligible patients with muscle-invasive bladder cancer, demonstrating survival benefits in this population. Moitreyee Chatterjee-Kishore speaks to the importance of this data.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
We’re in San Francisco for ASCO #gu26!
While onsite, we’re sharing updates in #bladdercancer & #prostatecancer research, innovation guided by:
🔬10+ years of GU cancer research
🧬 A science-first approach
🤝 A commitment to progress for patients
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
We’ve been at the forefront of #prostatecancer research for over a decade, driven by a deep commitment to making a real difference for people living with this disease.
Don’t miss our latest breakthroughs at ASCO #gu26.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Don’t wait until geographic atrophy (GA) takes root. Early diagnosis is key to catching GA in its initial stages.
Learn more: askaboutga.com
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
How can #artificialintelligence and #robotics change lives? At Astellas, we’re using digital solutions to accelerate #drugdiscovery and bring novel medicines to patients faster. Learn more here: newsroom.astellas.com/2025-04-22-The-Future-of-Drug-Disco…
#changingtomorrow -
Astellas Pharma US
@AstellasUS
For Age-Related Macular Degeneration (AMD) and Low Vision Awareness Month, we’re reinforcing the importance of proactive eye care. AMD is a progressive eye condition that can advance to geographic atrophy. Regular eye exams can help detect changes early.
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
On @UNESCO's International Day of Women and Girls in Science, we celebrate the women pioneering science that will shape the future of healthcare and inspire the next generation. #womeninscience #girlsinstem #changingtomorrow #astellaspioneeringscience
-
Astellas Pharma US
@AstellasUS
174 million+ patients. 100+ countries. That’s the impact of our medicines to date. From cancer to chronic conditions, Astellas therapies are making a difference.
And we’re just getting started. Learn more here: www.astellas.com/en/science/research-and-development
#changingtomorrow -
Astellas Pharma US
@AstellasUS
Our own Emily Mason (National Vice President, Patient Access & Affordability Solutions) is in the spotlight as a 2026 @PhRMA Working for Cures Champion. Learn more about Emily’s leadership in Patient Access & Affordability Solutions: youtube.com/watch?v=xJiE2L8-KYM #workingforcures
-
Astellas Pharma US
@AstellasUS
Vision loss may come with age, but geographic atrophy (GA) can speed it up unpredictably for some people. While the clock on GA progression can’t be turned back, it may be slowed down.
Learn More: askaboutga.com
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Putting the AI in Hawaii: Astellas is proud to host “HI, AI” at Hawaiian Eye and Retina 2026. This summit will examine how artificial intelligence is dramatically reshaping ophthalmic care. Please join us, industry partners and leading experts for this event.
For US ECPs only. -
Astellas Pharma US
@AstellasUS
The Astellas team is onsite at ASCO #gi26, sharing our latest research updates in #gastriccancer and #pancreaticcancer.
🤝 Stop by booth #117 to discover how we’re applying our biomarker-driven approach to precision medicine for those affected by GI cancers. -
Astellas Pharma US
@AstellasUS
We’re excited to share our story and strategy with peers and other health leaders at the J.P. Morgan Healthcare Conference, Biotech Showcase and Fierce JPM Week in San Francisco this January. Learn more about our participation at JPM: newsroom.astellas.com/2026-01-07-astellas-to-present-at-4…
-
Astellas Pharma US
@AstellasUS
We’re excited to kick off 2026 at this year’s J.P. Morgan Healthcare Conference, Biotech Showcase and Fierce JPM Week in San Francisco. Looking forward to sharing key milestones & connecting with peers across the healthcare community. Learn more: newsroom.astellas.com/JPM-2026-Pioneering-science-to-chan… #jpm2026
-
Astellas Pharma US
@AstellasUS
At Astellas, we’re committed to pioneering innovative science with impact and integrity. Excited to join #jpm26, #biotechshowcase & #fiercejpmweek this January. If you’re heading to San Francisco, get in touch: www.astellas.com/en/partnering #changingtomorrow
-
Astellas Pharma US
@AstellasUS
New today: positive topline results in cisplatin-eligible muscle-invasive #bladdercancer from a Phase 3 trial with @Pfizer and Merck.
Learn more: newsroom.astellas.com/2025-12-17-PADCEVTM-Plus-KeytrudaTM…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
We’ve announced a new partnership with Autobahn Labs to advance academic research and discoveries into novel therapeutics. Learn how we’re accelerating the translation of breakthrough discoveries here: www.globenewswire.com/news-release/2025/12/11/3203807/0/e…
-
Astellas Pharma US
@AstellasUS
Just announced: Astellas will present new data in #pancreaticcancer and #gastriccancer at ASCO #gi26.
Learn more about our presentations and biomarker-driven approach to cancer innovation: newsroom.astellas.com/2025-12-10-Astellas-to-Present-New-…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
At the @ASH_hematology Annual Meeting, we engaged with oncology experts to explore innovations in cancer care. Our commitment to enhancing patient care remains steadfast as we strive to deliver solutions for patients with acute myeloid leukemia (AML). #ash25
-
Astellas Pharma US
@AstellasUS
In a new post on @PhRMA’s blog, our own Michael Petroutsas highlights how the #medicare Prescription Payment Plan can help some seniors better manage their expenses and adhere to their prescribed treatments. phrma.org/blog/guest-blog-making-the-most-of-the-medicare…
-
Astellas Pharma US
@AstellasUS
We’re excited to be at the @ASH_hematology Annual Meeting to present new data that reinforces our progress in FLT3m+ acute myeloid leukemia (AML) care. Visit our booth #2031 to hear more. #ash25 Read more: newsroom.astellas.com/2025-12-07-Astellas-To-Present-New-…
-
Astellas Pharma US
@AstellasUS
From lighting our Northbrook HQ in periwinkle to attending inspiring summits with our advocacy partners, November was filled with impactful activities for #stomachcancerawarenessmonth. Together, we’re committed to creating change for this community! 💜
-
Astellas Pharma US
@AstellasUS
This National Family History Awareness Day, we're spotlighting the connection between hereditary health patterns and geographic atrophy (GA). Having a family history of GA increases risk of vision loss – knowing your family background is the first step.
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Adults with muscle-invasive #bladdercancer who are ineligible for cisplatin-based chemotherapy have long faced few treatment options, but the landscape is changing.
Learn more about our new FDA approval for these patients: www.businesswire.com/news/home/20251117031627/en/U.S.-FDA…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
If you or a loved one is facing a #stomachcancer diagnosis, know that you are not alone. Hearing insights from patients, caregivers, & healthcare providers can help. Watch more on GI Cancer Chronicles: www.youtube.com/@GICancerChronicles?cbrd=1&ucbcb=1
#stomachcancerawarenessmonth
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
At Astellas, on this year's #worldscienceday, we celebrate bold ideas, breakthrough innovation & the pursuit of what’s never been done. Watch how we’re pioneering science to change tomorrow. #changingtomorrow #astellaspioneeringscience
This media couldn't be displayed. See it on the original post. -
Astellas Pharma US
@AstellasUS
Providing physical and emotional support, caregivers embody strength and resilience. Sue, a care partner to her husband Dan for many years, offers her advice for others supporting a loved one living with #prostatecancer. See more: www.knowyourprostateplan.com/resources-caregivers
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
Attending OSN New York & Retina? Be sure to stop by booth #1 and don’t miss the symposia featuring R. Ross Lakhanpal, MD, FACS, FASRS and Carl Danzig, MD to learn more about protecting healthy retina cells for longer in patients with geographic atrophy.
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
At a recent @StatBrandStudio Open Doors event hosted by Astellas, industry leaders explored how partnership and open innovation keep the Boston biotech community at the cutting edge of global innovation. Find out more: www.statnews.com/sponsor/2025/11/03/boston-at-a-crossroad… #changingtomorrrow
-
Astellas Pharma US
@AstellasUS
Thank you to those who visited our booth at @MenopauseOrg! We're energized by the conversations around women’s health care. Your insights will help shape our commitment to innovative solutions for women experiencing moderate to severe vasomotor symptoms due to menopause. #tms25
-
Astellas Pharma US
@AstellasUS
Hot flashes and night sweats due to menopause aren’t just uncomfortable, they’re a real medical condition that can be treated. At Astellas, we are dedicated to research that helps women address some of the challenges of their menopausal journeys. newsroom.astellas.com/2025-10-22-Astellas-Presents-Prelim… #tms25
-
Astellas Pharma US
@AstellasUS
Just Announced: a supplemental biologics license application (sBLA) for our therapy for certain patients with muscle-invasive bladder cancer has been accepted by the U.S. FDA and granted priority review. #bladdercancer
See more: newsroom.astellas.com/2025-10-21-PADCEV-TM-enfortumab-ved…
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Visit our booth #303 at @MenopauseOrg to discover how our latest research is exploring the unique challenges women face when experiencing hot flashes and night sweats due to menopause. #tms25
-
Astellas Pharma US
@AstellasUS
We’re excited to present new Phase 1 data from our #targetedproteindegradation pipeline at #targets25. Learn more about our TPD efforts here: www.astellas.com/en/science/research-and-development/prim…. Hope to see you there!
-
Astellas Pharma US
@AstellasUS
We’re excited to present data at @MenopauseOrg 2025 in Orlando. Our team is dedicated to impacting women’s health care through innovation. Learn more: newsroom.astellas.com/2025-10-15-VEOZAH-TM-fezolinetant-2025 #tms25
-
Astellas Pharma US
@AstellasUS
Today at #esmo25 and in the New England Journal of Medicine: new overall survival data in a form of non-metastatic hormone-sensitive #prostatecancer. Learn more about this development in our 10+ years of research in this space: newsroom.astellas.com/2025-10-19-XTANDI-R-Plus-Leuprolide…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
We're presenting positive survival results in cisplatin-ineligible patients with muscle-invasive bladder cancer from a Phase 3 trial with Pfizer and Merck today at #esmo25.
Learn about our work in advancing #bladdercancer care: www.prnewswire.com/news-releases/padcev-plus-keytruda-giv…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Our Menopause Experience & Attitudes Study has shown that menopause may substantially affect women’s mental health, often stemming from limited awareness. The #worldmenopauseday theme “Lifestyle Medicine” reminds us to combat stigma and support the wellbeing of women in midlife.
-
Astellas Pharma US
@AstellasUS
Astellas leaders recently shared their views with @endpts on pioneering allogeneic #celltherapies to restore sight in those affected by retinal diseases like geographic atrophy: endpoints.news/sp/in-sight-advancing-cell-therapy-for-ret…
#changingtomorrow #astellaspioneeringscience -
Astellas Pharma US
@AstellasUS
Ahead of #esmo2025, a few of our leaders spoke with @FiercePharma about how Astellas is working to shape #cancer care. Hear from their unique perspectives here: www.fiercepharma.com/sponsored/redefining-precision-oncol…
-
Astellas Pharma US
@AstellasUS
Imagine checking the weather, but blurred spots in your vision make it hard to read. This may be a sign of geographic atrophy (GA), a condition that may cause irreversible vision loss.
Learn more about the signs of GA: askaboutga.com.
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Our own Live Gagne (Global Patient Partnerships Lead, Women's Health) is in the spotlight as a 2024 @PhRMA Working for Cures Champion. Learn more about Liv's leadership in improving women's health at midlife. #workingforcures
Video Link: www.youtube.com/watch?v=ek2kafaf0P8 -
Astellas Pharma US
@AstellasUS
As #prostatecancerawarenessmonth wraps up, we’re moving forward with a continued focus on our goal of ensuring that no one faces advanced prostate cancer alone. @ZEROCancer 💙🔗 Learn more: www.knowyourprostateplan.com
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
We’re proud to be part of North Carolina’s thriving #lifesciences ecosystem. Our Sanford facility is advancing #genetherapies, creating local jobs, and delivering hope to patients around the world. Learn more in this new @PhRMA video: innovation.org/casestudy/astellas-expands-manufacturing-f…
-
Astellas Pharma US
@AstellasUS
Eyesight is important to your loved one's independence. Awareness of the signs of geographic atrophy (GA) may support your loved one in receiving an early diagnosis.
Learn more about GA and the importance of early detection: askaboutga.com.
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Black men are disproportionately affected by #prostatecancer, due in part to lack of awareness & access, a roundtable with @BHMinfo & @apa1906NETwork showed. Together, we’re working to reduce the disparity through education. #prostatecancerawarenessmonth
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
Our Head of Oncology Research, Chinatsu Sakata, spoke with @INVIVOnow to discuss how we’re using our #ai platform, human-in-the-loop, to develop the next generation of #oncology therapies and more.
Read the full article here: insights.citeline.com/in-vivo/innovation/ai-in-the-loop-h…
#changingtomorrow -
Astellas Pharma US
@AstellasUS
In a new @Citeline podcast, our Primary Focus Lead for Genetic Regulation, Richard Wilson shares how Astellas is advancing #genetherapy with AAV, patient focus and manufacturing strength. Listen here: insights.citeline.com/in-vivo/podcasts/podcast-astellas-s…
#changingtomorrow -
Astellas Pharma US
@AstellasUS
Today, we announced positive topline results from a Phase 3 trial with @Pfizer and Merck in cisplatin-ineligible patients with muscle-invasive bladder cancer. See more about how we’re pursuing innovative science: newsroom.astellas.com/2025-08-12-PADCEVTM-Plus-KEYTRUDATM…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Today concludes an insightful week engaging with retina specialists on geographic atrophy and retina care at @asrsdocs 2025. Looking forward to the next opportunity to collaborate with fellow industry experts.
#asrs2025 #geographicatrophy
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
Attending the @asrsdocs 2025 Annual Meeting? Visit the Astellas team at booth 215 to discuss geographic atrophy and explore the latest innovations shaping the future of retina care.
Excited to connect in Long Beach!
#asrs2025 #geographicatrophy
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
Seeing in low light – at the movies, the theater or even at home – may become more challenging with geographic atrophy (GA).
This is what life with GA may look like. Knowing the signs may lead to early detection. Learn more: askaboutga.com?sf227437874=1.
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
New today: topline overall survival results in certain men with non-metastatic castration-sensitive #prostatecancer. Read more about our latest research: newsroom.astellas.com/2025-07-10-XTANDI-R-Plus-Leuprolide…
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
Richard Wilson, Primary Focus Lead, Genetic Regulation and Lisa Deschamps, CEO of our partner AviadoBio, spoke with @_CellandGene on how the power of partnership accelerates the development of potentially transformative gene therapies: www.cellandgene.com/doc/inside-aviadobio-and-astellas-s-s… #changingtomorrow
-
Astellas Pharma US
@AstellasUS
Tadaaki Taniguchi, our Chief Research and Development Officer, shared insights with the @BosBizJournal on Astellas’ growing presence in Massachusetts and the partnerships accelerating next-generation therapies to patients. Read more: www.bizjournals.com/boston/news/2025/07/03/astellas-cambr… #changingtomorrow
-
Astellas Pharma US
@AstellasUS
We recently hosted Bay Area labor leaders at our West Coast Innovation Center to highlight the vital role skilled labor plays in constructing high-tech life-sciences research facilities. Learn how we’re building the future of medicine together. @_PILMA www.youtube.com/watch?v=cyn4rpfKPkM&sf227399830=1
-
Astellas Pharma US
@AstellasUS
When vision changes interfere with your loved one’s ability to recognize familiar faces, it can be distressing. Understanding the signs of geographic atrophy may help identify and manage it early.
Learn how to spot the signs: askaboutga.com?sf227155448=1
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
We are honored to join @AOAConnect’s Optometry’s Meeting in Minneapolis! Visit booth #612 and catch Dr. Mohammad Rafieetary, OD, FAAO who will discuss geographic atrophy (GA) management at the Product Theater on June 25 at 12:00pm.
#optometrysmeeting
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Thank you to all organizations who participated in Patient Advocacy Organization (PAO) Action Week! We look forward to continuing to work together to drive awareness and engagement for patients, caregivers and advocates. www.paoactionweek.com?sf226969565=1 #paoactionweek
-
Astellas Pharma US
@AstellasUS
This weekend, Astellas will attend Clinical Trials at the Summit (CTS) 2025 in Las Vegas. We look forward to collaborating with retina experts to discuss clinical trials, new data and best practices related to retinal innovation.
#ctsretina
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
During #paoactionweek, we encourage everyone to find and get connected with a patient advocacy organization (PAO) that is meaningful to them. Whether a patient, caregiver, physician, nurse, patient advocate, or community member – reach out and get involved!
-
Astellas Pharma US
@AstellasUS
Did you know there are more than 1,200 patient advocacy organizations (PAOs) across the United States? Learn more about how to locate a PAO that is relevant to you. #paoactionweek
-
Astellas Pharma US
@AstellasUS
The second annual Patient Advocacy Organization (PAO) Action Week begins today! Use #paoactionweek and join us in raising awareness of the critical work of PAOs across the U.S. and the invaluable support and resources they offer for patients.
www.paoactionweek.com -
Astellas Pharma US
@AstellasUS
Two of our researchers visited DC this week to share with legislators how they are working to advance science in ophthalmology and cancer – and to underscore the importance of policies that help protect and promote life sciences innovation. #phrmaflyin25
-
Astellas Pharma US
@AstellasUS
We pioneer science in breakthrough areas of R&D and know partnering is essential to achieve more for patients, sooner. If you are a like-minded, ambitious innovator, come and meet us at #bio2025, June 16-19, Boston, or get in touch here: www.astellas.com/en/partnering?sf226752044=1
-
Astellas Pharma US
@AstellasUS
Biomarkers help personalize cancer care. Alyssa shares more about how she discussed biomarkers with her care team following her #gastriccancer diagnosis. See more on GI Cancer Chronicles: www.youtube.com/@GICancerChronicles?sf226731919=1&cbrd=1&…
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
As #asco25 ends, we caught up with Chief R&D Officer Tadaaki Taniguchi on why ASCO is such an important event every year and what’s on the horizon for Astellas in oncology.
-
Astellas Pharma US
@AstellasUS
Today at #asco25: Dr. Andrew Armstrong (@AArmstrongDuke) is presenting updates from our research in metastatic hormone-sensitive #prostatecancer, conducted in partnership with @Pfizer. See more: newsroom.astellas.com/404
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Patient Advocacy Organization (PAO) Action Week returns next week for its second year! This collaborative initiative is dedicated to raising awareness and connecting patients to relevant PAOs.
Follow #paoactionweek and visit www.paoactionweek.com for more info. -
Astellas Pharma US
@AstellasUS
We’re pleased to share that Astellas has entered into an exclusive license agreement with Evopoint Biosciences for XNW27011, a novel clinical-stage #adc targeting CLDN18.2.
Learn more: newsroom.astellas.com/2025-05-30-Astellas-Enters-Exclusiv… -
Astellas Pharma US
@AstellasUS
#asco25 starts tomorrow! We are proud to share our commitment to impacting the cancer treatment landscape with our latest oncology research. #prostatecancer #bladdercancer #gastriccancer #aml
-
Astellas Pharma US
@AstellasUS
Ahead of #asco25, our Chief R&D Officer, Tadaaki Taniguchi, shared with @FiercePharma how Astellas is harnessing new therapeutic approaches and technologies to change the future of #cancer care. Read the article here: www.fiercepharma.com/pharma/pioneering-science-deliver-on…
#changingtomorrow -
Astellas Pharma US
@AstellasUS
Now available: overall survival updates in metastatic hormone-sensitive #prostatecancer. newsroom.astellas.com/404
We're excited to build on our 10-year+ commitment to this community and help drive progress for those with hormone-sensitive disease. #asco25
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
In honor of Mental Health Awareness Month, we’re partnering with @_BrightFocus for a Macular Chat to discuss the impact of vision loss on mental health and the emotional challenges faced by those with low vision. Register here: www.brightfocus.org/macular/resource-search/macular-chats…
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Bladder cancer symptoms don’t always look the same in men and women—and that can lead to missed or delayed diagnoses, especially in women.
During #bladdercancerawarenessmonth, learn more about the importance of recognizing signs and taking action early: www.youtube.com/@LetsTalkBladderCancer?sf223622532=1&cbrd… -
Astellas Pharma US
@AstellasUS
At Astellas, we’re pushing the boundaries of cancer treatment. See what we’ll be sharing at #asco25: newsroom.astellas.com/2025-05-19-Astellas-Presents-New-Da…
-
Astellas Pharma US
@AstellasUS
We’re excited to be presenting data at @ACOG 2025 here in Minneapolis. Improving patient outcomes is a critical focus of ours, particularly through research and education, so be sure to visit us at booth #1011 to learn more about our latest advancements in women’s health! #acog25
-
Astellas Pharma US
@AstellasUS
In honor of Global Accessibility Awareness Day, we are sharing pointers from Sam Seavey, low vision expert, on how to keep accessibility top of mind. Improving accessibility is key to ensuring all patients can access care and resources.
#gaad #visionloss
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
This Mental Health Awareness Month, we’re taking a moment to recognize the impact geographic atrophy can have on mental health and emotional well-being. By understanding this connection, we can provide better support for individuals with low vision.
For U.S. Audiences Only
Astellas Pharma US
@AstellasUS
-
Astellas Pharma US
@AstellasUS
We had a great week discussing the latest geographic atrophy insights with the retina community at @ARVOinfo Annual Meeting. We’re already looking forward to next year!
#arvo2025
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
For Army veteran Dan, his time serving equipped him with the skills needed to take on a new fight: #prostatecancer.
We’re thankful for Dan, his service, and his willingness to share his story so that others facing prostate cancer don’t feel alone.
#militaryappreciationmonth -
Astellas Pharma US
@AstellasUS
When it comes to #bladdercancer, knowing what to look for—and when to speak up—can lead to earlier diagnosis and potentially better outcomes.
This #bladdercancerawarenessmonth, learn more about risk factors, symptoms, and more: www.youtube.com/@LetsTalkBladderCancer?sf223622426=1&cbrd… -
Astellas Pharma US
@AstellasUS
Our team is on the ground in Salt Lake City and excited to kick off the @ARVOinfo Annual Meeting. Stop by the Astellas booth (#1925) to learn about our new data in geographic atrophy biomarkers, mechanism of disease and more.
#arvo2025
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
The Astellas team is heading to ARVO and RWC! We're excited to present data featuring analyses on geographic atrophy biomarkers, patient experience and more.
Learn about the data we're sharing: newsroom.astellas.com/2025-05-01-Astellas-to-Present-New-…
#arvo2025 #retinaworldcongress
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
Astellas has announced a collaboration with the Japanese Foundation for Cancer Research to accelerate translational and clinical oncology research. We look forward to working with this world-class comprehensive cancer research center. Learn more: newsroom.astellas.com/2025-04-02-Astellas-and-Japanese-Fo…
-
Astellas Pharma US
@AstellasUS
Struggling to read – such as when cooking, paying bills or driving – could be a sign of geographic atrophy (GA). Encouraging your loved one to receive regular eye exams may help detect GA earlier.
Learn more: askaboutga.com?sf217247842=1
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
At #uscap2025, we invited pathologists to test their stain interpretation skills and brush up on the latest research around CLDN18.2 in #gastriccancer.
Try it yourself – learn more at www.claudin182.com.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Today at #uscap2025, Dr. Kevin Waters, Assoc. Professor of Pathology at Cedars-Sinai Medical Center, will present on CLDN18.2 as a biomarker target in #gastriccancer, a key focus of our research. Learn more about CLDN18.2 in gastric/GEJ cancer below.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Our team is excited to be in Boston for #uscap2025! Stop by booth #107 to learn more about our biomarker research in #gastriccancer.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Today is World Optometry Day. At Astellas, we appreciate the important role optometrists and vision care providers play in protecting patients’ vision and maintaining eye health.
#worldoptometryday #visionloss #ophthalmology
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
March is National Save Your Vision Month– a reminder to prioritize eye health. Annual eye exams are key to protecting vision and detecting eye diseases early. Schedule an appointment with an eye care provider today!
#saveyourvisionmonth
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
We’re pioneering cell & gene therapies to restore sight and free patients from the fear of deteriorating vision. Learn more about our innovative ophthalmology approaches targeting diseases stemming from retinal cell loss: go.nature.com/3R9AY1f
#changingtomorrow #eyehealth -
Astellas Pharma US
@AstellasUS
At Astellas, we’re committed to addressing the areas of greatest unmet medical need, including women’s health in midlife. That’s why we’ve partnered with experts to better understand the impact of menopause and related stigma. #iwd25
-
Astellas Pharma US
@AstellasUS
Though #gastriccancer is considered a rare disease in the U.S., more than 30,000 people will be newly diagnosed this year. Education is a crucial first step toward progress. Check out GI Cancer Chronicles: www.youtube.com/@GICancerChronicles?sf216559858=1&cbrd=1&…
#rarediseaseday | For U.S. audiences only -
Astellas Pharma US
@AstellasUS
Did you know that signs of geographic atrophy (GA) are often mistaken for normal aging? Noticing subtle vision changes – like straight lines appearing wavy or curved – is key to early detection. Learn more about the signs of GA: askaboutga.com?sf215882213=1
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Last week, our team joined leading experts at the Macula Society Annual Meeting to discuss the latest advancements in technology and patient care for geographic atrophy.
Learn more about our commitment to ophthalmology: www.astellas.com/en/science/research-and-development/prim…
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
For more than 10 years, we’ve worked with @Pfizer to help evolve the #prostatecancer landscape through breakthrough science. At ASCO #gu25, we’ll be sharing our latest research updates in prostate cancer care.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
We’re excited to share the FDA has approved an updated label for our #geographicatrophy treatment, offering eye care providers and patients continued management of a chronic, progressive disease.
Learn more: newsroom.astellas.com/404
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Visit us at booth #46 at ASCO #gu25 Feb 13-15 to discover how we’re working to improve outcomes for those impacted by genitourinary cancers.
We look forward to connecting and sharing advancements in #bladdercancer research.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Today is @UNESCO's #internationaldayofwomenandgirlsinscience. Hear from some of our inspiring female leaders on what drives them to advance scientific breakthroughs that could transform the lives of patients. #changingtomorrow #womeninstem. Learn more: www.un.org/en/observances/women-and-girls-in-science-day
-
Astellas Pharma US
@AstellasUS
At ASCO #gu25, we're presenting with @Pfizer our Phase 3 trial results showing additional overall survival data in advanced bladder cancer.
Learn more about how we're working to advance care in #bladdercancer: newsroom.astellas.com/2025-02-10-Pfizer-and-Astellas-PADC….
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Low vision simulation goggles have given us a glimpse into the experience of people living with retinal diseases like age-related macular degeneration (AMD). Learn about our commitment to the low vision community: www.astellas.com/en/science/research-and-development/prim…
#amdawarenessmonth
For U.S. Audiences Only -
Astellas Pharma US
@AstellasUS
Receiving a #prostatecancer diagnosis can spark many emotions. Dan, who has been navigating life with the disease since 2008, shares his advice for those grappling with a diagnosis of their own.
Find more resources at Know Your Prostate Plan: www.knowyourprostateplan.com?sf214663889=1 -
Astellas Pharma US
@AstellasUS
Our Chief Medical Officer, Tadaaki Taniguchi, spoke with @medcitynews about how we’re driving forward a broad pipeline focused on new therapeutic targets, spanning oncology, gene therapy and more. Read here: medcitynews.com/2025/01/astellas-pharma-taniguci-cancer-g…. For U.S. audiences only. #changingtomorrow
-
Astellas Pharma US
@AstellasUS
Our team is onsite at ASCO #gi25 in San Francisco. Stop by booth #72 to learn more about our latest #gi cancer research.
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
New #gastriccancer stories from patients, caregivers, and healthcare providers are now available on GI Cancer Chronicles. Learn more about their tips for navigating the disease: www.youtube.com/@GICancerChronicles?cbrd=1&ucbcb=1
-
Astellas Pharma US
@AstellasUS
Congratulations to Patient Partnerships Lead Liv Gagne, our @PhRMA 2025 Working for Cures Champion! Liv was chosen for her efforts to advance public policies supporting women’s health at midlife. Check out the video shared by PhRMA President & CEO @steveubl below for details.
Stephen J. Ubl
@steveubl
Meet our second #workingforcures champion, Liv Gagne, from @AstellasUS. She has raised the profile of women’s health at midlife, highlighting the importance of menopause awareness and access to care by advocating for meaningful policy changes in Congress and state legislatures. Congratulations on this honor!
-
Astellas Pharma US
@AstellasUS
Blurred vision with geographic atrophy (GA) may start subtly but can quickly advance. That’s why early detection is crucial to managing this condition.
Learn more about GA: askaboutga.com?sf207471648=1
#geographicatrophy
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Our claudin 18.2-targeted therapy has been approved in China for the treatment of advanced gastric/GEJ cancer, offering a new precision medicine option for these patients' cancer care. Read: newsroom.astellas.com/2025-01-06-Chinas-National-Medical-…
#gastriccancer #cancerresearch
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Life's colors may diminish with geographic atrophy, with washed-out hues becoming a visual reality as the disease progresses. Change may be fast, underscoring the need for early detection.
Learn more: askaboutga.com?sf207471637=1
#geographicatrophy
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Our Chief Medical Officer, Tadaaki Taniguchi, shared his insights with @PharmaVoice on bringing our first-in-class #oncology precision medicine for gastric and gastroesophageal junction cancer to market.
Read the interview here: www.pharmavoice.com/news/astellas-vyloy-precision-medicin…
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
This Geographic Atrophy (GA) Awareness Week, we’re inspired by patients like Toni, who find the positive in their diagnosis. Learn more about GA, a disease affecting over five million people worldwide: askaboutga.com?sf209560466=1
#geographicatrophy
For U.S. audiences only -
Astellas Pharma US
@AstellasUS
This November, in partnership with @StomachCancer_, we lit up our Northbrook HQ to bring awareness to #stomachcancer. Starting this conversation is just the first step, and we look forward to continued work alongside this community as we help create change, together.
-
Astellas Pharma US
@AstellasUS
Geographic atrophy (GA) starts subtly, but over time, large blank spots may appear in the central vision. The swift progression can disrupt daily routines and affect independence. Learn more about GA: askaboutga.com?sf207471632=1
#geographicatrophy
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Today on World Pancreatic Cancer Day, join us in raising awareness about this cancer that impacts so many and educating on the signs and symptoms. Learn more about #wpcd and see how you can get involved: www.worldpancreaticcancercoalition.org/world-pancreatic-c…
#pancreaticcancerawarenessmonth -
Astellas Pharma US
@AstellasUS
Astellas US President Michael Petroutsas recently shared his perspective on the importance of having open conversations around #gastriccancer and #pancreaticcancer and how these can potentially lead to improved care. Read more: www.linkedin.com/pulse/championing-research-awareness-cre…
-
Astellas Pharma US
@AstellasUS
When you're caring for your loved one with advanced bladder cancer, it's important to keep lines of communication open.
Remember that it’s okay to ask for support.
Learn more on the #letstalkbladdercancer YouTube channel: www.youtube.com/playlist?list=PLnXlYZq1zK1CAprreoCiKlRvD9…. -
Astellas Pharma US
@AstellasUS
#gastriccancer and #gejcancer are hard-to-treat diseases with poor prognoses. We’re working to help change the course of this disease for people with advanced, Claudin 18.2-positive tumors through innovative, biomarker-driven approaches.
-
Astellas Pharma US
@AstellasUS
As @aao_ophth 2024 wraps up in Chicago, we're energized by our discussions about geographic atrophy (GA), the insights from the AI symposium and the engaging activities at our booth. Learn more about our commitment: www.astellas.com/en/science/research-and-development/prim…
#aao2024
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
With our latest FDA approval, we are excited to introduce a new treatment option in Claudin 18.2-positive advanced #gastriccancer and GEJ adenocarcinoma.
-
Astellas Pharma US
@AstellasUS
We’re excited to bring a new option to adults with locally advanced unresectable or metastatic HER2-negative #gastriccancer or #gejcancer and claudin (CLDN) 18.2-positive tumors. Read more about today’s milestone: newsroom.astellas.com/404
Astellas Pharma US
@AstellasUS
📢 #breakingnews: the @US_FDA has approved our claudin 18.2-directed antibody for advanced #gastriccancer or GEJ adenocarcinoma. newsroom.astellas.com/404
-
Astellas Pharma US
@AstellasUS
📢 #breakingnews: the @US_FDA has approved our claudin 18.2-directed antibody for advanced #gastriccancer or GEJ adenocarcinoma. newsroom.astellas.com/404
-
Astellas Pharma US
@AstellasUS
Today is #worldmenopauseday. In recognition of women worldwide who are experiencing vasomotor symptoms (VMS) due to menopause, we’ve turned up the heat on Astellas leaders. Here's what they said while wearing the menopausal hot flash simulator, the MenoVest, from @overthebmoon.
-
Astellas Pharma US
@AstellasUS
Experience Astellas' leadership in ophthalmology at @aao_ophth (booth 4237). We look forward to engaging with experts, showcasing advancements in eye care and highlighting the impact of vision loss. Mark your calendars for October 18-21!
#aao2024
For U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Medicare’s new “cap & smoothing” policies will make a real difference for patients. It’s crucial patients know about these changes in Part D and understand their options. US Commercial Head Mike Petroutsas discusses the positive benefits for seniors here: www.linkedin.com/pulse/new-medicare-prescription-payment-…
-
Astellas Pharma US
@AstellasUS
Confronting a #bladdercancer diagnosis is something no one should face alone. Check out our latest #letstalkbladdercancer series to learn about the importance of communication and prioritizing mental health: www.youtube.com/playlist?list=PLnXlYZq1zK1CAprreoCiKlRvD9…
-
Astellas Pharma US
@AstellasUS
For individuals living with geographic atrophy (GA), many aspects of day-to-day life, including reading, driving or recognizing loved ones, may become difficult. Learn more: askaboutga.com?sf200108291=1
#geographicatrophy #visionloss #ophthalmology
Intended for U.S. audiences only. -
Astellas Pharma US
@AstellasUS
This month, Astellas colleagues across the country joined the #prostatecancer community (and our partners at @Pfizer) for the @ZEROCancer Run/Walk events. See more from the Chicago event:
-
Astellas Pharma US
@AstellasUS
This week, we’re headed to @MenopauseOrg’s 2024 Annual Meeting held here in Chicago! We look forward to presenting 5 abstracts showing data on vasomotor symptoms (VMS) due to menopause. Visit us at booth 305 and learn more at: newsroom.astellas.com/404
#menopausesocietymtg -
Astellas Pharma US
@AstellasUS
Our #partnerships are advancing science and bringing groundbreaking new treatments to patients. We will be at #lsxusa, Boston, MA, Sept 11-12 to discuss opportunities for collaboration. Get in touch: www.astellas.com/en/partnering
-
Astellas Pharma US
@AstellasUS
Vision loss may significantly affect daily life, not only for those diagnosed but also for loved ones and caregivers. Learn more about our focus on impacting patients with retinal diseases like geographic atrophy (GA): askaboutga.com
Intended for U.S. audiences only.
Astellas Pharma US
@AstellasUS
-
Astellas Pharma US
@AstellasUS
#prostatecancerawarenessmonth represents something unique for everyone – it’s a time to learn more about the disease, have important conversations with doctors, and more. For us, it’s a reminder of the progress made over the last decade and the work still ahead of us.
-
Astellas Pharma US
@AstellasUS
The 2024 Summer Symposium hosted by @WIO_WomenInOpht was an unparalleled experience for our team, focused on championing the role of women in ophthalmology. We left feeling motivated to continue illuminating the path for women in eye care.
#wio2024 #ophthalmology #eyehealth -
Astellas Pharma US
@AstellasUS
For those living with geographic atrophy (GA), the effects of vision loss may bring on feelings of anxiety and fear, even though symptoms may develop gradually. Explore the impact of GA: askaboutga.com
#geographicatrophy #eyehealth
Intended for U.S. audiences only. -
Astellas Pharma US
@AstellasUS
During the early stages of geographic atrophy (GA), patients may overlook indicators or rely on other senses to compensate for their vision loss. Learn more about how GA can progress: askaboutga.com
#geographicatrophy #visionloss
Intended for U.S. audiences only. -
Astellas Pharma US
@AstellasUS
Recently, our VP of Government Affairs and Policy Christie Bloomquist moderated a Congressional briefing on how public policies can improve women's health during #menopause and midlife. Thanks to @WCPInst for supporting this important event. #wcpihealth www.wcpinst.org/events/menopause-and-midlife-womens-health/
-
Astellas Pharma US
@AstellasUS
Celebrating a year of innovation and hope! Thanks to the clinical trial investigators, patients, caregivers and scientists who made our geographic atrophy treatment possible.
Onward in our mission to make an impact in the retinal field!
Intended for U.S. audiences only.
Astellas Pharma US
@AstellasUS
-
Astellas Pharma US
@AstellasUS
Our own Biopharma Development Head Marci English is in the spotlight as a @PhRMA Working for Cures Champion. Learn more about Marci's leadership in improving women's health at midlife in the video here: www.youtube.com/watch?v=WFDjMrYjihg #workingforcures
-
Astellas Pharma US
@AstellasUS
Living with #bladdercancer is more than a physical challenge – it’s emotional too. For our #letstalkbladdercancer series, we partnered with oncology social workers to talk about the emotional and mental challenges of navigating life with bladder cancer: www.youtube.com/playlist?list=PLnXlYZq1zK1CAprreoCiKlRvD9…
-
Astellas Pharma US
@AstellasUS
At the 2024 @asrsdocs meeting, we connected with retinal specialists to discuss how we can make a difference in managing vision loss in patients with geographic atrophy (GA). Learn more about our commitment to driving innovation in GA: www.astellas.com/en/science/research-and-development/prim…
Astellas Pharma US
@AstellasUS
-
Astellas Pharma US
@AstellasUS
Vision loss can take a heavy emotional toll on people living with geographic atrophy. It's crucial to consult a doctor when you notice any changes in your vision to aid in early detection and intervention.
Learn more: askaboutga.com
#geographicatrophy #ophthalmology -
Astellas Pharma US
@AstellasUS
To optimize outcomes for people with #gastriccancer, HCPs may look for ways to personalize treatment, often using biomarkers. Hear more from oncologist Dr. Marshall – along with patients, caregivers, and nurses – on the treatment decision-making process: www.youtube.com/playlist?list=PLSl754eCFLEk62A1a9S4PHOoeC…
-
Astellas Pharma US
@AstellasUS
Thank you to all who shared their stories for #paoactionweek earlier this month! Seeing the true impact of patient advocacy organizations every day inspires our work, and we look forward to continuing to work together to drive awareness and engagement. www.paoactionweek.com?sf191828247=1
-
Astellas Pharma US
@AstellasUS
Geographic atrophy can progress without warning, causing permanent vision loss and blindness. If you or a loved one are over 55, prompt eye exams are vital for early detection and intervention that may help maintain your sight for longer.
Learn more: askaboutga.com
Astellas Pharma US
@AstellasUS
-
Astellas Pharma US
@AstellasUS
We’re pleased to announce a research agreement with @UMassChan. Together, we aim to advance research for an #aav vector #genetherapy for the treatment of #alexanderdisease and turn the promise of gene therapy into meaningful treatments for patients: newsroom.astellas.com/2024-06-20-Astellas-Announces-Spons…
-
Astellas Pharma US
@AstellasUS
At this year’s @Optometrysmtg? Stop by booth #602 for more details on Astellas and presentations from Drs. Yackey and Majcher on the role optometrists play in the early detection of geographic atrophy, which can make a critical difference in mitigating its effect.
Astellas Pharma US
@AstellasUS
-
Astellas Pharma US
@AstellasUS
Thank you to those who participated in #paoactionweek. Together we are helping bring awareness to the value of PAOs across the U.S. that support patients & caregivers. We hope this week inspires everyone to support a PAO that is meaningful to you! www.paoactionweek.com
-
Astellas Pharma US
@AstellasUS
We’re partnering with @IAPB1 as part of a collective effort to tackle the global burden of avoidable sight loss. Learn more about how we can make a positive impact on eye health: www.iapb.org/news/astellas-joins-international-agency-for…
#visionloss #eyehealth #ophthamology -
Astellas Pharma US
@AstellasUS
Whether you are a patient, caregiver, healthcare professional or community member, there are patient advocacy organizations relevant to you. Learn more about how to connect with a PAO here: www.paoactionweek.com #paoactionweek
-
Astellas Pharma US
@AstellasUS
Today is the start of the inaugural Patient Advocacy Organization (PAO) Action Week! Use #paoactionweek and join us in raising awareness of the critical work of PAOs across the U.S. and the invaluable support and resources they offer for patients. www.paoactionweek.com
-
Astellas Pharma US
@AstellasUS
Our Head of U.S. Commercial, Michael Petroutsas, attended his first ASCO meeting with Astellas. See how it went. #asco2024
This media couldn't be displayed. See it on the original post. -
Astellas Pharma US
@AstellasUS
This weekend, we’re headed to Park City, UT, for @CTS_Tahoe. Leaders from our team will unite with experts on current clinical trials, the latest data and best practices. Don’t miss the presentations from Astellas leaders and retinal specialist, Dr. Chang, highlighted below!
Astellas Pharma US
@AstellasUS
-
Astellas Pharma US
@AstellasUS
We are looking forward to participating in Patient Advocacy Organization (PAO) Action Week next week! This first-ever grassroots initiative is dedicated to raising awareness and connecting patients to relevant PAOs. Follow #paoactionweek. Visit www.paoactionweek.com for more.
-
Astellas Pharma US
@AstellasUS
Biomarkers like claudin 18.2 may reveal more opportunities to improve care for advanced gastric or gastroesophageal junction (GEJ) cancer. Explore how oncologists can use biomarkers to learn more about their patients: gastriccancerbiomarkers.com #asco24
-
Astellas Pharma US
@AstellasUS
We’re delighted to be at #asco2024 today presenting our latest #cancer research reaffirming our dedication to advancing treatment options in #urothelialcancer in partnership with @Pfizer. Explore our ongoing efforts: astellasoncology.com
-
Astellas Pharma US
@AstellasUS
Today at #asco24, we’re sharing the latest research from our #gastriccancer program. Learn more: meetings.asco.org/abstracts-presentations/232477
-
Astellas Pharma US
@AstellasUS
Join us today at #asco24 for an oral presentation where we’ll learn more about a health-related quality of life analysis in patients with high-risk biochemically recurrent #prostatecancer (Abstract 5005).
-
Astellas Pharma US
@AstellasUS
📍 Chicago, IL for #asco24
We’re thrilled to be onsite once again sharing our #oncology research and connecting with this community that shares our commitment to changing the course of cancer treatment. Stop by booth #25000 and learn more about our work! -
Astellas Pharma US
@AstellasUS
Innovation #partnerships are advancing the next generation of healthcare. Looking to collaborate? We will be at #bio2024, June 3-6 to discuss how together, we can bring transformative therapies to patients faster. Get in touch: www.astellas.com/en/partnering
-
Astellas Pharma US
@AstellasUS
Update on our investigational #gastriccancer treatment: the U.S. FDA acknowledged the Biologics License Application (BLA) Resubmission for our CLDN18.2-targeted therapy.
-
Astellas Pharma US
@AstellasUS
The countdown is on – #asco24 is one week away! Make note of #oncology presentations to expect this year from Astellas: newsroom.astellas.com/404
-
Astellas Pharma US
@AstellasUS
Did you know #bladdercancer diagnoses are on the rise in the US? Our latest #letstalkbladdercancer video delves into the potential impact on those living with the disease. Watch the video to learn more and help us spread awareness. www.youtube.com/watch?v=TnSp6DiTHVo
-
Astellas Pharma US
@AstellasUS
Living with #geographicatrophy (GA) means facing the reality of vision loss. This progressive disease can greatly impact one's life, causing frustration, loneliness and fear. Awareness of GA and its symptoms are key to managing the disease. Learn more: askaboutga.com
-
Astellas Pharma US
@AstellasUS
This #internationalclinicaltrialsday, we recognize and thank all the trailblazing patients, researchers and healthcare professionals who make clinical trials and #clinicalresearch possible.
Learn more: www.clinicaltrials.astellas.com/about-clinical-trials?tab=1
#clinicaltrialsday #ctd2024 -
Astellas Pharma US
@AstellasUS
We are attending the 2024 ACOG Annual Clinical & Scientific Meeting in San Francisco, joining professionals from across the country who share our commitment to innovation in women’s health. Visit us at booth #601! #acog2024
-
Astellas Pharma US
@AstellasUS
GAAD reminds us of the challenges many, including the visually impaired, face when trying to access digital health information. That is why, at Astellas, we are striving to optimize the patient information journey. Visit the GAAD website to learn more at accessibility.day
Astellas Pharma US
@AstellasUS
-
Astellas Pharma US
@AstellasUS
Congratulations, Dr. @tompowles1 on being named one of @TIME’s most influential people in health. Your work is a testament to the power of curiosity. We are honored to work with you in our mission to change the course for people living with #bladdercancer. time.com/collections/time100-health/6967129/thomas-powles/
TIME
@TIME
Introducing the 100 most influential people in health in 2024 ti.me/44nqUb0
-
Astellas Pharma US
@AstellasUS
Biomarkers are important tools for interpreting and treating cancers, including #gastriccancer.
However, understanding biomarkers can be challenging. In GI Cancer Chronicles, HCPs, patients, and caregivers share their “must-knows” about biomarkers. -
Astellas Pharma US
@AstellasUS
Did you miss us at this year’s @ARVOinfo meeting? We shared the latest insights from the GATHER trials in #geographicatrophy. Learn more about Astellas' focus on blindness and regeneration: www.astellas.com/en/science/research-and-development/prim…
#arvo2024 #ophthalmology -
Astellas Pharma US
@AstellasUS
Our #asco24 presentations underscore the breadth of our oncology portfolio. See what we’ll be sharing at this year’s meeting: newsroom.astellas.com/404
-
Astellas Pharma US
@AstellasUS
The @RetinaWCongress starts tomorrow. Will you be attending? Stop by Dr. Durga Borkar's presentation on the GATHER trials to hear more about our work in #geographicatrophy.
-
Astellas Pharma US
@AstellasUS
At Astellas Oncology, we celebrate nurses for their courage.
Thank you to nurses everywhere for your bravery and strong voices as we work to change the course of cancer treatment together. -
Astellas Pharma US
@AstellasUS
In 2024, it is estimated that there will be approximately 83,190 new cases of #bladdercancer in the U.S. This #bladdercancerawarenessmonth and every month, we’re committed to supporting those impacted and raising awareness around #bladdercancer signs and symptoms.
-
Astellas Pharma US
@AstellasUS
As we reflect on #amlworldawarenessday, we are inspired by the strength of those impacted by acute myeloid leukemia (#aml), from patients to caregivers. Learn more about AML, its impact, and the importance of genetic testing at know-aml.com.
-
Astellas Pharma US
@AstellasUS
From diagnosis, #geographicatrophy(GA) can spread to the center of the eye in just 2.5 years, potentially leading to blindness. That's why it's crucial to take charge of your eye health and protect your vision! Learn more about the symptoms GA: askaboutga.com
-
Astellas Pharma US
@AstellasUS
At Astellas, we recognize the impact acute myeloid leukemia (#aml) can have on patients and their caregivers. This #amlworldawarenessday, we’re joining @Know AML to shine a light on the instrumental role caregivers play in supporting patients with AML. know-aml.com/understanding-aml/caregivers.
-
Astellas Pharma US
@AstellasUS
Acute myeloid leukemia (#aml) can be caused by harmful mutations in genes which tell blood cells how to work, affecting more than 20,000 people in the U.S. in 2023.
This #amlworldawarenessday, we encourage you to learn more and help raise awareness at know-aml.com/get-involved/world-awareness-day. -
Astellas Pharma US
@AstellasUS
#geographicatrophy(GA) can start to develop with subtle symptoms, or even no symptoms at all. Regular eye exams are essential in detecting diseases like GA to stay ahead of vision loss.
Learn more about monitoring for GA: askaboutga.com -
Astellas Pharma US
@AstellasUS
We look forward to connecting with leaders in optometry at the annual @VisionSourceLP Exchange Meeting in Orlando, Florida. Stop by booth #532 to hear why we are so passionate about the role of optometrists in the early detection and management of geographic atrophy.
-
Astellas Pharma US
@AstellasUS
Our team is eager to collaborate with retina specialists at the 12th Annual @VitBuckleSoc Meeting. Hear more about our commitment to pioneering research for treatments in AMD and #geographicatrophy by stopping at booth #4.
-
Astellas Pharma US
@AstellasUS
We’re thrilled to be recognized on @FastCompany's 2024 list of Most Innovative Companies in Medicine and Therapeutics! As a life science innovator, our focus is on developing pioneering medicines to help solve medical needs for patients: www.fastcompany.com/91037063/medicines-therapeutics-most-…
#fcmostinnovative -
Astellas Pharma US
@AstellasUS
Our application has been accepted by China’s National Medical Products Administration for a combination therapy for advanced #urothelialcancer, investigated with @Pfizer_news and Merck.
Read more: newsroom.astellas.com/2024-03-28-Chinas-National-Medical-… -
Astellas Pharma US
@AstellasUS
We are excited to share that we have received a permanent J-Code (J2782) from the U.S. @CMSGov for our treatment of #geographicatrophy. This milestone advances our efforts to ensure timely patient access to our treatment.
Read the full press release: newsroom.astellas.com/2024-03-26-Astellas-Receives-Perman… -
Astellas Pharma US
@AstellasUS
Our anti-claudin 18.2 (CLDN18.2) antibody for the treatment of HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent #gastriccancer is now approved in Japan. Read more: newsroom.astellas.com/2024-03-26-Astellas-VYLOY-TM-zolbet…
-
Astellas Pharma US
@AstellasUS
The European Medicines Agency’s #chmp (Committee for Medicinal Products for Human Use) issued a positive opinion recommending marketing authorization of our #prostatecancer therapy, which may expand use to an add’l recurrent early form of the disease. newsroom.astellas.com/2024-03-22-Astellas-Receives-Positi…
-
Astellas Pharma US
@AstellasUS
Jim, who has been living with #prostatecancer on and off for 15+ years, shares his story in the hope of inspiring and educating others navigating a prostate cancer diagnosis of their own: newsroom.astellas.com/404
-
Astellas Pharma US
@AstellasUS
A #gastriccancer diagnosis can be devastating, and navigating all the information that comes with it can be an added burden. Our new YouTube channel, GI Cancer Chronicles, features real-life stories from those living with the disease: www.youtube.com/@GICancerChronicles?cbrd=1&ucbcb=1
-
Astellas Pharma US
@AstellasUS
We’re excited to announce that following our December 2023 approval, the #fda has granted #orphandrug and pediatric exclusivity to our #antifungal treatment for #invasiveaspergillosis and #invasivemucormycosis in appropriate pediatric patients 1 to less than 18 years old.
-
Astellas Pharma US
@AstellasUS
Today, @NEJM published our latest research in advanced #bladdercancer. This exciting new data is a testament to our commitment to bringing treatment options to patients with hard-to-treat #cancers. Learn more here: www.nejm.org/doi/full/10.1056/NEJMoa2312117
-
Astellas Pharma US
@AstellasUS
Introducing GI Cancer Chronicles, a new collection of #gastriccancer stories from patients, caregivers, and healthcare providers who navigate the disease daily. They’re sharing their real-life stories in the hopes of making the journey easier for others: www.youtube.com/@GICancerChronicles?cbrd=1&ucbcb=1
-
Astellas Pharma US
@AstellasUS
#rarediseaseday is about generating change for those affected by #raredisease. Hear from our leaders about why they are passionate about working in rare diseases.
-
Astellas Pharma US
@AstellasUS
The new @testbiomarkers campaign has an important goal: ensure that patients, caregivers, and HCPs understand the role of biomarker testing in #gastriccancer care. We’re proud to be a founding supporter of this initiative – learn more: testyourbiomarkers.org #testyourbiomarkers
-
Astellas Pharma US
@AstellasUS
Around 200 million people worldwide are thought to be living with AMD. Our team proudly supports AMD/Low Vision Awareness Month by amplifying the importance of routine eye care to monitor for retinal diseases like AMD and #geographicatrophy. Learn more: askaboutga.com
-
Astellas Pharma US
@AstellasUS
We have named Michael Petroutsas as our new Head of US Commercial, effective March 18. Learn more here: newsroom.astellas.com/2024-02-22-Astellas-Names-Michael-P…
-
Astellas Pharma US
@AstellasUS
Congratulations to @IvericBio, An Astellas Company, on this well-deserved award! The team’s innovation led to incredible advancements in the treatment of geographic atrophy.
#bionjdinner2024 #geographicatrophy -
Astellas Pharma US
@AstellasUS
Last month, Astellas partnered with @thehill to host a #menopause-focused roundtable with experts from Congress, medicine, advocacy, and more. Read the executive summary for highlights from the conversation on ways to improve education, care and related public policies.
-
Astellas Pharma US
@AstellasUS
Did you know that millions of women in the U.S. watch the #superbowl? Learn more about why we aired our commercial for our treatment for moderate to severe vasomotor symptoms (VMS) AKA hot flashes / night sweats, due to #menopause, on this national stage: newsroom.astellas.com/2024-02-01-Astellas-to-Air-New-VEOZ…
-
Astellas Pharma US
@AstellasUS
This AMD/Low Vision Awareness Month, we aim to raise awareness about retinal diseases. Age-related macular degeneration (AMD) can blur central vision and progress into #geographicatrophy, which can advance quickly once it takes hold.
Learn more: askaboutga.com -
Astellas Pharma US
@AstellasUS
Astellas is returning to the #superbowl! We’ll be kicking off a new version of the TV spot for our treatment for moderate to severe vasomotor symptoms (VMS), AKA hot flashes / night sweats, due to #menopause. Learn more here: newsroom.astellas.com/2024-02-01-Astellas-to-Air-New-VEOZ…
-
Astellas Pharma US
@AstellasUS
Our US President Mark Reisenauer recently spoke with @PhRMA CEO @SteveUbl about new developments in our #cancer portfolio and how policymakers can help protect patients’ access to the care they need. Read more: onphr.ma/3vSvmBj
-
Astellas Pharma US
@AstellasUS
We have submitted a Supplemental New Drug Application to Japan’s MHLW for a combination therapy for advanced #urothelialcancer with Pfizer and Merck. Read more: newsroom.astellas.com/2024-01-30-Astellas-Submits-Supplem…
-
Astellas Pharma US
@AstellasUS
We are pleased to announce a strategic collaboration with leading biomedical research organization @MassGenBrigham, aiming to advance translational medicine and accelerate early development, initially in oncology, rare disease, and cell and gene therapy: newsroom.astellas.com/404
-
Astellas Pharma US
@AstellasUS
The EMA has validated our Type II variation application for a combination therapy for advanced urothelial cancer, investigated in partnership with Pfizer and Merck. Read more: newsroom.astellas.com/404
-
Astellas Pharma US
@AstellasUS
Today at ASCO #gu24, we are presenting our latest research on a treatment combination for #urothelialcancer.
-
Astellas Pharma US
@AstellasUS
Through our #prostatecancer research, we’re working to understand the “how” and “why” of biochemical recurrence so that we can help improve outcomes for men who experience it. #gu24
-
Astellas Pharma US
@AstellasUS
This week at ASCO #gu24, we’re sharing our latest research in #bladdercancer. We’re committed to the continued exploration of treatment options and advancements in this space.
-
Astellas Pharma US
@AstellasUS
Head of Development Immuno-oncology and Cell Therapy Moitreyee Chatterjee-Kishore speaks to @ConferenceForum about Astellas’ efforts to advance pioneering immuno-oncology therapies. Read on: www.fiercebiotech.com/editorial/pushing-io-and-cell-thera….
-
Astellas Pharma US
@AstellasUS
Attending #gu24? Join us today for an oral presentation on our research in men with high-risk biochemically recurrent #prostatecancer.
-
Astellas Pharma US
@AstellasUS
We’re at #gu24, where we’re joining the genitourinary cancer community to share our latest updates in #prostatecancer and #bladdercancer.
-
Astellas Pharma US
@AstellasUS
We’re proud to join the #gastriccancer community for #gi24. Stop by our booth #65 and check out our posters at the meeting to learn more about how we’re working to advance treatment options for this disease.
-
Astellas Pharma US
@AstellasUS
Delivering next-generation therapies through new modalities will depend on close collaboration, both internally and with ambitious partners across the industry. Astellas leaders share their views with @Endpts on what is needed to drive shared success: endpoints.news/sp/breaking-barriers-to-innovation-integra…
-
Astellas Pharma US
@AstellasUS
Astellas has completed the acquisition of Propella Therapeutics, Inc. For more information, see press release here. www.astellas.com/en/news/28766
-
Astellas Pharma US
@AstellasUS
Just as innovation needs adaptability, so too must our approach to #partnerships. In January, we will be exploring the future of flexible dealmaking at #biotechshowcase and #fiercejpmweek. Get in touch to learn more: www.astellas.com/en/partnering
-
Astellas Pharma US
@AstellasUS
For those with acute myeloid leukemia (#aml), there remains unmet needs and limited treatment options. At Astellas, we are unwavering in our commitment to addressing these needs throughout the patient journey through ongoing innovation.
-
Astellas Pharma US
@AstellasUS
Today we announced that the U.S. FDA approved our combination therapy for locally advanced or metastatic #urothelialcancer, which we investigated in partnership with Pfizer and Merck. Read more: newsroom.astellas.com/2023-12-15-PADCEV-R-enfortumab-vedo…
-
Astellas Pharma US
@AstellasUS
Our Vice President and Head of BioPharma Development Marci English was recently honored as a @PhRMA Working for Cures Employee Champion for improving awareness and care for the health challenges women at midlife experience during #menopause. Learn more: onphr.ma/47ZVZT9
-
Astellas Pharma US
@AstellasUS
Are you or a loved one living with #bladdercancer? Visit our latest #letstalkbladdercancer video series to hear how Peg found moments of normalcy with her loved ones during her bladder cancer journey.
-
Astellas Pharma US
@AstellasUS
As we wrap up #ash23, our gratitude goes out to the #hematology and #oncology communities. Your unwavering commitment to research and rare cancer awareness helps those with acute myeloid leukemia (#aml). Looking forward to next year!
-
Astellas Pharma US
@AstellasUS
Today marks an important step forward in addressing the needs of midlife women in Europe. Our treatment for vasomotor symptoms associated with menopause has been approved by the European Commission (EC).
-
Astellas Pharma US
@AstellasUS
Come visit us at booth #2311 at #ash23 to learn more about our milestone in treating patients with hard-to-treat cancer, like acute myeloid leukemia (#aml)!
-
Astellas Pharma US
@AstellasUS
We're excited to be at #ash23, celebrating our longstanding commitment to the acute myeloid leukemia (#aml) community and the progress made in treatment options available for those with hard-to-treat cancers. To learn more, visit our booth.
-
Astellas Pharma US
@AstellasUS
We are excited to announce that our antifungal drug is now approved by the FDA for the treatment of #invasiveaspergillosis or #invasivemucormycosis in appropriate pediatric patients aged 1 to 17 years old. Read more: newsroom.astellas.com/2023-12-08-FDA-Approves-Expanded-Us…
-
Astellas Pharma US
@AstellasUS
#geographicatrophy (GA), a form of AMD, is a leading cause of blindness in the world, yet it often goes undiagnosed. This GA Awareness Week, remind your loved ones and yourself to talk to your eye care provider to prioritize eye health.
Learn more: askaboutga.com -
Astellas Pharma US
@AstellasUS
A #bladdercancer diagnosis may feel overwhelming, but it can be made a little easier with the right people by your side. Watch our new #letstalkbladdercancer video, in partnership with @SeagenGlobal, to hear about Peg’s bladder cancer experience and advice for others.
-
Astellas Pharma US
@AstellasUS
Today, the U.S. FDA has accepted for priority review our Supplemental Biologics License Application (sBLA) for a treatment for advanced #urothelialcancer, in partnership with @SeagenGlobal and Merck. Read more: newsroom.astellas.com/2023-11-30-FDA-Grants-Priority-Revi…
-
Astellas Pharma US
@AstellasUS
This month and always, we’re proud to be working alongside the #stomachcancer community to help make an impact in this space through education and innovation.
#stomachcancerawarenessmonth -
Astellas Pharma US
@AstellasUS
There is no “universal” experience when it comes to #stomachcancer. Understanding the disease from various perspectives helps us approach treatment differently.
Learn more about the disease: newsroom.astellas.us/gastriccancer
#stomachcancerawarenessmonth -
Astellas Pharma US
@AstellasUS
The @US_FDA has approved our and @Pfizer’s #prostatecancer therapy for men with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis, expanding its indication into an earlier form of the disease. See more about the milestone:
-
Astellas Pharma US
@AstellasUS
This #veteransday, we honor our colleagues who served or are actively serving our country. Your unique experiences and diverse skills help enhance the support we provide to patient communities. Thank you to all veterans for your service, bravery, courageous spirit and sacrifice.
-
Astellas Pharma US
@AstellasUS
There is an important need for more inclusive participation in clinical research to create more effective medicine for everyone. Astellas is proud to sponsor @CISCRP’s Patient Diversity Campaign honoring the Medical Heroes who have participated in clinical trials.
-
Astellas Pharma US
@AstellasUS
Join us today during #aao2023 at booth 5302 to learn more about the Astellas pipeline! We are excited to discuss innovative treatments for retinal diseases with those who will be attending.
#blindness #visionregeneration -
Astellas Pharma US
@AstellasUS
We are excited to join everyone at #aao2023! Come visit us at booth 7601 in Moscone West!
#geographicatrophy -
Astellas Pharma US
@AstellasUS
We are encouraged to see leaders in Congress spearhead a resolution to increase awareness and support for women’s health experiences at midlife. Throughout#WorldMenopauseMonth, we share a commitment to end the stigma and alleviate symptoms of #menopause.
-
Astellas Pharma US
@AstellasUS
While #idweek2023 is over, our research in #invasiveaspergillosis and #invasivemucormycosis continues. Thanks to all who joined us this year – we look forward to all that’s ahead in infectious disease research!
-
Astellas Pharma US
@AstellasUS
ONE WEEK LEFT to enter the Astellas Future Innovator Prize 2023. Don’t miss your chance to work with @MBiolabs and Astellas to develop your biotech innovation! www.astellas.com/en/astellasfutureinnovator/san-francisco…
#incubator #biotechstartup #entrepreneurs -
Astellas Pharma US
@AstellasUS
We strive to support our people as much as our patients by looking after everyone’s well-being in a caring and open environment. Our US President Mark Reisenauer shares the five ways Astellas supports #worklifebalance for employees. www.linkedin.com/top-content/
-
Astellas Pharma US
@AstellasUS
We’re excited to share our latest EDEI Report Card, encompassing the initiatives we’re supporting to advance engagement, diversity, equity and inclusion here at Astellas. Learn more about our EDEI initiatives and our progress to date here: www.astellas.com/en/sustainability/diversity-management
-
Astellas Pharma US
@AstellasUS
Emerging biomarkers, including Claudin 18.2, are expanding our treatment horizons, and biomarker testing is playing a bigger role in personalizing #gastriccancer care. #esmo23
-
Astellas Pharma US
@AstellasUS
We are presenting late-breaking data at #esmo23 from our Phase 3 clinical trial with @SeagenGlobal and Merck in adults with locally advanced/metastatic urothelial cancer. Read more below.
-
Astellas Pharma US
@AstellasUS
Urothelial cancer accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra. We're at #esmo23 sharing our latest research as we work to advance potential treatment options for this disease. #bladdercancer
-
Astellas Pharma US
@AstellasUS
Biomarkers are helping physicians make more informed clinical decisions in #gastriccancer and other diseases. Explore the biomarker landscape for more on emerging biomarkers like Claudin 18.2. #esmo23
-
Astellas Pharma US
@AstellasUS
Around the world approximately 573,000 new cases of #bladdercancer are reported annually. Join us at #esmo23 to learn more about our commitment to advancing research in this space.
-
Astellas Pharma US
@AstellasUS
Today, @NEJM published our latest research in non-metastatic hormone-sensitive #prostatecancer.
-
Astellas Pharma US
@AstellasUS
Today is #worldmenopauseday. Join us in shining a spotlight on vasomotor symptoms (VMS) due to menopause – AKA hot flashes and night sweats – and celebrating the progress made in the treatment options now available for women in midlife. #wmd2023
-
Astellas Pharma US
@AstellasUS
We’re excited to share updates from our oncology research at #esmo2023. Take a look at our abstracts in hard-to-treat cancers, including #prostatecancer, #gastriccancer and #bladdercancer.
-
Astellas Pharma US
@AstellasUS
As we continue to pursue regulatory approval worldwide, in Europe, today, we announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of our investigational treatment. newsroom.astellas.com/2023-10-13-Astellas-Receives-Positi…
#vmsduetomenopause -
Astellas Pharma US
@AstellasUS
We’re on a mission to understand how to help address #invasiveaspergillosis & #invasivemucormycosis infections in vulnerable populations, like children. Join us today at #idweek2023 to learn more.
-
Astellas Pharma US
@AstellasUS
Long-term, collaborative relationships are key to advancing the most promising innovations. Next week, we’ll be at the #fiercebiotechsummit to explore how flexible, tailored approaches can unlock a partnership’s full potential.
Get in touch: www.astellas.com/en/partnering -
Astellas Pharma US
@AstellasUS
Our team is headed to #idweek2023 today, where we’ll share updates from our research in pediatric #invasiveaspergillosis and #invasivemucormycosis.
Join us onsite from October 11-15 to learn more about our infectious disease research. idweek2023.eventscribe.net -
Astellas Pharma US
@AstellasUS
We’re proud to announce our 2023 Working Parents of the Year, Joseph Zenus and Julie Budzynski. Read about their experiences as working parents and how they aim to bring their best selves to both work and their families. newsroom.astellas.com/404 #seramount100best
-
Astellas Pharma US
@AstellasUS
We’re excited to be named for the ninth consecutive year as a @Seramount 100 Best Company, exemplifying our ongoing commitment to support working parents. Learn more here: newsroom.astellas.com/404 #seramount100best
-
Astellas Pharma US
@AstellasUS
We’re proud to celebrate Global Diversity Awareness Month this October, in honor of our commitment to fostering a diverse and inclusive culture where employees of all backgrounds are welcome. Learn more about our EDEI initiatives here.
-
Astellas Pharma US
@AstellasUS
Last week, colleagues attended events that celebrate visionaries in different areas of health care: the @Aging_Research’s #heroesinhealth program and @PreventCancer’s annual #preventcancergala. It’s inspiring to hear from leaders who share our goal of improving patients’ health.
-
Astellas Pharma US
@AstellasUS
This weekend at @MenopauseOrg’s annual meeting, we had empowering discussions about women’s health in midlife, perfectly timed to kick off #worldmenopausemonth. Join us in recognizing the women in our lives experiencing the menopausal transition. #menopausesocietymtg
-
Astellas Pharma US
@AstellasUS
Today marks the start of #worldmenopausemonth – an opportunity to educate and show support for every woman experiencing menopause and menopausal symptoms, such as VMS, AKA hot flashes & night sweats. Learn more at whatsvms.com.
-
Astellas Pharma US
@AstellasUS
We’re passionate about women’s health, helping those who experience vasomotor symptoms (VMS, AKA hot flashes and night sweats) due to menopause. We’re at @MenopauseOrg’s annual meeting ahead of #worldmenopausemonth - visit us at booth #105! #menopausesocietymtg
-
Astellas Pharma US
@AstellasUS
Patients are our purpose. We’re honored to be at @MenopauseOrg’s annual meeting, raising awareness of vasomotor symptoms (VMS) due to #menopause.
Will you be attending? Come see us at booth #105. #menopausesocietymtg -
Astellas Pharma US
@AstellasUS
This #bloodcancerawarenessmonth we’re raising awareness of acute myeloid leukemia (#aml). For patients diagnosed with AML, it is important to test for genetic mutations at diagnosis and relapse as status of mutations, like FLT3, can change over time.
-
Astellas Pharma US
@AstellasUS
This week, we’re headed to @MenopauseOrg’s annual meeting as a premier sponsor! We’re looking forward to presenting 7 abstracts (2 oral presentations and 5 posters) on vasomotor symptoms (VMS) due to #menopause. Join the conversation at booth #105. #menopausesocietymtg
-
Astellas Pharma US
@AstellasUS
Tadaaki Taniguchi, Chief Medical Officer, shares his insights with @PharmaVoice on how to help teams adopt agile ways of working and thrive outside their comfort zones to meet the urgent needs of patients. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Today, we’re sharing topline results from our Phase 3 clinical trial in locally advanced/metastatic #urothelialcancer. In partnership with @SeagenGlobal and Merck, we look forward to continuing to advance options for this hard-to-treat cancer.
-
Astellas Pharma US
@AstellasUS
We are excited to announce positive 24-month topline results from @IvericBio's GATHER2 study in patients with #geographicatrophy. #ivericimpact newsroom.astellas.com/2023-09-18-Iveric-Bio-Announces-Pos…
-
Astellas Pharma US
@AstellasUS
Acute myeloid leukemia (#aml) has been associated with genetic mutations, one of the most common of which is FMS-like tyrosine kinase 3 (FLT3). Patients with FLT3 AML face potentially worse outcomes than those without this mutation. #bloodcancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
The @EMA_News has validated a Type II variation for our #prostatecancer therapy in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, marking an important step forward in bringing new treatment options to patients with this disease.
-
Astellas Pharma US
@AstellasUS
We are thrilled to announce positive 12-month data from @Ivericbio's GATHER2 clinical trial were published in @TheLancet. Read the full publication here: www.thelancet.com/journals/lancet/article/PIIS0140-6736(2… #ivericbio #geographicatrophy
-
Astellas Pharma US
@AstellasUS
#dyk acute myeloid leukemia (#aml) is one of the most common types of leukemia in adults? This #worldleukemiaday it’s time to #beleukemiaaware.
-
Astellas Pharma US
@AstellasUS
It’s #worldleukemiaday! Join us, alongside the acute myeloid leukemia (#aml) community, to raise awareness about this hard-to-treat cancer. From knowing the signs and symptoms associated with AML to understanding the importance of mutation testing - it’s time to #beleukemiaaware.
-
Astellas Pharma US
@AstellasUS
Today is the start of #bloodcancerawarenessmonth, a time to honor patients and caregivers impacted by blood cancers like acute myeloid leukemia (#aml). Join us as we raise awareness about the needs of people with AML, including more education, research and treatment options.
-
Astellas Pharma US
@AstellasUS
#dyk #bloodcancerawarenessmonth and #worldleukemiaday are right around the corner? Explore ways to support and honor those around the world battling rare cancers like acute myeloid leukemia (#aml).
-
Astellas Pharma US
@AstellasUS
Alongside our partners at @Pfizer, we’re proud to share that the @US_FDA has accepted and granted Priority Review designation to our #prostatecancer therapy in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
-
Astellas Pharma US
@AstellasUS
We are delighted to share that the European Medicines Agency (@EMA_News) has accepted the Marketing Authorization Application (MAA) for @Ivericbio’s treatment of #geographicatrophy (GA). #ivericimpact
-
Astellas Pharma US
@AstellasUS
FDA News: A supplemental New Drug Application (sNDA) was accepted by the FDA for our antifungal drug seeking approval for the treatment of #invasiveaspergillosis (IA) or #invasivemucormycosis (IM) in pediatric patients aged 1 to 17 years old.
-
Astellas Pharma US
@AstellasUS
We are pleased to share the @US_FDA has approved @IvericBio's therapy for the treatment of geographic atrophy (GA).
#geographicatrophy #ivericimpact -
Astellas Pharma US
@AstellasUS
Our own Lori Magnoni was recently honored as a @PhRMA Working for Cures Employee Champion for her work educating colleagues on emerging policy and legislative developments and communicating the value the industry delivers to patients, health systems and economies.
-
Astellas Pharma US
@AstellasUS
If you have questions about how your advanced #bladdercancer diagnosis will affect you and your loved ones, there are resources available. The latest #letstalkbladdercancer article with @SeagenGlobal in @TIME shares more.
-
Astellas Pharma US
@AstellasUS
A new Biologics License Application for our investigational Claudin 18.2-targeted antibody has been accepted by the Center for Drug Evaluation of the China National Medical Product Administration. We’re thrilled about this update in our #gastriccancer research program.
-
Astellas Pharma US
@AstellasUS
Our US President Mark Reisenauer sat down with @Nature to share how we take smart risks in science to create meaningful, faster solutions for patients. Learn how Astellas forges #partnerships that help propel its strategic focus areas forward.
-
Astellas Pharma US
@AstellasUS
We’re proud to share an update on our third global regulatory filing in #gastriccancer: the European Medicines Agency accepted a marketing authorization application for our first-in-class investigational Claudin 18.2-targeted antibody.
-
Astellas Pharma US
@AstellasUS
For the fourth year in a row, Astellas earned the top score on the Disability Equality Index, remaining a #bestplacetowork for #disabilityinclusion by @DisabilityIN and @AAPD. #dei23
-
Astellas Pharma US
@AstellasUS
FDA News: A new Biologics License Application was accepted for Priority Review by the FDA today for our investigational therapy in Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic #gastriccancer or gastroesophageal junction adenocarcinoma.
-
Astellas Pharma US
@AstellasUS
“Hearing a patient at a conference talking about her experience of a clinical trial inspired me to think about how we can be better at understanding and acting on what matters to patients.” shared Chief Strategy Officer Adam Pearson. #patientcentricitymonth2023 #patientsarewhy
-
Astellas Pharma US
@AstellasUS
As we continue to pursue regulatory approval in other countries and regions, today, we are excited to announce Phase 3b topline results from our investigational study. #menopause #womenshealth
-
Astellas Pharma US
@AstellasUS
Last weekend, employees and families rode in our Astellas float at the Chicago Pride parade in celebration of #pridemonth. Check out our commitment to the LGBTQ+ community along with other biopharmas in PhRMA’s blog post here.
-
Astellas Pharma US
@AstellasUS
SVP, Primary Focus Lead #immunooncology, Peter Sandor spoke with @PharmaBoardroom on how innovative approaches, platforms and partnerships are helping advance new potential IO therapies for patients in need. Read on below. #sciencefirstforpatients #changingtomorrow
-
Astellas Pharma US
@AstellasUS
At #asco23, our US President Mark Reisenauer reflected on the need to balance patient access and affordability with an environment that encourages innovation. His thoughts are captured in this new @PhRMA video: www.youtube.com/watch?v=qeXVtSmNvJQ
-
Astellas Pharma US
@AstellasUS
Last week in DC, several of our team members had the opportunity to meet with Members of Congress and staff to discuss how they are working every day to help bring new medicines to patients in areas of unmet medical need. We appreciate the time invested by all at #phrmaflyin23
-
Astellas Pharma US
@AstellasUS
Patients with relapsed or refractory (R/R) acute myeloid leukemia (#aml) can test positive for FMS-like tyrosine kinase 3 (FLT3) mutations. R/R AML occurs when the disease comes back after improvement or does not improve after previous treatment.
-
Astellas Pharma US
@AstellasUS
As #eha2023 comes to a close, we are grateful to the #oncology and #hematology communities for your continued commitment to advancing research and treatment options for patients with acute myeloid leukemia (#aml) and other rare cancers.
-
Astellas Pharma US
@AstellasUS
Happening now at #eha2023, we are presenting primary data from our Phase 3 clinical trial studying post-transplant maintenance therapy for patients with FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) mutation–positive acute myeloid leukemia (#aml).
-
Astellas Pharma US
@AstellasUS
Acute myeloid leukemia (#aml) is an aggressive type of blood cancer that affects more than 20,000 people across the United States each year. AML has been associated with genetic mutations that can develop over time. Learn about the importance of accurate testing for mutations.
-
Astellas Pharma US
@AstellasUS
We are proud to see our newly FDA approved treatment included as a recommended option in The North American Menopause Society 2023 nonhormone therapy position statement. Read more here journals.lww.com/menopausejournal/Abstract/2023/06000/The…
Menopause Journal
@MenopauseJrnl
NAMS Position Statement: The 2023 #nonhormone #therapy position statement of The North American Menopause Society journals.lww.com/menopausejournal/Fulltext/2023/06000/The… @MenopauseOrg @LippincottMed #menopause
-
Astellas Pharma US
@AstellasUS
Today, we are proud to share our latest #gastriccancer update: the submission of a New Drug Application to Japan's Ministry of Health, Labour and Welfare (MHLW) for our investigational first-in-class Claudin 18.2 (CLDN18.2) targeted monoclonal antibody in gastric/GEJ cancer.
-
Astellas Pharma US
@AstellasUS
We are pleased to be sharing data at the #eha2023 Hybrid Congress today for our research of acute myeloid leukemia (#aml), a hard-to-treat cancer.
-
Astellas Pharma US
@AstellasUS
We aim to abolish the stigma and insecurity that exist for people with cancer in the workplace. Join us, as we pledge to end the stigma. #workingwithcancer
-
Astellas Pharma US
@AstellasUS
Attending #eha2023? Check us out at booth C103 as we share about our ongoing research to advance innovation for patients with acute myeloid leukemia (#aml).
-
Astellas Pharma US
@AstellasUS
We are proud to sponsor a symposium at #eha2023, featuring leading international experts who will discuss recent advances in the management of relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML).
-
Astellas Pharma US
@AstellasUS
Acute myeloid leukemia (#aml), one of the most common types of leukemia in adults, has been associated with various genetic mutations. One of the most common mutations is FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD), or FLT3-ITD.
-
Astellas Pharma US
@AstellasUS
#asco23 is coming to an end, but we’re invigorated by all that we’ve seen this year and are inspired to carry the momentum forward as we continue to innovate for people impacted by cancer. Thanks to all who joined us this year – we’re looking forward to all that’s ahead.
-
Astellas Pharma US
@AstellasUS
There’s not a “one size fits all” approach for treating #gastriccancer. See why Dr. Mark Lewis takes a personalized approach with each patient. #asco23
-
Astellas Pharma US
@AstellasUS
This #bladdercancerawarenessmonth, our colleagues supported the @BladderCancerUS Walk to End Bladder Cancer. We were proud to see all who showed up in support of #bladdercancer research, education, and awareness.
-
Astellas Pharma US
@AstellasUS
Today at #asco23, Astellas Oncology colleague Tim Fergus sheds light on the latest #prostatecancer updates being shared at the meeting.
-
Astellas Pharma US
@AstellasUS
On day three of #asco23, we caught up with Astellas Head of Oncology Development, Ahsan Arozullah, to hear more about #bladdercancer research and our work with this patient community.
-
Astellas Pharma US
@AstellasUS
#gastriccancer is the fifth most diagnosed cancer globally, and it’s one in need of new clinical approaches. New and emerging biomarkers, like Claudin 18.2, have the potential to inform clinical decisions and help individualize care. #asco23
-
Astellas Pharma US
@AstellasUS
We’re sharing our latest #gastriccancer research at #asco23 this weekend. Shelley Shaw, a leader of our commercial global GI cancer team, shares how, through this research, partnerships, and more, we’re working to make an impact for people living with gastric and #gej cancer.
-
Astellas Pharma US
@AstellasUS
In a rapid oral session at #asco23 today, investigational data from our Phase 3 trial in advanced gastric/gastroesophageal junction adenocarcinoma will be shared as a follow-up to the Plenary Session Series in March. #gastriccancer
-
Astellas Pharma US
@AstellasUS
The 2023 @ASCO Annual Meeting has officially begun, and our team is onsite connecting with the #oncology community and sharing our latest research.
John Demaree, Head of Global Oncology Marketing, gives us a glimpse into the meeting. -
Astellas Pharma US
@AstellasUS
Together, we can collectively meet the pressing needs of patients. Next week, we will be at #bio23 with @MassBio exploring how we can take collaboration in the Massachusetts #innovation ecosystem and beyond to the next level.
-
Astellas Pharma US
@AstellasUS
Today starts #patientcentricitymonth2023 at Astellas. This year our theme is ‘Inspiring Voices’. We will listen to and learn from our partners about the importance of the whole person’s needs, to make impactful patient-centered decisions. Stay tuned for more. #patientsarewhy
-
Astellas Pharma US
@AstellasUS
This #bladdercancerawarenessmonth, in partnership with @SeagenGlobal, we’re highlighting the #bladdercancer caregiver perspective in our latest #letstalkbladdercancer series. Jackie and Carrie share practical ways in which they have helped their mother, including meal prepping.
-
Astellas Pharma US
@AstellasUS
We’re heading to #asco23, where we’ll share updates from our research in hard-to-treat cancers, including #prostatecancer, #gastriccancer, #aml, and #bladdercancer.
Join us onsite from June 2-6 to learn more about our #oncology portfolio. -
Astellas Pharma US
@AstellasUS
In recognition of #bladdercancerawarenessmonth, in partnership with @SeagenGlobal, we’ve launched a new #letstalkbladdercancer series featuring #bladdercancer caregivers. Carrie and Jackie share their experience and advice for others.
-
Astellas Pharma US
@AstellasUS
Our very own Marci English, Vice President, Head of BioPharma Development speaks to data being presented at the @ACOG Annual Clinical & Scientific Meeting. #womenshealth #acsm2023
-
Astellas Pharma US
@AstellasUS
We are proud to be at this year’s @ACOG Annual Clinical & Scientific Meeting with data on our newly FDA approved treatment for vasomotor symptoms (VMS). #acsm2023
-
Astellas Pharma US
@AstellasUS
Dr. Risa Kagan, OB/GYN, shares her perspective on vasomotor symptoms (VMS), AKA #hotflashes due to #menopause and our recent FDA approval.
-
Astellas Pharma US
@AstellasUS
This weekend, we’ll be attending the @ACOG annual meeting. We’re looking forward to meaningful discussions about our recent product approval. Visit us at booth #2413 for information, skee ball, and more #acsm2023 #womenshealth
-
Astellas Pharma US
@AstellasUS
Up to 80% of women will experience vasomotor symptoms (#vms) during the menopausal transition, AKA #hotflashes and night sweats. Learn more here.
-
Astellas Pharma US
@AstellasUS
Hear from Dr. Neal-Perry as she shares her perspective on the recent FDA approval of our treatment for women experiencing moderate to severe vasomotor symptoms due to #menopause, AKA #hotflashes.
-
Astellas Pharma US
@AstellasUS
We are proud to announce that the US FDA has approved our nonhormonal treatment for moderate to severe vasomotor symptoms (VMS) due to #menopause, also known as #hotflashes and #nightsweats.
-
Astellas Pharma US
@AstellasUS
#breakingnews: Today, the US FDA has approved our nonhormonal treatment for moderate to severe vasomotor symptoms (VMS) due to #menopause, also known as #hotflashes and #nightsweats.
-
Astellas Pharma US
@AstellasUS
LISTEN IN: This podcast episode from @UrologyCareFdn features Dr. Heather Honoré Goltz sharing the challenges one may face as a #bladdercancer caregiver, and her best advice for new caregivers. Click the link below for the full podcast #bladdercancerawarenessmonth:
Urology Care Foundation
@UrologyCareFdn
Listen as Dr. Heather Honoré Goltz talks about her caregiver experience. This podcast is part of the Bladder Cancer Caregivers Podcast series, a series to help provide more understanding and guidance for people impacted by bladder cancer. www.urologyhealth.org/healthy-living/urology-care-podcast…
-
Astellas Pharma US
@AstellasUS
In this podcast episode from the @UrologyCareFdn, Dr. Sima Porten, urologic oncologist, shares her advice for staying informed as you or a loved one navigate a #bladdercancer diagnosis. #bladdercancerawarenessmonth
Urology Care Foundation
@UrologyCareFdn
This podcast is part of the Bladder Cancer Caregivers Podcast series, a series to help provide more understanding and guidance for people impacted by bladder cancer. Listen as @SimaPorten talks about getting more informed. www.urologyhealth.org/healthy-living/urology-care-podcast…
-
Astellas Pharma US
@AstellasUS
Exposure to carcinogens may put firefighters at an increased risk of #bladdercancer. This #bladdercancerawarenessmonth, we’re urging everyone—firefighters and civilians alike—to know the symptoms. #letstalkbladdercancer @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
Despite advancements in the treatment and management of #prostatecancer over the past decade and beyond, continued research in this disease space is vital. We’re working to research new options for men with forms of prostate cancer that have not yet advanced. #aua23
-
Astellas Pharma US
@AstellasUS
New results from our Phase 3 trial in non-metastatic hormone-sensitive #prostatecancer (nmHSPC) with high-risk biochemical recurrence (BCR) are now available. Learn more at #aua23.
-
Astellas Pharma US
@AstellasUS
Recently Medical Affairs Head Shontelle Dodson and VP, Head of Biopharma Development Marci English joined the @Axios Smart Brevity Studio to discuss #womenshealth and our ongoing work to raise awareness of women's unique health needs and the related research efforts. @PhRMA
-
Astellas Pharma US
@AstellasUS
Today is #amlworldawarenessday – a day to join together to raise awareness about acute myeloid leukemia (#aml). We encourage you to learn more about AML, its impacts and the significant unmet needs faced by the AML community. #knowaml
-
Astellas Pharma US
@AstellasUS
We recently hosted a Health Disparities Forum with @DrWinkfield to gain deeper understanding of the gap in health equity for our industry and the broader healthcare ecosystem. Her inspirational words demonstrated the opportunities to help increase accessibility to health for all.
-
Astellas Pharma US
@AstellasUS
It is less than one week out from #amlworldawarenessday. #dyk that #aml has been associated with various genetic mutations? One of the most common is FLT3. Join us as we spotlight the AML community to increase awareness and understanding around this hard-to-treat cancer. #knowaml
-
Astellas Pharma US
@AstellasUS
Today, we’re sharing data from our #gastriccancer research program published in @TheLancet from our trial in Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
-
Astellas Pharma US
@AstellasUS
Check out how partnered with @CSUPharmacy to create an exclusive PharmD biopharma industry rotation program, and see what students like Aundriana are saying about their experience at Astellas. #csucop #pharmd #pharmacystudent
-
Astellas Pharma US
@AstellasUS
Our combination therapy with @SeagenGlobal and Merck has received accelerated approval from the US FDA as a first-line treatment option for cisplatin-ineligible adult patients with locally advanced/metastatic urothelial cancer. #bladdercancer
-
Astellas Pharma US
@AstellasUS
Our Senior Vice President of Market Access and Commercial Capabilities Lei Ding joined other healthcare ecosystem leaders to discuss solutions to improve patient access and affordability. Learn more about @TheHillEvents discussion here. #thehillhealth
-
Astellas Pharma US
@AstellasUS
Congrats to Judy Kannenberg, Vice President of Regulatory Affairs Therapeutic Area Head of Medical Specialties, on her recognition as a @HBAnet 2023 Luminary! #hbawoty23 #hbaimpact
-
Astellas Pharma US
@AstellasUS
We’re thrilled to share detailed results from our second Phase 3 trial in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Astellas Pharma US
@AstellasUS
Join today’s ASCO Plenary Series Session to hear the full presentation from Manish Shah, M.D., Weill Cornell Medicine: old-prod.asco.org/meetings-education/monthly-plenary-seri…
-
Astellas Pharma US
@AstellasUS
Today with @Pfizer_News, we announced the latest update in our #prostatecancer research: positive top-line results from our Phase 3 trial in non-metastatic hormone-sensitive #prostatecancer (nmHSPC).
-
Astellas Pharma US
@AstellasUS
Next week, we’re sharing our latest #gastriccancer data as part of the March ASCO Plenary Series Session. Tune in on March 22 to learn more about our research.
-
Astellas Pharma US
@AstellasUS
ICYMI: @TheLancet has published pivotal Phase 3 data of our investigational treatment for vasomotor symptoms (VMS) associated with #menopause, also known as hot flashes and night sweats. Learn about these findings for #womenshealth.
-
Astellas Pharma US
@AstellasUS
We’re proud to share that @TheLancet published pivotal Phase 3 clinical trial results of our investigational treatment for vasomotor symptoms (VMS) associated with #menopause (hot flashes/ night sweats). At Astellas, we're committed to supporting #womenshealth in midlife.
-
Astellas Pharma US
@AstellasUS
We’re proud to join in sharing our colors to raise awareness this #rarediseaseday. Thank you to Astellas’ partners in the rare disease space for supporting us in our mission to develop life-changing therapies for those in need.
-
Astellas Pharma US
@AstellasUS
Astellas stands w/ the rare disease community today & every day w/ our unwavering commitment to developing therapies & resources w/ the potential to make meaningful differences in people’s lives, & the lives of their families/caregivers. Hear more from our team this #rdd2023.
-
Astellas Pharma US
@AstellasUS
*For U.S. Healthcare Professionals Only*
Today we announced an update on preliminary safety & efficacy data from our FORTIS study of AT845 in adults with late-onset #pompe disease at the 19th Annual @WORLDSymposia. #worldsymposium -
Astellas Pharma US
@AstellasUS
What does this year hold for deal-making in #pharma? Our Head of Search & Evaluation, Business Development, Mike Luther, spoke with @INVIVOnow outlining his vision for 2023 and how Astellas is setting itself apart.
-
Astellas Pharma US
@AstellasUS
Tune in to our sponsored segment on @PostLive around #menopause – specifically hot flashes and night sweats, also known as #vasomotorsymptoms, or VMS featuring Dr. Shayna Mancuso, board-certified OB/GYN & Medical Director, US Medical Affairs, Astellas. #postlive
-
Astellas Pharma US
@AstellasUS
Attending #gu23 in San Francisco? Come see us at booths #28 and #32, where we’re sharing more about our ongoing research in GU cancers, like advanced #prostatecancer and metastatic #bladdercancer.
-
Astellas Pharma US
@AstellasUS
Say it with us: #menopause. We’re on a mission to break down barriers and encourage conversations about vasomotor symptoms (#vms), aka #hotflashes and night sweats due to menopause. Don’t sweat it, embrace the dialogue – like we did during the Big Game. ICYMI, watch our full ad.
-
Astellas Pharma US
@AstellasUS
The players won’t be the only ones feeling the heat during the Big Game this Sunday. Get ready as we tackle an important stage in women’s midlife health and talk #hotflashes. #whatsvms
-
Astellas Pharma US
@AstellasUS
Our US President Mark Reisenauer joins @PhRMA’s @steveubl to highlight solutions state policymakers can take to meaningfully lower costs for patients while fostering future biopharmaceutical innovation.
-
Astellas Pharma US
@AstellasUS
Dr Frank Sloan, a #bladdercancer survivor, shares his perspective on the importance of self-care and support following diagnosis and his experience of treatment and recovery. Listen to the full podcast episode from the @UrologyCareFdn:
-
Astellas Pharma US
@AstellasUS
Collaborations are key in defining new ways to treat and potentially cure some of the most challenging diseases. SVP, Head of Business Development, Issei Tsukamoto spoke with @fwpharma on our business development strategy and new innovation partnerships.
-
Astellas Pharma US
@AstellasUS
The evolving field of #genetherapy cannot be navigated alone. Our SVP, Primary Focus Lead for Genetic Regulation, Richard Wilson, shares insights with @medcitynews on partnerships helping to transform novel gene therapies into VALUE for patients.
-
Astellas Pharma US
@AstellasUS
This year at #gi23, we shared our latest data in advanced #gastriccancer and GEJ cancer and learned more about new research in the works. Hear more from our colleagues who were onsite.
This media couldn't be displayed. See it on the original post. -
Astellas Pharma US
@AstellasUS
A #gastriccancer diagnosis can look different depending on if you are a physician, patient, or caregiver, and we’re on a mission to understand the disease from all angles. #gi23
-
Astellas Pharma US
@AstellasUS
We’re exploring a potential approach in advanced #gastriccancer. See the latest results in Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, shared this week at #gi23.
-
Astellas Pharma US
@AstellasUS
Announced today at #gi23: data from our Phase 3 trial in Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
-
Astellas Pharma US
@AstellasUS
We’ve arrived in San Francisco for #gi23 and are looking forward to the next three days of connecting with the gastrointestinal cancer community. Stop by booth #22 to learn more about our latest research in this space!
-
Astellas Pharma US
@AstellasUS
More than ever, #partnership must help expedite innovation in pharma, translating scientific advances into patient benefits. Our leaders share their perspectives with @endpts on how partnering approaches can meet the challenges of an evolving industry: endpoints.news/sp/a-new-era-of-collaboration-promises-to-…
-
Astellas Pharma US
@AstellasUS
Through open collaboration and #innovation, we are working with ambitious partners to meet the pressing needs of patients, faster.
This week, we are at #biotechshowcase exploring the future of #partnering in pharma. -
Astellas Pharma US
@AstellasUS
What does the future hold for pharma partnering? SVP and Head of Business Development, Issei Tsukamoto, shares his reflections with @PharmExec and identifies five essential principles to stand out in today’s competitive #partnering landscape.
-
Astellas Pharma US
@AstellasUS
With growing recognition that partnerships are vital to accelerate our innovation, SVP, Primary Focus Lead Immuno-oncology, Peter Sandor shared his thoughts with @_CellandGene on how to advance a new era of cancer cell therapies. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Along with our brand new @AstellasGeneTx manufacturing facility in North Carolina, Astellas is proud to have opened several other global offices around the world in 2022. #astellasglobal
-
Astellas Pharma US
@AstellasUS
Astellas’ hybrid workstyle unlocks a world of opportunity. Recently our US President Mark Reisenauer shared with @CrainsChicago how our approach to long-term flexibility empowers us to define effective ways of working – and keep adapting them as we evolve.
-
Astellas Pharma US
@AstellasUS
We’re pleased to announce with @SeagenGlobal and Merck that the US FDA has accepted for review supplemental Biologics License Applications for locally advanced/metastatic urothelial cancer. #bladdercancer
-
Astellas Pharma US
@AstellasUS
This week, we announced positive topline results from our second Phase 3 trial in advanced #gastriccancer. Learn more about our commitment to investigating Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma.
-
Astellas Pharma US
@AstellasUS
Today, we’re proud to announce another milestone in our #gastriccancer development program: topline results from our second Phase 3 trial in Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
-
Astellas Pharma US
@AstellasUS
As #ash22 comes to an end, we thank the #hematology and #oncology communities for your continued dedication to advancing research and elevating care for patients with rare cancers, like acute myeloid leukemia (#aml). See you next year!
-
Astellas Pharma US
@AstellasUS
Happening now at #ash22: We’re presenting data on real-world treatment patterns and outcomes in patients with FMS-like tyrosine kinase 3 (FLT3) mutation-positive (FLT3+) R/R #aml and real-world outcomes in AML patients following stem-cell transplantation maintenance treatment.
-
Astellas Pharma US
@AstellasUS
We’re excited to be at #ash22, sharing data on treatment options for FLT3 mutation-positive relapsed/refractory (R/R) acute myeloid leukemia (#aml). To learn more, you can view our abstract publications.
-
Astellas Pharma US
@AstellasUS
At Astellas, we are committed to making meaningful scientific advancements and creating value for patients with hard-to-treat cancers, like acute myeloid leukemia (#aml). See the data being shared at #ash22 that features our research on AML.
-
Astellas Pharma US
@AstellasUS
#healthbehavior has a huge impact on outcomes – but do we really understand what makes people act the way they do? The Astellas’ Behavioral Science Consortium and Patient Partnerships team aim to find out. #patientcentricty
-
Astellas Pharma US
@AstellasUS
As the pharma industry rethinks clinical trial approaches, Marie Rosenfeld, SVP, Head of Clinical Science shares her thoughts with @ClinicalLeader1 about what Astellas has learned so far: www.clinicalleader.com/doc/what-astellas-has-learned-abou….
#changingtomorrow #sciencefirstforpatients -
Astellas Pharma US
@AstellasUS
Throughout November, we asked our colleagues to share their “Mo’Moments,” or moments that resonate or connect them to #prostatecancer, and how these moments inspire their work at Astellas. See what they had to say. #movember
-
Astellas Pharma US
@AstellasUS
People’s health outcomes are determined by many factors beyond the medicines and treatments they take. Discover how Astellas is supporting patient-focused medicines development. #patientcentricity
-
Astellas Pharma US
@AstellasUS
We are thrilled to announce the positive topline results from our Phase 3 trial in Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
-
Astellas Pharma US
@AstellasUS
We’re pleased to announce our own Lori Magnoni has been named a 2022 Working for Cures Employee Champion by @PhRMA in recognition of her work in driving enthusiasm for voluntary employee engagement campaigns and promoting the value our industry delivers to patients.
-
Astellas Pharma US
@AstellasUS
Today, we are pleased to share topline results from our Phase 3 trial of an investigational medicine as first-line treatment for Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
-
Astellas Pharma US
@AstellasUS
In our latest #letstalkbladdercancer video series, Dr. Ashish Kamat tackles important questions #bladdercancer patients may have, such as, will bladder cancer affect my sex life? @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
The Astellas Behavioral Science Consortium and Patient Partnerships listen, learn and collaborate with patients to understand the cultural, social, and environmental factors that influence #healthbehavior and outcomes. Read more here. #patientcentricity
-
Astellas Pharma US
@AstellasUS
Through our #letstalkbladdercancer campaign, hear from healthcare professionals and people in the #bladdercancer community as they share insights and answers to tough bladder cancer questions. @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
Learning to cope with the challenges of advanced #bladdercancer is not easy. In the latest #letstalkbladdercancer video series, Dr. Arlene Siefker-Radtke shares a few words of advice. @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
A shared culture of quality is a critical enabler of accelerating innovation. Our Head of Quality Assurance, David Fryrear, shares his thoughts with
@PharmExec.
#changingtomorrow #sciencefirstforpatients -
Astellas Pharma US
@AstellasUS
It’s normal to have a lot of questions following a #bladdercancer diagnosis. Get answers to your difficult questions and advice on how to feel comfortable discussing your condition by checking out our
#letstalkbladdercancer YouTube channel. @SeagenGlobal -
Astellas Pharma US
@AstellasUS
Physicians like Dr. Arlene Seifker-Ratdke highlight the importance of having an open dialogue with your doctor when it comes to advanced #bladdercancer. Check out the latest #letstalkbladdercancer videos to learn more. @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
There are many ways for people living with #bladdercancer to better understand and manage life with an ostomy. Check out @HealthyWomen for helpful resources to support you through your journey, including a new video highlighting ostomy basics like caring for your stoma.
-
Astellas Pharma US
@AstellasUS
If you or a loved one have recently been diagnosed with #bladdercancer, you may need to prepare for certain lifestyle adjustments. Hear from real patients about how bladder cancer has impacted their daily lives on our #letstalkbladdercancer YouTube channel. @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
Entries to the Astellas Future Innovator Prize 2022 competition close on Nov. 4. The winner will gain one year’s lab access and equipment at @MBC BioLabs and access to Astellas’ R&D scientists, mentors, business leaders and network. #incubator #biotechstartup #entrepreneurs
-
Astellas Pharma US
@AstellasUS
Astellas is proud to support seven Employee Impact Groups available to all employees, that foster creativity, inclusiveness, and diversity. #globaldiversityawarenessmonth
-
Astellas Pharma US
@AstellasUS
Listening to patients and care partners helps shape medicines that tackle unmet need. Read how the Behavioral Science Consortium and Patient Partnerships team are changing insights into action here. #patientcentricity
-
Astellas Pharma US
@AstellasUS
Dr. @marklewismd speaks to the role of emerging biomarkers – such as CLDN18.2 and FGFR2b – in shedding light on tumor profiles and informing approaches in #gastriccancer.
-
Astellas Pharma US
@AstellasUS
Did you know that vasomotor symptoms (VMS) associated with menopause can impact sleep, mood, work and relationships? Take a pause and get the facts about VMS also known as hot flashes. #worldmenopauseday #womenshealth
-
Astellas Pharma US
@AstellasUS
Today is #worldmenopauseday and as a proud supporter of @IntlMenopause, we join them in raising awareness about #menopause, #vasomotorsymptoms (VMS) associated with menopause, and advancing midlife womens health. #wmd2022
-
Astellas Pharma US
@AstellasUS
Tomorrow is #worldmenopauseday and in recognition, we invite you to take a pause and get the facts about #vasomotorsymptoms (VMS) associated with menopause - commonly known as hot flashes and night sweats. #wmd2022 #womenshealth
-
Astellas Pharma US
@AstellasUS
Hear from Astellas’ very own Dr. Shayna Mancuso, Medical Director, US Medical Affairs, on the ground at this year’s #nams2022 #namsmtg #vasomotorsymptoms
-
Astellas Pharma US
@AstellasUS
It’s time to ignite conversation & draw a greater focus to women’s health & well-being during the menopausal transition, & work to address the unmet needs of people experiencing #vasomotorsymptoms AKA #hotflashes. Learn more. #nams2022 #namsmtg
-
Astellas Pharma US
@AstellasUS
We’re excited to be at #nams2022 today, presenting data on #vasomotorsymptoms associated with menopause (VMS), also known as #hotflashes and night sweats. Learn more. #namsmtg
-
Astellas Pharma US
@AstellasUS
We’re proud to join @MenopauseOrg this week at #nams2022 as a premier sponsor and have 7 abstracts accepted (2 oral presentations and 5 posters) on #vasomotorsymptoms (VMS) associated with #menopause. Learn more. #namsmtg
-
Astellas Pharma US
@AstellasUS
Receiving a #bladdercancer diagnosis can be overwhelming and lead to a lot of questions. In partnership with @SeagenGlobal, we’re providing resources for the bladder cancer community. Learn more in this #letstalkbladdercancer article:
-
Astellas Pharma US
@AstellasUS
Research and clinical trials are innovative avenues needed to advance the #gastriccancer treatment landscape. Dr. @marklewismd shares his expert insights on the importance of evolving care to prioritize individualized treatments.
-
Astellas Pharma US
@AstellasUS
Up to 80% of women will experience #vasomotorsymptoms (VMS), AKA hot flashes, during the #menopause transition. This October is #worldmenopausemonth and we are raising awareness of VMS and its impact on midlife #womenshealth.
-
Astellas Pharma US
@AstellasUS
Thanks to all who joined us and @endpts last week as we shared lessons from our decade-long journey to build an oncology powerhouse from the ground up.
Missed it? Watch on-demand at webinars.endpoints.news. -
Astellas Pharma US
@AstellasUS
We were honored to welcome California policymakers to our research affiliate Universal Cells last week. While there, legislators toured the facility and learned about our efforts to advance cell therapies for diseases with few or no treatment options. @CABiotech @PhRMA @biocom
-
Astellas Pharma US
@AstellasUS
Throughout #prostatecancerawarenessmonth, our colleagues across the country have been joining the prostate cancer community for the @ZEROCancer Run/Walk events to help support prostate cancer awareness and education. See some of the highlights!
-
Astellas Pharma US
@AstellasUS
For Dr. @marklewismd, the fight against #gastriccancer is a personal one. His own experience with a cancer diagnosis now inspires his research and his passion for treating patients with the disease.
-
Astellas Pharma US
@AstellasUS
The Astellas Future Innovator Prize 2022 is now open! Apply today to accelerate your biotech innovation with Astellas in @MBiolabs state-of-the-art #incubator.
-
Astellas Pharma US
@AstellasUS
In the US, #prostatecancer is the most frequently diagnosed cancer among men, aside from skin cancer. Being informed on the different types of advanced disease is an important step in fighting it. #prostatecancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
We’re thrilled to announce our 2022 Working Parents of the Year, Angelica Medley and Brad Mickey. Learn how they manage their work-life balance while leading successful careers. #seramount100best #seramountbestfordad
-
Astellas Pharma US
@AstellasUS
We’re proud to be named eight years in a row as a 100 Best Company and four years in a row as a Best Company for Dads by @seramount. #seramount100best
-
Astellas Pharma US
@AstellasUS
What do you know about acute myeloid leukemia (#aml)? This #bloodcancerawarenessmonth, learn about relapsed/refractory AML and how to be prepared for the journey ahead, from understanding the importance of genetic testing to learning about FLT3 mutations.
-
Astellas Pharma US
@AstellasUS
#bloodcancerawarenessmonth is a time to join together to raise awareness of acute myeloid leukemia (#aml). AML symptoms can be non-specific, so staying informed and knowing what to look out for can lead to early diagnosis and potentially improve outcomes.
-
Astellas Pharma US
@AstellasUS
Join us @MassBio Partnering Week where we’ll be discussing how we drive innovation through partnerships to transform the lives of patients. Meet our senior leaders and find out more about partnering with Astellas. Register at www.massbio.org/innovation-services/partneringweek2022/. #massbiopartneringweek
-
Astellas Pharma US
@AstellasUS
Our Global Head of Patient Centricity Anthony Yanni recently spoke with @cure_today about the Astellas Oncology #c3prize and its impact in the cancer community since it started in 2016.
-
Astellas Pharma US
@AstellasUS
During #esmo22 and beyond, we’re working to shed light on the complex landscape of gastric and GEJ cancers. Hear from experts and get educational resources on our #gastriccancer website.
-
Astellas Pharma US
@AstellasUS
Let’s face it, it can be uncomfortable to talk about #bladdercancer. Through #letstalkbladdercancer, hear from people like John as they share their personal experiences with bladder cancer in hopes of making the journey a little easier for others. @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
Along with @SeagenGlobal and Merck we’re proud to announce clinical trial results in first-line locally advanced/metastatic urothelial cancer that will be presented as late-breaking data at #esmo22. Learn about the significance of these findings for the #bladdercancer community:
-
Astellas Pharma US
@AstellasUS
Gastric cancer is the fifth most diagnosed cancer globally, and outcomes are typically poor. There’s a need for more treatment options, and biomarkers can play a role in advancing personalized care for patients with gastric cancer. #esmo22
-
Astellas Pharma US
@AstellasUS
For over 10 years, we’ve been exploring science to fight advanced #prostatecancer. See the posters being shared at #esmo22 that feature our research updates in this space:
-
Astellas Pharma US
@AstellasUS
Addressing disparities in #prostatecancer requires strong voices, like @RAPCancer. See how they’re rallying the prostate cancer community through educational summits, all #prostatecancerawarenessmonth long.
-
Astellas Pharma US
@AstellasUS
Even though #bladdercancer is the fourth most common cancer in men in the U.S., awareness and education around this disease is limited. We’re partnering with @SeagenGlobal to change that through our educational campaign #letstalkbladdercancer.
-
Astellas Pharma US
@AstellasUS
Astellas is proud to be ranked #5 for the first time on the @GPTW_US 2022 Best Workplaces in BioPharma™! #bestworkplaces #gptwcertified
-
Astellas Pharma US
@AstellasUS
What does it take to deliver next generation #cancer therapies and build a leadership position from the ground up?
Join us and @endpts as we discuss all things strategy, innovation, culture and partnerships. #sciencefirstforpatients -
Astellas Pharma US
@AstellasUS
September is designated as #bloodcancerawarenessmonth to support the patients and their loved ones affected by #leukemia, #lymphomas, and #myeloma. See how we’re committed to changing the course of cancer treatment.
-
Astellas Pharma US
@AstellasUS
On #worldleukemiaday, we recognize those impacted by acute myeloid leukemia (#aml). Approximately one-third of newly diagnosed AML patients may have a FLT3 mutation. Learn about the importance of genetic testing for AML. #beleukemiaaware
-
Astellas Pharma US
@AstellasUS
Join #astellasoncology this September in bringing awareness to #prostatecancer and showing support for everyone affected by this disease. #prostatecancerawareness
-
Astellas Pharma US
@AstellasUS
September is #bloodcancerawarenessmonth, and Astellas is committed to raising awareness about the challenges of those affected by acute myeloid leukemia (#aml) and the importance of genetic testing for actionable mutations like FLT3.
-
Astellas Pharma US
@AstellasUS
Our President & CEO Kenji Yasukawa, Ph.D., shares his perspectives with @Business on how the company is moving toward achieving the goals set forth in the Corporate Strategic Plan 2021 and the progress toward launching several new therapies.
www.bloomberg.com/news/articles/2022-08-22/astellas-to-se… -
Astellas Pharma US
@AstellasUS
SVP, Primary Focus Lead Immuno-oncology, Peter Sandor speaks to @fwpharma, exploring how partnerships with a shared commitment to creating the right environment for innovation to flourish are some of the most powerful. Learn more firstwordpharma.com/story/5641113 #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Today, the US FDA accepted for review our New Drug Application (NDA) for our investigational treatment for moderate to severe vasomotor symptoms (VMS) associated with #menopause, also known as #hotflashes and/or #nightsweats.
-
Astellas Pharma US
@AstellasUS
Astellas Oncology is thrilled to announce the Astellas #c3prize Grand Prize winner, Aimee DeGolyer, @REPROSENT1, whose idea can meaningfully impact the lives of people with cancer and their loved ones. Learn more about the C3 Prize Grand Prize Winner.
@MATTERHealth @slalom -
Astellas Pharma US
@AstellasUS
How can pharma evolve its approach to decentralized #clinicaltrials to give patients more choices? Our Head of Clinical Sciences Marie Rosenfeld shares her views with @medcitynews medcitynews.com/2022/08/digital-transformation-reimaginin…. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Today we announced topline results from a phase 1b/2 trial investigating first-line treatment for patients with locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy. Click below to learn more.
-
Astellas Pharma US
@AstellasUS
We will be establishing a new #innovation center for #research and development in South San Francisco. More information on our plans is available here. #agt #xyphos #genetherapy #celltherapy #bayarea
-
Astellas Pharma US
@AstellasUS
Astellas is honored to be included in the Disability Equality Index and earn the top score as a #bestplacetowork for #disabilityinclusion by @DisabilityIN and @AAPD. #dei22
-
Astellas Pharma US
@AstellasUS
Our US President Mark Reisenauer recently joined @PhRMA Senior Vice President of State Advocacy Scott LaGanga for a discussion on the role of state policies in supporting patient access to innovative medicines.
-
Astellas Pharma US
@AstellasUS
We are excited to announce the three finalists of Astellas #c3prize. Join Astellas Oncology and the global cancer community as we await the results of the pitch event and name the Grand Prize Winner that will have a chance to #changecancercare.
@Slalom @MATTERhealth -
Astellas Pharma US
@AstellasUS
Next week, we announce the finalists of the 6th annual #c3prize, a global challenge to fund the best ideas in cancer care beyond medicine. @slalom @MATTERhealth
-
Astellas Pharma US
@AstellasUS
#dyk that women who smoke have a higher chance of developing #bladdercancer? Learn more about bladder cancer from @HealthyWomen
-
Astellas Pharma US
@AstellasUS
Thank you #c3prize applicants! We share in your passion and commitment to the cancer community. The semi-finalists and Grand Prize winner announcements are coming soon. @MATTERhealth @slalom
-
Astellas Pharma US
@AstellasUS
We’re proud to partner with @SeagenGlobal and @HealthyWomen to highlight the gap in care people of color living with #bladdercancer face.
-
Astellas Pharma US
@AstellasUS
What are the key challenges standing in the way of decentralized trials and how can pharma overcome them?
Our Head of Clinical Sciences Marie Rosenfeld shares her views with @EMG_GOLD www.emjreviews.com/emj-gold/article/overcoming-decentrali…. #sciencefirstforpatients -
Astellas Pharma US
@AstellasUS
During #pridemonth our global leaders share what it means to be part of an organization that embraces #dei which shapes our culture. See how our Head of Medical Affairs Shontelle Dodson supports the LGBTQ+ community as an ally. #astellasglobal
-
Astellas Pharma US
@AstellasUS
Last week, members of our research and govt. affairs teams had an opportunity to share with federal legislators our efforts to advance science in areas of women’s health, oncology, and cell & gene therapy. Thanks to @PhRMA & @alliancerm for convening these events #phrmaflyin22
-
Astellas Pharma US
@AstellasUS
We’re honored to be #10 on the @GPTW_US Best Workplaces in Chicago™ 2022! This isn't possible without our amazing team! Learn more about this achievement. #bestworkplaces #gptwcertified
-
Astellas Pharma US
@AstellasUS
As #endo2022 comes to a close, we’d like to take a moment to thank the @TheEndoSociety for bringing experts together to discuss advances in midlife #womenshealth.
-
Astellas Pharma US
@AstellasUS
We are grateful to have been a part of #eha2022! Thank you to the #hematology and #oncology communities for your continued commitment to advancing research and treatment options for patients in need.
-
Astellas Pharma US
@AstellasUS
Happening now at #eha2022: We’re presenting data on changes in FLT3 gene mutations during disease progression in patients with acute myeloid leukemia (#aml). Learn more about our latest research: www.astellas.com/en/news/25816
-
Astellas Pharma US
@AstellasUS
We’re pleased to be at #endo2022 today, where we’ll be presenting data on vasomotor symptoms associated with menopause (VMS), also known as #hotflashes and/or #nightsweats. Learn more.
-
Astellas Pharma US
@AstellasUS
We look forward to joining @TheEndoSociety for #endo2022, where we’ll be meeting endocrine professionals from across the country to learn more about new research in midlife women’s health.
-
Astellas Pharma US
@AstellasUS
Today at #eha2022, we’re sharing data from our Phase 3 COMMODORE trial in adult patients with relapsed or refractory (R/R) FLT3 mutation-positive acute myeloid leukemia (#aml). Learn more about these findings: www.astellas.com/en/news/25816
-
Astellas Pharma US
@AstellasUS
Learn more from @AstellasGeneTx about our new state-of-the-art manufacturing facility opening in Sanford, NC that will support the creation of 200 jobs through 2026.
-
Astellas Pharma US
@AstellasUS
We are looking forward to joining the #hematology and #oncology communities at the #eha2022 Hybrid Congress where we will be sharing data in relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (#aml).
-
Astellas Pharma US
@AstellasUS
As we wrap up #asco22, we’re reflecting on the importance of this in-person time with the oncology community. We’re excited about the updates shared this year and look forward to driving innovation forward for people impacted by cancer.
-
Astellas Pharma US
@AstellasUS
During #asco22, we’ve had the privilege of learning new insights and information from the #oncology community on hard-to-treat cancers like acute myeloid leukemia (#aml), where we strive to make a positive impact.
-
Astellas Pharma US
@AstellasUS
Our passion for people and our innovative science drive us forward in our mission to change lives of those impacted by cancer. #asco22
-
Astellas Pharma US
@AstellasUS
We’ve been exploring therapeutic approaches in advanced #prostatecancer for more than a decade, and there’s still work to be done for those impacted for this disease. Liz Dalton shares an update from #asco22.
-
Astellas Pharma US
@AstellasUS
Pancreatic cancer is a disease expected to be diagnosed in an estimated 62K people in the US this year alone. We’re investigating new approaches for people impacted by this disease and are proud to share an update at #asco22.
-
Astellas Pharma US
@AstellasUS
That’s a wrap on the first day of #asco22. We’re thrilled to have colleagues back onsite alongside the #oncology community. If you’re onsite, come see us at booth #10135.
-
Astellas Pharma US
@AstellasUS
The gastric cancer landscape is complex, and there is still so much to learn. Explore different perspectives on treatment, life with gastric cancer, supporting loved ones, and more on the Astellas Newsroom.
-
Astellas Pharma US
@AstellasUS
Through our innovative science, we’re working to create value for patients and families impacted by cancer. At #asco22, we’re sharing updates from our oncology portfolio that are helping us make progress toward this goal.
-
Astellas Pharma US
@AstellasUS
Throughout #pridemonth we’re sharing thoughts from our global leaders on what it means to be part of an organization that embraces diversity, equity and inclusion and how it shapes our culture. Read more about our focus on inclusion. #astellasglobal #dei
-
Astellas Pharma US
@AstellasUS
Despite recent advances in gastric cancer, there is still progress to be made – including exploring the potential impact of biomarkers like Claudin 18.2. Dive deeper and explore the established and emerging biomarker landscape for this disease.
-
Astellas Pharma US
@AstellasUS
Our Medical Affairs Head Shontelle Dodson recently presented the @SWHR Health Visionary Award to @Pfizer for their work to co-develop a safe & effective COVID19 vaccine. We were thrilled to sponsor an evening celebrating achievements and innovations in women’s health.
SWHR
@SWHR
Thank you to all who supported this year's SWHR 2022 Annual Awards Gala! We are so grateful for your ongoing work to help us make #womenshealth mainstream. See a recap from the evening at the tag #swhrgala and here: myemail.constantcontact.com/subject.html?soid=11267576907…
-
Astellas Pharma US
@AstellasUS
As #bladdercancerawarenessmonth comes to a close, we’re working with our partners at @SeagenGlobal to keep the conversation going year-round. Tune in as we highlight expert answers to tough #bladdercancer questions on the #letstalkbladdercancer YouTube page.
-
Astellas Pharma US
@AstellasUS
Only 5 days left to apply for the #c3prize! Don’t miss your chance to apply for grants and additional resources to help advance your idea to #changecancercare.
-
Astellas Pharma US
@AstellasUS
In just one week at #asco22, we’ll share an overview of our research in pancreatic cancer, a disease that will be newly diagnosed in an estimated 62K+ people in the US this year.
-
Astellas Pharma US
@AstellasUS
Personalized medicines could transform the way we treat diseases. Our Head of Regulatory Affairs Stef Schutte shares how he is working to translate that potential into value for patients. Read on to learn more. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Thank you to everyone who participated in the @BladderCancerUS Walk to End Bladder Cancer! We were proud to walk alongside the patients, caregivers, families and advocates who make up the #bladdercancer community. #bladdercancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
Finding honest answers to the tough questions after a #bladdercancer diagnosis can be difficult. Hearing from others who have been through it can help. #bladdercancerawarenessmonth #letstalkbladdercancer @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
A growing body of evidence points to the role a population of neurons in the hypothalamus may play in mediating vasomotor symptoms associated with menopause (VMS). Check out a newly released White Paper to learn more.
-
Astellas Pharma US
@AstellasUS
We’re working with the cancer community to find and accelerate the cures of tomorrow. Our Primary Focus Lead Immuno-oncology, Peter Sandor, shares how collaboration and new ways of working are driving progress for patients. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
We’re relentless in our pursuit of scientific knowledge and progress. In a new White Paper @risakmd, @DrGRichardDavi1, @Ektasinghkapoor, Pauline Maki and Richard Payne, MD explore emerging science on the cause of vasomotor symptoms associated with menopause (VMS). Learn more.
-
Astellas Pharma US
@AstellasUS
On our radar: #asco22 and #eha22. Get a sneak peek at the 13 combined abstracts from our robust oncology pipeline that will be presented at the meetings.
-
Astellas Pharma US
@AstellasUS
Astellas Oncology thanks oncology nurses for the work they do for patients with cancer. Learn more about our gratitude and oncology commitment ssshare.it/VjJZ
#internationalnursesday #astellasoncology #changingthecourse #thankyounurses -
Astellas Pharma US
@AstellasUS
We were excited to participate in @PhRMA’s CA Researcher Fly-In. Dr. Gary Starling, a scientist at our research affiliate Xyphos, met with state legislators to discuss the work his team is doing to produce innovative cell therapies for patients with cancer.
-
Astellas Pharma US
@AstellasUS
As #acog2022 comes to an end, we’d like to thank those who participated in this year's event for your continued work to advance #menopause education and research.
-
Astellas Pharma US
@AstellasUS
A #hotflash typically lasts between 1 and 5 minutes, and may be accompanied by sweating, chills, anxiety and heart palpitations. Visit us at booth 1729 to “feel the heat” and learn more. #acog2022
-
Astellas Pharma US
@AstellasUS
We are excited to participate in #acog2022 and help contribute to deepening the understanding of vasomotor symptoms associated with #menopause (#vms), also known as #hotflashes and/or #nightsweats. Visit us at booth 1729 to “feel the heat” and learn more.
-
Astellas Pharma US
@AstellasUS
At #acog2022, we are pleased to announce the presentation of 12-week data from our Phase 3 clinical trial investigating treatment for moderate to severe vasomotor symptoms associated with menopause (VMS), also known as #hotflashes and/or #nightsweats. Learn more.
-
Astellas Pharma US
@AstellasUS
Learn more and apply today for the #c3prize, awarding a total of $100,000 in grants and additional resources to ideas that tackle everyday challenges facing people impacted by cancer. Don’t miss your chance to #changecancercare!
-
Astellas Pharma US
@AstellasUS
Read how Astellas Oncology is changing the course of cancer care by embracing bold thinking and challenging ourselves in new ways from SVP Steve Sabus.
-
Astellas Pharma US
@AstellasUS
Even though it’s considered a rare cancer, esophageal cancer is a disease impacting tens of thousands of people in the US. New research and innovative approaches are essential for those impacted by this disease. #esophagealcancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
Tough questions. Expert answers. Healthy dialogue. Get answers to your difficult #bladdercancer questions by checking out Let’s Talk Bladder Cancer. #letstalkbladdercancer @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
Regulatory reform is ongoing globally and we have a unique opportunity to assess how we can deliver even greater value for patients. Our Head of Regulatory Affairs Stef Schutte shares his thoughts with @PharmExec. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Today we announced the call for entries for the 6th annual #c3prize, a global challenge that funds the best ideas in cancer care beyond medicine.
-
Astellas Pharma US
@AstellasUS
Click the link below to hear from healthcare professionals and people in the #bladdercancer community as they share insights and answers to tough bladder cancer questions. #letstalkbladdercancer @SeagenGlobal
-
Astellas Pharma US reposted
Know AML 🔴⚫️
@KNOW_AML
@KNOW_AML is proud to be supported by the following organizations: AbbVie, Bristol Myers Squibb, Amgen, Astellas, Jazz Pharmaceuticals, and Novartis. Thank you!
#knowaml #amlworldawarenessday -
Astellas Pharma US
@AstellasUS
Astellas is working hard to meet the urgent needs of patients faced by hard-to-treat cancers like #aml. Our US President Mark Reisenauer shares his thoughts on #amlworldawarenessday. Read on to learn more.
-
Astellas Pharma US
@AstellasUS
On #amlworldawarenessday we hope to empower, provide increased awareness, and emphasize the essential need for communication between patients, caregivers, and their health care team. Click below for more information and resources on AML and the importance of AML genetic testing.
-
Astellas Pharma US
@AstellasUS
This #amlworldawarenessday we are joining the community by sharing knowledge and raising awareness of those battling hard-to-treat cancers, like AML. View more resources and information on how to Be R/Ready for AML and the journey ahead.
-
Astellas Pharma US
@AstellasUS
If you or a loved one is living with #bladdercancer, know that you are not alone. Visit Let’s Talk Bladder Cancer to hear from others in the community as they share information and answers to difficult questions. #letstalkbladdercancer @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
Let’s face it, it can be uncomfortable to talk about #bladdercancer. Follow along on our YouTube channel to hear from the community about their personal experiences with bladder cancer in hopes of making the journey a little easier for others. #letstalkbladdercancer @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
Patient-centered drug development is the way of the future. Our SVP & Global Head of Patient Centricity Anthony Yanni shares his thoughts with @STATnews on what the confirmation of Robert Califf as head of the U.S. Food and Drug Administration means for patients.
-
Astellas Pharma US
@AstellasUS
Only 20% of people with cancer respond to current immunotherapies. Our goal is to turn 20% into 100%.
Today @ConferenceForum #io360nyc, SVP of immuno-oncology, Peter Sandor, shared how our cancer cell therapy platform could deliver value for the patients still waiting. -
Astellas Pharma US
@AstellasUS
Thank you @npcnow for highlighting the many ways women leaders are making a difference. We’re proud to see our own Medical Specialties SVP Shontelle Dodson join her fellow NPC board members in sharing her thoughts on the value of strong role models. #womenshistorymonth
NPC
@npcnow
When we asked Shontelle Dodson, SVP, Medical Specialties at @AstellasUS & member of NPC’s Board of Directors, to reflect on the importance & impact of having women in leadership, here’s what she said. Proud to celebrate the #womenofnpc & #womeninbiopharma. #womenshistorymonth
-
Astellas Pharma US
@AstellasUS
Our Chief Medical Officer Bernie Zeiher shares his five key lessons for innovating at the frontiers of science.
Read the article in @statnews to learn more.
#changingtomorrow
#sciencefirstforpatients -
Astellas Pharma US
@AstellasUS
We are dedicating our collective strengths to find new ways to treat more cancers in more patients. Hear how we are transforming R&D in #immuno-oncology to redefine expectations of #cancer care and read on to learn more. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Our Head of Quality Assurance David Fryrear shares his views on why embedding a shared culture of quality establishes the foundation to enable tomorrow’s innovation. Read on to learn more. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Changing Tomorrow Day: 1.2K Astellas employees have volunteered in local communities over the past three months, donating nearly 6K hours to support our Employee Impact Group Charity Partners. #changingtomorrow
-
Astellas Pharma US
@AstellasUS
Today, we are excited to announce Phase 3 topline
long-term safety results from a trial investigating treatment for moderate to severe vasomotor symptoms associated with menopause (VMS), also known as #hotflashes. Click below to learn more. -
Astellas Pharma US
@AstellasUS
Our US President Mark Reisenauer writes in @statnews about our company’s perspective on the development journey of our medicines for prostate cancer, the Bayh-Dole Act, and how “inappropriate march-in actions would jeopardize public-private partnerships.”
-
Astellas Pharma US
@AstellasUS
Our Chief Medical Officer Bernie Zeiher shares his perspectives on the key trends shaping the future of R&D in an exclusive interview with @pharmaphorum. Read on to learn more.
-
Astellas Pharma US
@AstellasUS
At Astellas Research, we recognize the importance of Rare Disease Day and the movement towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease.
-
Astellas Pharma US
@AstellasUS
On Rare Disease Day, Astellas Oncology reinforces its efforts to research rare cancers and diseases to seek positive outcomes. We are committed to changing the course today and in the future. astellasoncology.com
#rarediseaseday #astellasoncology #changingthecourse -
Astellas Pharma US
@AstellasUS
Rare diseases aren’t as rare as you may think… In fact, ~5% of the world’s population is currently affected by rare diseases. On this #rarediseaseday, #showyourstripes and learn more about what living with a rare disease means and how you can help support this community.
-
Astellas Pharma US
@AstellasUS
During #blackhistorymonth, our Medical Director, Specialty, Medical Affairs US, Astellas Pharma US Deanna King discusses how #vasomotorsymptoms associated with menopause can impact Black women differently. Learn more. www.linkedin.com/pulse/menopause-different-women-color-de…
-
Astellas Pharma US
@AstellasUS
Alongside our partners at @SeagenGlobal, we recently previewed data from across our #bladdercancer program that will be presented at #gu22 this week. Learn more about our research in #urothelialcarcinoma and #mibc.
-
Astellas Pharma US
@AstellasUS
It’s a little-known fact that menopause is different for women of color. In honor of #blackhistorymonth, our Medical Director, Specialty, Medical Affairs US, Astellas Pharma US Deanna King sheds light on the critical need for #menopause education among these women. Learn more.
-
Astellas Pharma US
@AstellasUS
We’re looking forward to seeing the latest in #prostatecancer research at #gu22, including an update from Dr. @AArmstrongDuke in advanced disease.
-
Astellas Pharma US
@AstellasUS
Meeting with members of the WA State Legislature at #phrmaflyin22, a senior scientist at our research affiliate, Universal Cells, discussed how her passion for science and helping patients is leading efforts to advance cell therapies for diseases with few or no treatment options.
-
Astellas Pharma US
@AstellasUS
Our Chief Medical Officer Bernie Zeiher shares his thoughts on the cultural evolution uniting big pharma and biotech’s strengths for the benefit of patients. Read on to learn more. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Astellas Institute for Regenerative Medicine President Dr. Masahide (Hide) Goto recently spoke with @PharmExec about cell and gene therapy at Astellas and how partnerships will help drive the next wave of science and innovation in those therapeutic areas.
-
Astellas Pharma US
@AstellasUS
We are proud to announce with @SeagenGlobal that updates from our clinical trial for #mibc will be presented as late-breaking data at #gu22 this week. Learn more about these early findings for the #bladdercancer community.
-
Astellas Pharma US
@AstellasUS
Are we doing all we can to unlock the full potential of #realworldevidence for patients? Our Medical Affairs leaders Charlotte Kremer and Judith Nelissen share their thoughts with @INVIVOnow. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Today is World Cancer Day, and Astellas Oncology acknowledges and honors all those impacted by cancer: from current patients, survivors, to the larger community. We are committed to changing the course today and in the future. astellasoncology.com
-
Astellas Pharma US
@AstellasUS
February is #heartmonth and Astellas is proudly supporting @WomenHeartOrg HeartScarves initiative to raise awareness of women’s heart health.
-
Astellas Pharma US
@AstellasUS
Astellas is committed to creating and supporting a diverse workforce. We are proud to be recognized for the 8th year as one of the Best Places to Work For LGBTQ+ Equality in @HRC Foundation’s Corporate Equality Index. #cei2022
-
Astellas Pharma US
@AstellasUS
How can we embody patient-defined value in the truest sense? Our Chief Medical Officer Bernie Zeiher shares his perspectives with @PharmaBoardroom.
-
Astellas Pharma US
@AstellasUS
We are at @ASCO #gi22 and look forward to sharing our latest updates with the #gastriccancer community. Hear about our research to help advance potential new treatment options for those living with advanced gastric or gastroesophageal junction (GEJ) cancer.
-
Astellas Pharma US
@AstellasUS
Stomach cancer is a disease with a high unmet need, especially since diagnoses are often made once the cancer has advanced. The first step in catching #stomachcancer early is knowing the signs and symptoms. Learn more about the disease at #gi22.
-
Astellas Pharma US
@AstellasUS
On Martin Luther King Jr’s Day of Service, we are coming together to complete our #changingtomorrow Day activities. Employees are giving back to the community and supporting our Employee Impact Group Charity Partners. Together, we’re #committingforchange.
-
Astellas Pharma US
@AstellasUS
Recently, Hide Goto, Ph.D., president, Astellas Institute of Regenerative Medicine (AIRM) shared with @_CellandGene how Astellas is progressing its work in areas of stem cell therapy, allogeneic cell technology & CAR cell therapy, and benefits from active and open collaboration.
-
Astellas Pharma US
@AstellasUS
Astellas has announced recent leadership promotions within M&D, Human Resources and Commercial Insights to help drive forward our vision to provide innovative therapies for patients in areas of high unmet need.
-
Astellas Pharma US
@AstellasUS
Thank you #ash21! If you weren’t able to hear us present live, our accepted abstracts are all available online for viewing at any time. Learn more about our #oncology data today.
-
Astellas Pharma US
@AstellasUS
Hear from our SVP and Head of Patient Centricity, Anthony Yanni, on how Astellas is putting concepts and processes into action to realize our #patientcentricity vision.
-
Astellas Pharma US
@AstellasUS
Weatherwax Biotechnologies and Vcreate win our two Astellas Future Innovator Prizes, granting a year’s access to @MBiolabs incubator and our R&D mentors! We are proud to support these #entrepreneurs to advance their #innovations. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Astellas is committed to understanding the evolving refractory/relapsed FLT3m+ AML testing and treatment paradigm to bring better treatments to patients. Do you know what it means to have refractory AML? #ash21
Astellas Pharma US
@AstellasUS
Refractory AML: The disease does not improve after previous treatment(s).
-
Astellas Pharma US
@AstellasUS
Happening now at #ash21: we’re presenting data from our Phase 3 COMMODORE trial in adult patients in China with relapsed/refractory FLT3m+ AML.
-
Astellas Pharma US
@AstellasUS
Today at #ash21 we’re presenting analysis from real-world data that could help us better understand treatment patterns and patient perspectives. Visit our Astellas at ASH page to learn more.
-
Astellas Pharma US
@AstellasUS
Astellas will be presenting results from the Phase 3 LACEWING trial at #ash21 today. Learn more by visiting our Astellas at ASH page.
-
Astellas Pharma US
@AstellasUS
At Astellas we continue to pursue targeted therapies for hard-to-treat cancers where few therapies exist. #ash21 represents our largest showing to date with 11 AML abstracts.
-
Astellas Pharma US
@AstellasUS
Instilling a culture of quality is key to realize the full potential of tomorrow’s innovation. Our Head of Quality Assurance David Fryrear shares his thoughts with @ThePharmaLetter. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Kicking off #ash21 with insights from three of our leaders: Steve Sabus, Phil Tennant, and Ashan Arozullah, MD. Hear more about Astellas’ presences at this year’s meeting and the research we’ll be sharing.
-
Astellas Pharma US
@AstellasUS
Today is the first day of #ashp21 and we’re looking forward to hearing new insights and ideas and making new connections in the #pharmacy community.
-
Astellas Pharma US
@AstellasUS
Excited for @AstellasGeneTx and the new #research collaboration that will potentially enable faster delivery of transformative gene-based therapies for patients with genetic diseases who currently have few or no effective treatment options.
-
Astellas Pharma US
@AstellasUS
Attending #ash21? Join us in person at booth #2623 or check out our team’s insights, latest data, and more at our Astellas ASH page.
-
Astellas Pharma US
@AstellasUS
On #givingtuesday, we are proud to share that our employees are volunteering this year to support more than 10 charity partners selected by the Employee Impact Groups. Learn more about how we are giving back. #committingforchange
-
Astellas Pharma US
@AstellasUS
What kind of end-of-life support is available for #bladdercancer caregivers and family? @garywinz shares his insights. #letstargetthetoughstuff @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
We work with the advocacy community to ensure the medicines we develop reflect what truly matters to patients, families and care partners. Read what advocacy organizations have to say about working with us.
-
Astellas Pharma US
@AstellasUS
We’re on a mission to identify novel #biomarkers and increase testing in #stomachcancer, since knowing a tumor’s profile and family history of the disease can help inform the treatment journey. Prepare for #nationalfamilyhealthhistoryday – learn more. #stomachcancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
Check out our latest #letstargetthetoughstuff video series. @garywinz shares insights related to palliative and hospice care, along with the tough questions to ask and why they are so important. @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
We're proud to be named a 2021 @Seramount Top Company for Executive Women! We promote a culture of inclusion supporting colleagues to succeed via our comprehensive benefits suite, mentorship and career development of our future leaders. #seramounttopcompaniesforexecutivewomen
-
Astellas Pharma US
@AstellasUS
What’s next when #bladdercancer treatment stops working? @garywinz shares insights. #letstargetthetoughstuff @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
Each year, our colleagues proudly sport real and faux facial hair for #noshavenovember to start conversations about #prostatecancer and the importance of screening, early detection and more. See why #menshealthawareness is personal to Astellas employees like Liz. (1/4)
Post not available here, view on X
Astellas Pharma US
@AstellasUS
Colleagues like Tom, who has experienced the impact of #prostatecancer firsthand with his father, remind us of the significance of working toward improvements against this disease. #noshavenovember #menshealthawareness (3/4)
Astellas Pharma US
@AstellasUS
This month sheds light on the need for continued progress in the fight against #prostatecancer. While we’re proud of the strides made, all those impacted by this disease will continue to drive us forward to help change outcomes. #noshavenovember #menshealthawareness (4/4)
-
Astellas Pharma US
@AstellasUS
Meet the Patient Partnerships team. We listen to patients, families and care partners to understand what truly matters to you and change the way we develop medicines at Astellas. Visit the Patient Partnerships page to discover why we love working with the advocacy community.
-
Astellas Pharma US
@AstellasUS
In 2021, approximately 26,560 people will be newly diagnosed with #stomachcancer in the U.S. Do you know which of the below is a risk factor for the disease?
Astellas Pharma US
@AstellasUS
Ethnicity, gender and age are some of the risk factors for #stomachcancer, along with infection with a certain bacterium and some lifestyle factors. This #stomachcancerawarenessmonth, learn more about the factors that could contribute to a diagnosis: www.cancer.org/cancer/stomach-cancer/causes-risks-prevent…
-
Astellas Pharma US
@AstellasUS
See how we’re reshaping our business to put patients, care partners and families at the heart of what we do. We value patient input by inviting you to visit our new page to tell us your story.
-
Astellas Pharma US
@AstellasUS
Thymmune Therapeutics and M13 Therapeutics win our two Astellas Future Innovator Prizes, granting a year’s access to @LabCentral incubator and our R&D mentors! We are proud to support these #entrepreneurs to advance their #innovations. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
At the recent @Reuters Pharma & Patients USA conference, our SVP and Head of Patient Centricity Anthony Yanni shared keynote remarks on how to reshape company infrastructure to be patient-centric at the core and include patient perspective across the business. #patientcentricity
-
Astellas Pharma US
@AstellasUS
What is palliative care? @garywinz explains its benefits and what to expect for people living with #bladdercancer and their caregivers. #letstargetthetoughstuff @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
We're excited to launch our new patient resource with educational resources and information on our clinical trials around the world. Learn more about Astellas #clinicaltrials.
-
Astellas Pharma US
@AstellasUS
What are some of the tough questions to ask during #bladdercancer, and why are they so important? Hear from @garywinz in the latest #letstargetthetoughstuff series. @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
Entries close November 1 for the Astellas Future Innovator Prize! Apply now to accelerate your innovation in @MBiolabs #incubator and gain access to Astellas’ R&D scientists and business leaders. #biotechstartup #entrepreneur #labspace #research
-
Astellas Pharma US
@AstellasUS
Discover how we’re bringing more patient and care partner voices into our work to support their needs through our medicines, and beyond. Visit the Patient Partnerships website to learn more.
-
Astellas Pharma US
@AstellasUS
Our US President Mark Reisenauer shares his perspective on the importance of empowering individuals to challenge the stigma around #menopause and #hotflashes. Learn more.
-
Astellas Pharma US
@AstellasUS
At Astellas, we’re committed to supporting midlife health, including those impacted by vasomotor symptoms (VMS) associated with #menopause, otherwise known as hot flashes or hot flushes and night sweats. #wmd2021 #hotflashes #womenshealth
-
Astellas Pharma US
@AstellasUS
In recognition of #worldmenopauseday, learn more about the impact of vasomotor symptoms (VMS) associated with #menopause, otherwise known as hot flashes or hot flushes and night sweats. #wmd2021
-
Astellas Pharma US
@AstellasUS
Today is #worldmenopauseday. As a proud supporter of @IntlMenopause, we join them in raising awareness of menopause, and to share our commitment to helping elevate the diverse experiences and symptoms individuals face during this stage of life. #menopause #womenshealth #wmd2021
-
Astellas Pharma US
@AstellasUS
Astellas is partnering with @MBiolabs for its next Future Innovator Prize, offering entrepreneurial scientists and emerging biotechs access to lab space and Astellas’ R&D capabilities and business leaders. #incubator #lifesciences #innovation #science
-
Astellas Pharma US
@AstellasUS
We're proud to sponsor the @CureDuchenne FUTURES National Conference. We look forward to sharing updates on Astellas' programs to support patients with Duchenne Muscular Dystrophy.
-
Astellas Pharma US
@AstellasUS
Congress doesn’t have to choose between drug affordability, access & lifesaving medical innovations. Our US President Mark Reisenauer, along with leaders from @HorizonNews and @LundbeckUS, explain how in a recent @ChicagoTribune piece:
-
Astellas Pharma US
@AstellasUS
Thank you @MyASNC for a great virtual session! We’re proud to be part of a community that continues to put the #patientfirst. #asnc2021
-
Astellas Pharma US
@AstellasUS
Today marks the start of #asnc2021 and we’re proud to be playing our part for the #nuclearcardiology communities who put the #patientfirst. See you there!
-
Astellas Pharma US
@AstellasUS
While we know that racial disparities exist in #prostatecancer, there is still research needed to determine why. One thing is clear across races – getting screened and catching the disease earlier can help to lead to better outcomes. #prostatecancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
Will there be an influx of physicians into the #medicalaffairs profession following the pandemic? Our Head of Medical Affairs, Charlotte Kremer shares her views with @EMG_GOLD.
-
Astellas Pharma US
@AstellasUS
Our 2021 Working Dad of the Year, Urology Area Sales Director Stara Wilkins, shares how the inclusive culture at Astellas inspires his parenting style. Learn how Astellas supports working dads to be their best selves at work and at home. #seramountbestfordads
-
Astellas Pharma US
@AstellasUS
Meet our 2021 Working Mother of the Year Executive Director Carrie Schimizzi of @AstellasGeneTx who stepped into a leadership role to help ensure the safety of 200 essential workers during the pandemic. Hear how Astellas supports our working moms to excel. #seramount100best2021
-
Astellas Pharma US
@AstellasUS
We’re honored to be named seven years in a row a 100 Best Company for Working Mothers & Best Company for Dads for third year by @Seramount. Learn more about our workplace culture that supports all working parents to thrive. #seramount100best2021 #seramountbestfordads
-
Astellas Pharma US
@AstellasUS
As we wrap up #nams2021, we’d like to thank those who participated in this year's event for all your work to improve #menopause education and research.
-
Astellas Pharma US
@AstellasUS
New real-world data presented at #namsmtg sheds light on potential unmet needs of women with #vasomotorsymptoms associated with menopause – also known as #hotflashes. Learn more.
-
Astellas Pharma US
@AstellasUS
(6/6) In a U.K. study, women with #vasomotorsymptoms (VMS) associated with menopause experience an average of 17 hot flashes and 11 night sweats of any severity per week. #medthread
-
Astellas Pharma US
@AstellasUS
(5/6) #vasomotorsymptoms (VMS) can persist for a median duration of 7.4 years and are the most common menopausal symptoms for which people seek treatment. #medthread knowvms.com
-
Astellas Pharma US
@AstellasUS
(4/6) #vasomotorsymptoms (VMS) associated with menopause can impact daily life, including sleep, concentration, mood, energy, work, leisure/social activities, and sexual activity. #medthread
-
Astellas Pharma US
@AstellasUS
(3/6) While some experience no #vasomotorsymptoms (VMS) or only mild symptoms, about 34%-46% of postmenopausal individuals in the United States report moderate to severe VMS. #medthread
-
Astellas Pharma US
@AstellasUS
(2/6) #vasomotorsymptoms (VMS) have been reported in about 60% to 80% of women in the United States during or after the menopausal transition. #medthread knowvms.com
-
Astellas Pharma US
@AstellasUS
(1/6) To kick off #namsmtg, we want to highlight the burden of #vasomotorsymptoms (VMS), also known as hot flashes, which are a common symptom of menopause. #tweetorial #medthread knowvms.com
-
Astellas Pharma US
@AstellasUS
We are excited to be participating in #namsmtg and supporting efforts to advance research for #vasomotorsymptoms (VMS) associated with #menopause, also known as #hotflashes. Visit us at booth 215 to learn more about how VMS occur.
-
Astellas Pharma US
@AstellasUS
Today at #namsmtg we announced the presentation of Phase 3 efficacy results from our global trial investigating treatment for #vasomotorsymptoms (VMS) associated with #menopause – also known as #hotflashes. Learn more.
-
Astellas Pharma US
@AstellasUS
Astellas announces a new Future Innovator Prize, now with MBC BioLabs. Apply now to accelerate your biotech innovation in @MBiolabs state-of-the-art #incubator and gain access to Astellas’ R&D scientists and business leaders. #startup #lifescience
-
Astellas Pharma US
@AstellasUS
Every year, we look forward to supporting @ZEROCancer’s #prostatecancer Run/Walk events nationwide. This year, our colleagues traded their workwear for their best blue gear and teamed up virtually to support ZERO and the prostate #cancer community. #prostatecancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
We are excited to share Astellas leader Shontelle Dodson’s post about the impact of vasomotor symptoms (VMS), also known as #hotflashes, on well-being and her own experience with #menopause:
-
Astellas Pharma US
@AstellasUS
Our US President, Mark Reisenauer, joined other healthcare leaders for a roundtable discussion at @ResearchAmerica’s #raforum. Mark reflected on ways to improve patient affordability while preserving access and R&D. Watch the replay: www.youtube.com/watch?v=LbUV8WRI1Gg&list=PLQsqtXnJnFqWYml…
-
Astellas Pharma US
@AstellasUS
We’re committed to the ongoing investigation of our medicines, and we are proud to share overall survival results for our #prostatecancer therapy in men with advanced disease. #esmo21
-
Astellas Pharma US
@AstellasUS
Dr. Andrew Armstrong (@AArmstrongDuke), principal investigator in our advanced #prostatecancer trial, sheds light on the importance of the recently announced data. #esmo21
-
Astellas Pharma US
@AstellasUS
Announced today: New overall survival results for our #prostatecancer therapy in men with metastatic hormone-sensitive prostate cancer. Read more here in advance of the data presentation at #esmo21.
-
Astellas Pharma US
@AstellasUS
#aua21 may have gone virtual, but we’re committed to showcasing the way we are inspired by #prostatecancerawarenessmonth. Check out what we would have showed you onsite highlighting messages of inspiration from our colleagues and #prostatecancer patient partners.
-
Astellas Pharma US
@AstellasUS
September is #bloodcancerawarenessmonth and Astellas is committed to spreading the word about the importance of precision medicine and how genetic testing can inform treatment decisions.
-
Astellas Pharma US
@AstellasUS
Entries close Sept. 20 for the Astellas Future Innovator Prize! Apply now to accelerate your innovation in @LabCentral #incubator and gain access to Astellas’ R&D scientists and business leaders. #biotechstartup #entrepreneur
-
Astellas Pharma US
@AstellasUS
Update from #aua21: Dr. Neal Shore is presenting study results that explored different therapeutic approaches in localized #prostatecancer. Hear directly from him about his research.
-
Astellas Pharma US
@AstellasUS
See new research exploring different therapeutic approaches in localized #prostatecancer at #aua21.
-
Astellas Pharma US
@AstellasUS
We couldn’t be more excited for the kick-off of #aua21!
-
Astellas Pharma US
@AstellasUS
The COVID-19 pandemic has significantly impacted the rate people are being screened for cancer, including #prostatecancer. This #prostatecancerawarenessmonth, men and their physicians should consider having essential conversations about the importance of screening.
-
Astellas Pharma US
@AstellasUS
SVP Joe Fleishaker shares how Astellas’ expert Clinical Pharmacology and Exploratory Development team helps to maximize the value of our therapies for patients. Read on to learn more. #clinicalpharmacology #sciencefirstforpatients #2021accp
-
Astellas Pharma US
@AstellasUS
In the U.S., Black men are ~1.8x as likely to receive a #prostatecancer diagnosis as white men, due in part to factors like family history and screening trends. Find out more about screening and its essential role in early detection. #prostatecancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
Astellas Venture Management and @LabCentral are partnering to support innovative entrepreneurs to accelerate new directions in therapeutic research with the Astellas Future Innovator Prize competition. #incubator #biotechstartup #scientists
-
Astellas Pharma US
@AstellasUS
In a @STATnews First Opinion piece, our SVP and Head of Patient Centricity Anthony Yanni shares lessons learned from the COVID-19 pandemic as it relates to #patientcentricity. Read Anthony's contribution here.
-
Astellas Pharma US
@AstellasUS
The Astellas Future Innovator Prize competition is now open! Apply today to accelerate your biotech innovation in @LabCentral state-of-the-art #incubator and gain access to Astellas’ R&D scientists and business leaders. #biotechstartup #entrepreneur
-
Astellas Pharma US
@AstellasUS
Astellas and Minovia Therapeutics have announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.
-
Astellas Pharma US
@AstellasUS
We’re proud to announce that @PharmaVOICE recognized our SVP and Head of Global Patient Centricity, Anthony Yanni, today as one of the most inspiring people in the life-sciences industry on its 2021 PharmaVOICE 100 list. #pv100 #pharmavoice100
-
Astellas Pharma US
@AstellasUS
In a @MorningConsult opinion piece, our US President, Mark Reisenauer, shares three policy solutions that could help address the high out-of-pocket costs for medicines faced by too many patients.
-
Astellas Pharma US
@AstellasUS
“Quality and excellence are the foundation of our work in healthcare.” CMO Bernie Zeiher shares insights with @PharmExec on the importance of embracing a ‘quality by design’ mindset to meet the needs of patients. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Congratulations to our own Don Raineri, a 2021 @weworkforhealth employee champion. His efforts to strengthen our innovation and regulatory ecosystems help advance biopharmaceutical science for all patients.
-
Astellas Pharma US
@AstellasUS
SVP of Primary Focus Lead Immuno-oncology, Peter Sandor, shares his perspectives with @INVIVOnow on the value of design thinking to solving R&D challenges of the future. #sciencefirstforpatients #changingtomorrow
-
Astellas Pharma US
@AstellasUS
Tune in to hear leading #oncology experts discuss the patient journey navigating COVID-19 and beyond. This panel will focus on the patient #cancer care experience, how physicians navigate treatment, and best practice opportunities.
-
Astellas Pharma US
@AstellasUS
We are pleased to announce that the U.S. FDA approved our immunosuppressant for the prevention of organ rejection in adults and children receiving lung transplants, making it the first approved therapy in this indication. Read more:
-
Astellas Pharma US
@AstellasUS
Disability inclusion drives #innovation. We value all talent and are proud to have earned a top score on the #dei by @DisabilityIN and @AAPD as a #bestplacetowork! Learn more about how we strive to create an inclusive workplace where people with disabilities can thrive.
-
Astellas Pharma US
@AstellasUS
Chief Medical Officer Bernie Zeiher shares his thoughts on the key lessons the pandemic taught biopharma and what they may hold for the future. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Nearly half of metastatic bladder #cancer patients are unable to receive cisplatin chemotherapy treatment. Additional research and treatments are critical to win the fight against this disease.
-
Astellas Pharma US
@AstellasUS
Today, the U.S. FDA granted regular approval for our locally advanced or metastatic urothelial #cancer treatment and extended its indication to a broader group of patients. We are proud of this step toward progress for the bladder cancer community.
-
Astellas Pharma US
@AstellasUS
Tune in to this recent @ReachMD-hosted discussion for expert insights on the advanced #prostatecancer landscape from Dr. Maha Hussain and Dr. Christopher Evans.
ReachMD
@ReachMD
The advanced #prostatecancer clinical landscape is evolving. Stay up to date with a
recent expert panel. reachmd.com/programs/medical-industry-feature/the-evoluti… #oncology #onctwitter #medtwitter -
Astellas Pharma US
@AstellasUS
As our #patient Centricity Month closes, Corporate Advocacy VP of Sustainability Shingo Iino reflects on how we continue to ensure patients are at the center of all we do, including working closely with NGOs & nonprofits across the industry to ensure the best patient outcomes.
-
Astellas Pharma US
@AstellasUS
Learn about a positive opinion relating to the use of our investigational treatment in adult patients with symptomatic anemia associated with chronic kidney disease in the EU, issued by the #chmp of the @EMA_News following a review. #news for #media and #investors
-
Astellas Pharma US
@AstellasUS
Today our SVP and Global Head of Patient Centricity Anthony Yanni gave a keynote at the Fearless in Pharma conf. on Patient Focused Medicine Development and Delivery, the importance of engaging with patients and why the patient centricity movement is gaining traction right now.
-
Astellas Pharma US
@AstellasUS
A @ReachMD segment with advanced #prostatecancer experts Dr. Christopher Evans and Dr. Maha Hussain sheds light on the ever-evolving treatment landscape for this disease. Tune in here:
-
Astellas Pharma US
@AstellasUS
Our US President Mark Reisenauer discussed ways to build a better health care system – including addressing patient affordability challenges – in a recent interview with @PhRMA CEO Steve Ubl.
-
Astellas Pharma US
@AstellasUS
Astellas and Mitobridge, an Astellas Company, have dosed the first participant in their Phase 2/3 clinical trial for ASP0367, an oral investigational drug that may potentially improve exercise intolerance and fatigue in Primary Mitochondrial Myopathy (PMM) patients.
-
Astellas Pharma US
@AstellasUS
We appreciated the chance to meet with Members of Congress and staff as part of #phrmaflyin21. Our researchers described their efforts to convert science into value for patients and underscored the importance of policies that spur innovation and help ensure affordable access.
-
Astellas Pharma US
@AstellasUS
The goal of #patient Centricity Month is to reinforce our patients-first mindset. Charlotte Kremer, EVP and Head of Medical Affairs, explains why this is so important for Astellas and the patients we serve.
-
Astellas Pharma US
@AstellasUS
Thank you @SNM_MI for a great virtual meeting! We’re proud to be part of the #nuclearmedicine and #molecularimaging communities. #snmmi21
-
Astellas Pharma US
@AstellasUS
#menshealthmonth is a good time to have conversations around key health topics like advanced #prostatecancer. Learn more from 13-year survivor Phil on the importance of having these conversations and his advice for other men with this disease:
-
Astellas Pharma US
@AstellasUS
Today marks the start of #snmmi21 and we’re proud to be playing our part for the #nuclearmedicine and #molecularimaging communities. See you there!
-
Astellas Pharma US
@AstellasUS
Another great #asco is in the books! Thank you to the #oncology community – from our industry peers to advocacy groups and, of course, the patients and HCPs who make it all possible – for your commitment to advancing research to help improve lives. #asco21
-
Astellas Pharma US
@AstellasUS
We’re constantly looking for ways to improve outcomes for men with advanced #prostatecancer, including understanding treatment patterns in a real-world setting. Learn more about the latest findings being shared at #asco21:
-
Astellas Pharma US
@AstellasUS
Community #oncology settings often help support patients through the long-term commitment of cancer care. We took a closer look at the treatment patterns for men with advanced #prostatecancer who were treated in these settings – learn more:
-
Astellas Pharma US
@AstellasUS
In 2021, an estimated 26K new cases of #gastriccancer will be diagnosed, but research is needed to improve outcomes. We’re searching for options for those with advanced disease – in addition to what we’re sharing at #asco21, learn more in our recent publication:
-
Astellas Pharma US
@AstellasUS
Racial disparities have always been prevalent in #prostatecancer, so recent research has looked at how advanced therapies are being utilized across racial groups to better understand gaps. We’re proud to share research of our own on this at #asco21.
-
Astellas Pharma US
@AstellasUS
June is Global #patient Centricity Month at Astellas. President and CEO Kenji Yasukawa explains why we’ve dedicated a month to bringing new energy to our vision: to turn innovative science into better value for patients & commit to always listen and prioritize them in all we do.
-
Astellas Pharma US
@AstellasUS
Joining the conversation at #asco21? Get all of our team’s insights, our latest data, and more at our Astellas at ASCO page to stay up to date on our #oncology news:
-
Astellas Pharma US
@AstellasUS
We’re committed to investigating potential options for those whose lives are impacted by advanced #gastriccancer. Learn more about our latest research at #asco21:
-
Astellas Pharma US
@AstellasUS
At #asco21, we are sharing follow-up data from our Phase 3 study in patients with relapsed or refractory acute myeloid leukemia (#aml). Learn more here:
-
Astellas Pharma US
@AstellasUS
Astellas announced changes to commercial leadership to focus our efforts in support of our current and future products while ensuring our team members are prepared with the capabilities, training, and tools to efficiently deliver value to our patients.
-
Astellas Pharma US
@AstellasUS
We’re excited to kick off #asco21 with insights from two of our leaders: Steve Sabus and Andy Krivoshik. Hear what they have to say about our presence at this year’s meeting and the #oncology research we’ll be sharing.
-
Astellas Pharma US
@AstellasUS
A #bladdercancer diagnosis comes with many questions, but you’re not alone. Hear firsthand from Dorothy, a bladder cancer patient, and John, her husband and caregiver, as they discuss their cancer journey. Learn more: @BladderCancerUS @SeagenGlobal
-
Astellas Pharma US
@AstellasUS
#asco21 is only a few days away! Prepare for the meeting with a visit to our Astellas at ASCO landing page, a hub for our latest research, leadership perspectives and more.
-
Astellas Pharma US
@AstellasUS
Our Chief Business Officer Percival Barretto-Ko was named to the inaugural list of director candidates for the @goodwinlaw GOOD Directors initiative, designed to accelerate diversity in leadership.
-
Astellas Pharma US
@AstellasUS
In partnership with @BladderCancerUS and @SeagenGlobal, we are featuring #bladdercancer patient Dorothy and her husband John as they share real-life experiences and advice. Register for the event and join us on June 3.
-
Astellas Pharma US
@AstellasUS
As #bladdercancerawarenessmonth comes to a close, follow the Let’s Target the Tough Stuff Youtube channel and be part of the ongoing dialogue about #bladdercancer.
-
Astellas Pharma US
@AstellasUS
Why is amplifying the patient voice key to improving healthcare outcomes? Learn how patients and caregivers are shaping the future of care, here.
-
Astellas Pharma US
@AstellasUS
Cancer that spreads from one part of the body to another part is described as _____ (fill in the blank)
Astellas Pharma US
@AstellasUS
The correct answer is B. Cancer that has spread from one part of the body to another is considered “metastatic.” This can occur when #bladdercancer advances, for example.
-
Astellas Pharma US
@AstellasUS
Do you know how many people are living with #bladdercancer in the U.S. (as of 2018 estimates)? #bladdercancerawarenessmonth
Astellas Pharma US
@AstellasUS
The correct answer is C. According to the National Cancer Institute, an estimated 723,745 people were living with #bladdercancer in the U.S. as of 2018.
-
Astellas Pharma US
@AstellasUS
Test your knowledge for #bladdercancerawarenessmonth. Certain risk factors are associated with #bladdercancer. Do you know how the prevalence of this cancer compares in men and women?
Astellas Pharma US
@AstellasUS
The correct answer is C. #bladdercancer is more prevalent in men, but it’s important to know that recent statistics show an increasing number of women being diagnosed.
-
Astellas Pharma US
@AstellasUS
New data from two of our trials in advanced #bladdercancer are now available. Learn more about our commitment to continued research and innovation for this patient community. #asco21
-
Astellas Pharma US
@AstellasUS
Get a pre-meeting look at our #asco21 abstracts. Learn more about our latest research:
-
Astellas Pharma US
@AstellasUS
The @BladderCancerUS Walk to End Bladder Cancer is an initiative we look forward to every year. Thank you to everyone who participated in this inspiring event including our Astellas colleagues! #bladdercancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
We’re inspired by the latest data shared at #aacr21 and are pleased to share our recent data publication with the cancer community, highlighting patient-reported outcomes in advanced #gastriccancer. Read more here:
-
Astellas Pharma US
@AstellasUS
Our Chief Business Officer Percival Barretto-Ko is named to this year’s @EMpoweriB Ethnic Minority Role Model list for promoting a culture that values all voices.
-
Astellas Pharma US
@AstellasUS
#bladdercancer can be uncomfortable to talk about, but it’s important to ask the tough questions. Learn more from Bob, a bladder cancer survivor. #bladdercancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
Our Human Resources Executive Director Anne Allison was recognized as an @HBAnet Luminary at the 2020 Woman of the Year Awards. Congratulations, Anne!
#hbawoty21 -
Astellas Pharma US
@AstellasUS
The Astellas Medical Affairs U.S. team launched astellasanswers.com, a portal for patients and healthcare practitioners who have medical information questions about Astellas products any time, day or night. Find out more about this new patient resource.
-
Astellas Pharma US
@AstellasUS
ICYMI: patient-reported outcomes from our phase 2 trial in advanced #gastriccancer and #gastroesophageal junction (GEJ) cancer were recently published in the peer-reviewed journal Gastric Cancer.
-
Astellas Pharma US
@AstellasUS
We are proud to sponsor #acog2021 as part of our commitment to #womenshealth. We look forward to sharing updates on our research focused on addressing unmet needs of women living with #hotflashes from #menopause.
-
Astellas Pharma US
@AstellasUS
Historically, Black men have been disproportionally impacted by #prostatecancer, with higher rates of diagnosis compared to white men – however, organizations like @AmericanCancer and others are working to improve this. Learn more. #minorityhealthmonth
-
Astellas Pharma US
@AstellasUS
Experts Drs. Arnold Bullock and Lannis Hall recently sat down with radio stations across the US – including @HealthProRadio – to share important information about racial disparities in #prostatecancer and what Black men need to know. Tune in:
-
Astellas Pharma US
@AstellasUS
Astellas is proud to support @UMDF and the Mitochondrial Disease community.
United Mitochondrial Disease Foundation
@UMDF
Thank you @AstellasUS for your support of Mitochondrial Medicine 2021.
-
Astellas Pharma US
@AstellasUS
We are proud to announce that the U.S. FDA accepted two supplements to the Biologics License Application (sBLA) for our locally advanced or metastatic urothelial #cancer treatment. If approved, this could help address significant unmet medical needs.
-
Astellas Pharma US
@AstellasUS
Racial disparities continue to persist in #prostatecancer, but conversations around risk factors, testing and care may help. This #minorityhealthmonth, hear from Drs. Arnold Bullock and Lannis Hall about how Black men can advocate for their own health.
-
Astellas Pharma US
@AstellasUS
Head of Regulatory Affairs Stef Schutte shared his perspectives with @PharmaPhorum on the importance of open dialogue and collaboration in accelerating progress for patients. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Improved diversity in clinical trials is a key step toward achieving better health equity. That’s why we are proud of our commitment to @PhRMA’s diversity in clinical trial participation principles.
-
Astellas Pharma US
@AstellasUS
Chief Business Officer Percival Barretto-Ko talks with @LEADERSMag about his new role driving innovation at Astellas, our inclusive culture and how we are focused on #sciencefirstforpatients to create new medical solutions that bring value to patients with high unmet needs.
-
Astellas Pharma US
@AstellasUS
As our first Chief Business Officer, Percival Barretto-Ko shares with @LifeSciLeader1 how leading with clarity of purpose and willingness to adapt to find the best path forward is foundational in his new role to advance innovation and evolve Astellas to prepare for future needs.
-
Astellas Pharma US
@AstellasUS
We welcome Astellas Gene Therapies (@AudentesTx) as the newest center of excellence leading our organization in the field of gene therapy research to develop potentially life-changing medicines.
-
Astellas Pharma US
@AstellasUS
“Keeping track of talent and nurturing future leaders is absolutely critical,” Bernie Zeiher, our Chief Medical Officer, shared his perspective with @LifeSciLeader1 on what it takes to be CMO in global #pharma. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Astellas recently created a new policy to support helping our transgender employees to transition on the job. We are proud to celebrate transgender employees, relatives and friends on International Transgender Day of Visibility. #tdov2021
-
Astellas Pharma US
@AstellasUS
We are excited to announce that the U.S. FDA approved our treatment for children with neurogenic detrusor overactivity (NDO), a neurological bladder dysfunction caused by nerve damage. Learn more.
-
Astellas Pharma US
@AstellasUS
Congratulations to our Canadian colleagues on their recognition as a Great Place to Work for women.
-
Astellas Pharma US
@AstellasUS
Now introducing our 5th Anniversary #c3prize Grand Prize winner! Congratulations to Dr. Omolola Salako of @oncopadiapp and thank you for your inspiring work to change cancer care beyond medicine.
-
Astellas Pharma US
@AstellasUS
We are thrilled to partner with @IllinoisBiotech to provide STEM Kits to Chicago-area schools. The kits are designed to address educational gaps created by the COVID-19 pandemic and help students explore topics in science, technology, engineering and math.
iBIO
@IllinoisBiotech
Excited to announce the expansion of our STEM Kit program to students in Wheeling and Chicago Public Schools thanks to the support of #astellasus ibio.org/ibiostemkitastellas/ CC @iBIOSTEM @ccsd21holmes @ccsd21london @CCDS21 @ChiPubSchools @HurleySchool @newberrybobcats
-
Astellas Pharma US
@AstellasUS
Today is the #c3prize Virtual Pitch Event! Tune in at 11am CT to find out who will win the Grand Prize of $100,000 and other resources to help advance their ideas.
-
Astellas Pharma US
@AstellasUS
“There’s nothing stopping us moving with the same sense of urgency and patient-partnership in the post COVID-19 world,” shared Bernie Zeiher, our CMO, with @INVIVOnow. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Congratulations to our incoming U.S. President, Mark Reisenauer, on being named to the Board for @PhRMA. He brings his experience and leadership to help ensure policies work for scientists and patients.
-
Astellas Pharma US
@AstellasUS
Great ideas have the power to change lives for the better. Tune in on March 23 for the #c3prize pitch event as three finalists pitch their unique ideas to improve the lives of people impacted by cancer, beyond medicine.
-
Astellas Pharma US
@AstellasUS
Did you know there are different subtypes of acute myeloid leukemia (#aml) that are each caused by a unique mutation (or change) in the body’s genes?
-
Astellas Pharma US
@AstellasUS
Anthony Yanni, Global Head of #patientcentricity, and Marie Rosenfeld, VP, Head of Clinical Science joined @Reuter’s Events Pharma to discuss how our teams deliver solutions that put our patients, and their perspectives, first. #patientpartnerships
-
Astellas Pharma US
@AstellasUS
“The need to rapidly pivot resources to potential breakthrough programs is often easier said than done.” CMO Bernie Zeiher shares insights with @PharmExec on the need to foster an organization-wide mindset that embraces risk. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
We want every voice to be heard - each of us plays a role in creating an equitable and inclusive workplace and we are committed to our culture of equality. Happy International Women’s Day. #iwd2021 #choosetochallenge
-
Astellas Pharma US
@AstellasUS
Today is #rarediseaseday. The zebra, known for its stripes, is the official symbol of rare diseases in the U.S. Show your stripes today and celebrate with us! Visit #rarediseaseday website for how you can show your stripes. Thank you @RareDiseases for your continued commitment!
-
Astellas Pharma US
@AstellasUS
See how we put patients, care partners and families at the very heart of what we do.
-
Astellas Pharma US
@AstellasUS
#dyk more than 25 million Americans are impacted by rare diseases? Visit #rarediseaseday website for more information and how you can show your stripes to help raise awareness of rare diseases and the impact they have on families across the country.
-
Astellas Pharma US
@AstellasUS
As part of our commitment to advance innovation in areas where there are unmet medical needs, we are excited to announce Phase 3 topline results from two global trials investigating treatment for moderate to severe vasomotor symptoms (VMS), also known as hot flashes. Learn more.
-
Astellas Pharma US
@AstellasUS
Today, we joined @SeagenGlobal in submitting two supplements to the Biologics License Application (sBLA) for our locally advanced or metastatic urothelial #cancer treatment. We look forward to working with the U.S. FDA as it reviews our application.
-
Astellas Pharma US
@AstellasUS
We’re proud to be a part of an industry that supports businesses, researchers, economies, and – most importantly – patients across the country.
PhRMA
@PhRMA
The American biopharmaceutical industry supports over 811,000 jobs, 81,000 individual vendors and has sponsored more than 4,500 clinical trials across the United States — and still continues to grow. Learn more about this incredible economic impact at catalyst.phrma.org/beyond-output-and-employment-the-impac…
-
Astellas Pharma US
@AstellasUS
That’s a wrap on #gu21 – thank you to @ASCO and all those in the genitourinary cancer community who shared your research in this new virtual format. Astellas Oncology continues to be inspired by those who work every day to combat cancer and the patients who face it with bravery.
-
Astellas Pharma US
@AstellasUS
Test your #bladdercancer knowledge: which of the following is the most common risk factor for this disease? #gu21
Astellas Pharma US
@AstellasUS
The correct answer is C – tobacco use. Learn more about #bladdercancer and what we’re doing to help advance research for patients: newsroom.astellas.com/ASCO-GU-2021
-
Astellas Pharma US
@AstellasUS
New at #gu21: results from the second cohort of our metastatic #urothelialcancer study that measure tumor shrinkage in patients. Take a look at the details of the study presented by Dr. Arjun Balar of @nyulangone.
-
Astellas Pharma US
@AstellasUS
Good morning, #gu21! Today, Dr. Thomas Powles of @QMBCI is presenting results from the first and only Phase 3 trial in metastatic #urothelialcancer to demonstrate superior overall survival vs. chemo. Get all the details here:
-
Astellas Pharma US
@AstellasUS
Over the next three days at #gu21, we’re excited to see what’s new in #prostatecancer. In addition to learning more about the latest research in the field, we’ll be joining the conversation by sharing data about advanced prostate #cancer – learn more.
-
Astellas Pharma US
@AstellasUS
Today we celebrate all our inspiring female scientists, who work tirelessly to make a meaningful difference to patients worldwide. @WomenScienceDay #womeninscienceday #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Today kicks off the annual @ASCO Genitourinary Cancers Symposium (#gu21)! We’re looking forward to connecting with the GU community virtually, learning more about the advances in this space, and sharing the latest from our #prostatecancer and #bladdercancer research – learn more.
-
Astellas Pharma US
@AstellasUS
Our #patientcentricity division is mobilizing globally to deliver insights in several important areas to ensure continuity of care.
-
Astellas Pharma US
@AstellasUS
Mark Reisenauer, SVP of the Oncology Business Unit, spoke at Digital Pharma Series #dpiweek2020 on how pharma can drive better care for patients and the medical community through innovation challenges like the #c3prize. Aligning with organizational goals and values is key.
-
Astellas Pharma US
@AstellasUS
“If capabilities and skills are the engine, then a culture supporting innovation is the rocket fuel.” Bernie Zeiher, our CMO, shares insights with @PharmaExec on redefining R&D approaches to accelerate innovation for patients. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Last week, Global Head of Patient Centricity Anthony Yanni spoke to our journey to deliver patient-centric care. We are devoted to incorporating patient perspectives and ideas beyond medicine, as exemplified by our #c3prize initiative. #patientseu2021
-
Astellas Pharma US
@AstellasUS
This American Heart Month visit #mindyourheartfacts to learn about the causes and risk factors of coronary heart disease. Learn more this #heartmonth.
-
Astellas Pharma US
@AstellasUS
#prostatecancer is one of the most common types of cancer impacting men around the world. For #worldcancerday, test your knowledge – do you know how many men were estimated to be diagnosed with prostate cancer in the U.S. in 2020?
Astellas Pharma US
@AstellasUS
In 2020 alone, @AmericanCancer estimated that approximately 192K men in the U.S. would be newly diagnosed with prostate cancer. Of those, older men and Black men were diagnosed at a higher rate. #worldcancerday
-
Astellas Pharma US
@AstellasUS
On #worldcancerday, let’s unite and act to lessen the impact of cancer. This year’s #c3prize finalists have been touched by cancer and are now working to empower others. Read more about their ideas to change cancer care beyond medicine in @statnews.
-
Astellas Pharma US
@AstellasUS
Astellas promoted Yoshitsugu Shitaka, President, Astellas Institute for Regenerative Medicine (AIRM) to Chief Scientific Officer, responsible for growing our drug discovery research platforms. Drug Discovery & Research Executive Director Hide Goto was named new AIRM President.
-
Astellas Pharma US
@AstellasUS
Astellas announced promotion of US President Percival Barretto-Ko to Chief Business Officer, leading external and internal innovation and implementation of the company’s strategic plan. Senior VP of Oncology Mark Reisenauer will succeed Barretto-Ko to lead the US organization.
-
Astellas Pharma US
@AstellasUS
Every patient and advocate has a story to tell and we are listening. We hear you and are striving daily to understand how we can better meet patient needs.
-
Astellas Pharma US
@AstellasUS
Congratulations to @AugmentBionics and @ArticulateLabs for winning the Astellas Rx+® Healthcare Innovation Challenge! We are proud to support #entrepreneurs with such a bright future to advance their innovations! #sciencefirstforpatients www.astellas.com/jp/en/news/16391
-
Astellas Pharma US
@AstellasUS
Watch Astellas US President Percival Barretto-Ko share with @AJMC_Journal how the biopharmaceutical industry can address patient inequities to better serve historically underserved populations and cultivate a more diverse workforce and inclusive culture.
-
Astellas Pharma US
@AstellasUS
The ability for our employees to bring their authentic selves to their work is core to our culture. We celebrate diversity and openness and are honored, for the seventh consecutive year, to earn a perfect score on the @HRC’s Corporate Equality index. #cei2021 #diversity #lgbtq
-
Astellas Pharma US
@AstellasUS
We recognize our advocacy partners in these changing times, as we work to strengthen our entire organization’s approach to better understand patients’ hopes, values and expectations in the real world. Watch the video to find out more.
-
Astellas Pharma US
@AstellasUS
Honoring our African American Employee Impact Group members and employees who are celebrating Black Greek Fraternities and Sororities Founders days this month! Learn more about our culture of diversity and inclusion at Astellas below:
-
Astellas Pharma US
@AstellasUS
Astellas joins #accumulussynergy to help transform global data exchanges with health authorities. It will support the rollout of a cloud-based platform with the potential to reduce regulatory review time & bring new medicines faster to patients.
-
Astellas Pharma US
@AstellasUS
600 Astellas employees volunteered as part of our #mlkdayofservice. Our seven Employee Impact Groups planned and implemented in-person and virtual opportunities benefiting 15 charity partners to honor the life and legacy of Dr. King. Together, we’re #committingforchange.
-
Astellas Pharma US
@AstellasUS
Discussing the future of real-world evidence! Our senior director of HEOR Oncology, Arijit Ganguli, spoke with leaders in the field on the future of #rwe at a @Pharmaceutical Executive and @Parexel roundtable. #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Engaging patients as partners is critical to developing medicines to improve health. Our Head of #patientcentricity Strategy & Integration, Tyler Marciniak, shares how Astellas reflects the diversity of patients to create & deliver globally-inclusive innovations. #myastellasway
-
Astellas Pharma US
@AstellasUS
Our #patientcentricity Division is proud to convene the BSC Faculty, comprised of five multidisciplinary global experts collaborating to develop a deep understanding of the patient journey.
-
Astellas Pharma US
@AstellasUS
We have announced the 2020 #c3prize finalists. We’re so inspired by the innovative ideas each of these women have put forward, which have the potential to positively impact the lives of people living with cancer and their caregivers.
-
Astellas Pharma US
@AstellasUS
US President Percival Barretto-Ko and Engagement, Diversity and Inclusion Executive Director Eloiza Domingo recently shared with PharmaVOICE the company's focus and strategic importance in growing employee diversity and cultural inclusion at Astellas. Learn more below:
-
Astellas Pharma US
@AstellasUS
Having a conscious awareness of the patient in all activities ensures we make the greatest impact possible throughout the healthcare journey. Learn more about the work Deepti Jaggi is doing as Head of Patient Insights and Solutions. #patientcentricity #myastellasway
-
Astellas Pharma US
@AstellasUS
As a company dedicated to improving the health of people around the world, Astellas is conducting its business activities in harmony with the global environment to contribute to the development of a sustainable society. Learn more below.
-
Astellas Pharma US
@AstellasUS
Our Chief Medical Officer, Bernie Zeiher, spoke to @EMG_GOLD, sharing insights from his 30+ year career about diversity and making decisions with the patient in mind. #sciencefirstforpatients www.emjreviews.com/emj-gold/article/astellas-bernie-zeihe…
EMJ GOLD
@EMJ_GOLD
In this issue's catalyst interview, we speak to Bernie Zeiher, Chief Medical Officer, @AstellasUS, about patient-minded decision-making, the power of diverse teams, and the value of curiosity and continuous learning. www.emjreviews.com/post/developing-a-medicine-is-never-th…
#toldbygold #pharma #medicalofficer -
Astellas Pharma US
@AstellasUS
Our US President Percival Barretto-Ko recently joined @PhRMA CEO @steveubl to discuss our response to COVID-19 and ways we’re prioritizing diversity and inclusion throughout our organization. Click below to read the full discussion.
-
Astellas Pharma US
@AstellasUS
Keyhole Therapeutics and Jupiter Therapeutics win our Golden Tickets, granting a year’s access to @MBioLabs’ incubator and our R&D mentors! We are proud to support these #entrepreneurs to advance their #innovations! #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Thank you #ash20! If you weren’t able to hear us live, all our accepted abstracts are available online for viewing at any time. Learn about our #oncology data for acute myeloid leukemia (#aml) today.
-
Astellas Pharma US
@AstellasUS
We’re looking forward to announcing the 2020 #c3prize finalists! Sign up for more information about the three finalists and for more details on our virtual pitch event this spring.
-
Astellas Pharma US
@AstellasUS
“You realize, yeah, this is not what I wanted, but let’s make the best out of it.”
Tune in to our video series with @ZEROCancer and see how Phil has shifted his perspective to adjust to life with advanced #prostatecancer and what advice he has for other patients. -
Astellas Pharma US
@AstellasUS
Our Global Head of #patientcentricity, Dr. Anthony Yanni, spoke to the importance of integrating patient perspectives across the drug development continuum, revolutionizing patient care. Watch part of Dr. Yanni’s Reuters Pharma & Patient presentation below. #repharmapatient
-
Astellas Pharma US
@AstellasUS
Learn more about how Doug Noland’s work as Head of Patient Partnerships enables Astellas to connect scientific innovation with patient experience, and be responsive to the unique needs of patients and their caregivers. #patientcentricity #myastellasway
-
Astellas Pharma US
@AstellasUS
Happening now at #ash20: we’re presenting the clinical outcomes in patients with relapsed or refractory acute myeloid leukemia (#aml) who received prior FLT3-tyrosine kinase inhibitors. Visit our site to learn more.
-
Astellas Pharma US
@AstellasUS
Today at #ash20, we’re presenting data from a collaboration study with Abbvie looking at novel combination therapies and treatment approaches to acute myeloid leukemia (#aml). Visit our site to learn more.
-
Astellas Pharma US
@AstellasUS
Happening now at #ash20: we’re presenting our Phase 3 data in newly diagnosed patients with acute myeloid leukemia (#aml) who are FLT3 mutation positive. Visit our site to learn more.
-
Astellas Pharma US
@AstellasUS
This morning at #ash20, we’ll be presenting data from our Phase 1 combination study with induction and consolidation chemotherapy in newly diagnosed patients with acute myeloid leukemia (#aml). Visit our site to learn more.
-
Astellas Pharma US
@AstellasUS
Today through Monday, we’ll be presenting our #ash20 e-poster on the secondary analysis of pivotal ADMIRAL trial comparing various clinical outcomes in FLT3-mutated acute myeloid leukemia (#aml). Visit our site to learn more.
-
Astellas Pharma US
@AstellasUS
Hello #ash20! We’re prepped and ready to share key data about our work in #oncology for the acute myeloid leukemia (#aml) community. Visit our site to learn about our eight accepted abstracts.
-
Astellas Pharma US
@AstellasUS
We're dedicated to helping those affected by #aml Be R/Ready for the road ahead. Browse our collection of helpful resources for patients, caregivers and HCPs.
-
Astellas Pharma US
@AstellasUS
On #givingtuesday, we’re excited to share our employees have volunteered 11,500 hours in 2020 to support local non-profit orgs since we kicked off our #committingforchange campaign one year ago. Learn more about how we are giving back.
-
Astellas Pharma US
@AstellasUS
From people who have lived with cancer to caregivers, many #c3prize winners have lived through the challenges of cancer, fueling their passion to ease the journey for others. We look forward to announcing the 2020 C3Prize finalists next month.
-
Astellas Pharma US
@AstellasUS
For those living with #stomachcancer, the disease affects more than just them alone – families, friends and caregivers also feel the impact of this disease and adjust to the “new normal” of life with cancer. #stomachcancerawarenessmonth #nationalcaregiversmonth
-
Astellas Pharma US
@AstellasUS
With #ash20 just around the corner, hear from our leaders about why our fight to improve the lives of those impacted by hard-to-treat cancers like acute myeloid leukemia (#aml) remains critically important.
-
Astellas Pharma US
@AstellasUS
During National Family Caregiver Month we were thrilled to be recognized by @Caregiving and nominated for a Visionary Award recognizing our support for caregiver employees. Learn about our benefits for caregivers. #caregivers
-
Astellas Pharma US
@AstellasUS
Lisa Mattle's personal experience as a caregiver drives her passion in her role as Senior Director, Behavioral Science Consortium. Hear how she and the #patientcentricity team are committed to applying real-world experiences to improve care. #myastellasway
-
Astellas Pharma US
@AstellasUS
Currently, there are limited treatment options for #stomachcancer. While surgery may help to eliminate the disease in some cases, it also comes with its own challenges. #stomachcancerawarenessmonth
-
Astellas Pharma US
@AstellasUS
For those living with advanced #prostatecancer, caregivers often play a significant role. This #nationalcaregiversmonth, hear more from Phil, a 13-year prostate cancer survivor, on the importance of caregivers and the ways we can support them.
-
Astellas Pharma US
@AstellasUS
Our Astellas US President Percival Barretto-Ko recently spoke with @AuthorityMgzine about his perspective on driving culture forward with purpose-driven leadership.
-
Astellas Pharma US
@AstellasUS
The 2019 #c3prize winners were all entrepreneurial women who wanted to #changecancercare. Innovation Prize winner @daniellakoren founded @ArchesTech to provide relevant information and evidence-based education to people impacted by cancer. #womenentrepreneurshipday
-
Astellas Pharma US
@AstellasUS
We commend @PhRMA for its leadership in fostering an industry-wide commitment to further enhance #diversity in clinical trial participation and help reduce health disparities. #clinicaltrials
PhRMA
@PhRMA
Systemic racism is as real as any disease. Learn about the biopharmaceutical industry’s commitment to driving real change and better health outcomes for patients through diversity in clinical trials. Learn more at phrma.org/equity
-
Astellas Pharma US
@AstellasUS
Early stage #stomachcancer rarely causes symptoms. That’s why this disease is often difficult to detect and treat early, before it spreads to other parts of the body. This #stomachcancerawarenessmonth, learn what signs to look for. @NoStomach4Cancr
-
Astellas Pharma US
@AstellasUS
Be R/Ready and learn about the importance of genetic testing for FLT3 mutations for relapsed acute myeloid leukemia (#aml). Resources available for patients, caregivers and HCPs.
-
Astellas Pharma US
@AstellasUS
According to @AmericanCancer, an estimated 27K+ new cases of #stomachcancer will be diagnosed this year. This #stomachcancerawarenessmonth and year-round, join the conversation to help shed light on this disease that impacts so many. @NoStomach4Cancr
-
Astellas Pharma US
@AstellasUS
Joe Collins is dedicated to improving the patient experience by always keeping the patient at the center of his work as Head of Medical Intelligence and Patient Insights. Learn more about the importance of understanding the patient in the real-world setting. #patientcentricity
-
Astellas Pharma US
@AstellasUS
On #veteransday, we hosted wounded warrior and paralympian @MStockwell01. Our Military EIG co-chair Jason Morhart shared how her story demonstrates the importance of service and praised Astellas' active support of military personnel and veterans.
-
Astellas Pharma US
@AstellasUS
#bladderhealthmonth is a great time to learn about the bladder and understand if you might be coping with #overactivebladder.
-
Astellas Pharma US
@AstellasUS
Our President Percival Barretto-Ko shares his perspective on the dynamics of running a pharmaceutical company in the COVID-19 environment with @previsionpolicy & @CancerResrch’s Biopharma Congress.
-
Astellas Pharma US
@AstellasUS
Caregivers play an important role in the lives of men with advanced #prostatecancer. Check out these resources from @PCFNews to help you best care for your loved one and yourself. #nationalcaregiversmonth
-
Astellas Pharma US
@AstellasUS
We’re turning innovative science into value for #patients. From bench to clinic to patients, we’re empowering talent in state-of-the-art facilities to focus on groundbreaking #science. Find out more here: www.astellas.com/en/science/innovation-hub. #sciencefirstforpatients #worldscienceday
-
Astellas Pharma US
@AstellasUS
Year-round, our colleagues dedicate themselves to making an impact in the lives of those affected by #prostatecancer. This #movember, find out why they are so committed to this mission.
-
Astellas Pharma US
@AstellasUS
We’re excited to share eight abstracts outlining the breadth of our work in acute myeloid leukemia (#aml) will be presented at #ash20. Learn more about our data and how we’re turning innovative science into treatments for patients with hard-to-treat cancers.
-
Astellas Pharma US
@AstellasUS
Congratulations to all the nominees & winners recognized at the @GalienFdn #prixgalien USA awards ceremony! We are honored the foundation recognized our work in acute myeloid leukemia as innovative and supportive of patients around the world.
-
Astellas Pharma US
@AstellasUS
Our Chief Medical Officer Bernie Zeiher shares with @IAmBiotech how we are obtaining direct patient input to help inform our clinical programs. www.youtube.com/watch?v=SNFjgiyqQ00 #biosummit20
-
Astellas Pharma US
@AstellasUS
We are pleased to announce that the U.S. FDA has granted Fast-Track Designation to our investigational imaging agent for ureter visualization. See our press release here.
-
Astellas Pharma US
@AstellasUS
We’re proud to support @IllinoisBiotech’s efforts to inspire the next generation of innovators. Thanks to this grant from @DeptofDefense, STEMKAMP will develop meaningful educational experiences for children of military families across the U.S.
iBIO
@IllinoisBiotech
iBIO EDUCATE and Goshen Education Consulting Receive Significant Grant from the U.S. Dept. of Defense news.ibio.org?read=https%3A%2F%2Fibio.org%2Fibio-educate-…
-
Astellas Pharma US
@AstellasUS
Proud to join the @GalienFdn #prixgalien USA Golden Jubilee awards ceremony this Thursday as a 2020 finalist for the Best Pharmaceutical Agent award for our acute myeloid leukemia therapy. Good luck to our fellow nominees.
-
Astellas Pharma US
@AstellasUS
The new Astellas Institute for Regenerative Medicine (AIRM) in Westborough, MA, a 262-sq-ft R&D and mfg site, houses 180+ employees working to develop new cell-based therapies. Follow us here for future highlights and our progress. #stemcells #regenerativemed
-
Astellas Pharma US
@AstellasUS
We are proud to support our fourth annual Ally Week, where employees will learn more about and understand how to support the LGBTQ+ community. We will welcome representatives from @OutandEqual to teach employees about “Intersectional Allyship” during Ally Week.
-
Astellas Pharma US
@AstellasUS
For #makeadifferenceday we’d like to spotlight Hernâni Oliveira, 2017 winner of the #c3prize for The HOPE Project and founder of BRIGHT Digital, whose work focuses on the humanization of health.
-
Astellas Pharma US
@AstellasUS
This month, 1,400 Astellas employees virtually volunteered together, giving a combined 6k hours to support our communities on our annual day of service in #committingforchange. www.astellas.com/en
-
Astellas Pharma US
@AstellasUS
We look forward to participating in the first virtual #idweek2020 and joining top #infectiousdisease experts at the conference. Visit our virtual booth to learn more about our #invasivefungalinfections work.
-
Astellas Pharma US
@AstellasUS
Entries close soon! Apply now to accelerate your innovation in @MBioLabs’ state-of-the-art #incubator and gain access to Astellas’ R&D scientists and business leaders – applications close October 27. www.astellas.com/en #biotech #startup #entrepreneur #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
Rising prostate-specific antigen (PSA) levels in patients with advanced #prostatecancer can indicate that it’s time to evaluate next steps in the treatment journey. It’s important to educate your patients about PSA tests and imaging.
-
Astellas Pharma US
@AstellasUS
Did you Raise Your Menopause IQ to honor #worldmenopauseday? Take the final challenge and don't forget to share the video to encourage others to do the same!
-
Astellas Pharma US
@AstellasUS
It's #worldmenopauseday! Raise Your Menopause IQ today and share the video to encourage others to increase their menopause knowledge.
-
Astellas Pharma US
@AstellasUS
Take a moment to Raise Your Menopause IQ ahead of #worldmenopauseday on Sunday and share the video to bring attention to this important topic in women's health. #raiseyourmiq
-
Astellas Pharma US
@AstellasUS
Charlotte Kremer, EVP, Head of Medical Affairs at Astellas, shares her vision for the future of the Medical Affairs function with @MAPSmedaffairs. Read the full article below medicalaffairs.org/charlotte-kremer-strategic-rise-medica…. #changingtomorrow #sciencefirstforpatients
MAPS
@MAPSmedaffairs
This important op-ed from Charlotte Kremer, MD, MBA, EVP and Head of #medicalaffairs with @AstellasUS lays out the future of the function: medicalaffairs.org/charlotte-kremer-strategic-rise-medica…
-
Astellas Pharma US
@AstellasUS
Join Astellas and Raise Your Menopause IQ in honor of #worldmenopauseday, taking place Sunday. Test your knowledge with this question.
-
Astellas Pharma US
@AstellasUS
On #worldfoodday, we thank our employees who have helped local food banks and other non-profits with hunger programs, donating 20,000+ items, including food and school supplies, through Astellas virtual drives in 2020. #committingforchange Learn more: newsroom.astellas.com/404
-
Astellas Pharma US
@AstellasUS
David Fryrear, our Head of Clinical and Research Quality Assurance, shares his thoughts on the importance of risk management approaches in transforming #clinical development and delivering value to patients. #changingtomorrow #sciencefirstforpatients
-
Astellas Pharma US
@AstellasUS
On Sunday, #worldmenopauseday, Astellas invites you to Raise Your Menopause IQ and learn more about how this stage of life impacts women. Ready to test your knowledge? P.S. Don't forget to share the videos to help address this knowledge gap in #womenshealth. #raiseyourmiq
-
Astellas Pharma US
@AstellasUS
Sunday is #worldmenopauseday, an @IntlMenopause society initiative to raise awareness of midlife #womenshealth. The burden of VMS associated with #menopause is under-recognized. Astellas is proud to help bring attention to the change in every woman's life.
-
Astellas Pharma US
@AstellasUS
Thank you to all who applied for the 2020 #c3prize. We are grateful to have the opportunity to help advance the most innovative ideas in cancer care beyond medicine. Stay tuned for our finalist announcement!
-
Astellas Pharma US
@AstellasUS
US President Percival Barretto-Ko speaks to @PharmExec about the intersection of innovation and patient needs to deliver the most value to patients as Astellas’ true North Star.
-
Astellas Pharma US
@AstellasUS
Applications close soon for the Astellas Rx+® Healthcare Innovation Challenge!
Don’t miss out on a chance to win proof of concepts and create a healthier world with Astellas. Go to: www.agorize.com/en/challenges/astellas-rxplus
#changingtomorrow #sciencefirstforpatients -
Astellas Pharma US
@AstellasUS
Announcing, with partner @SeagenGlobal, positive results from cohort 2 of our Phase 2 trial in previously treated locally advanced or metastatic urothelial cancer patients who have not received a platinum-containing chemotherapy and are ineligible for cisplatin. #bladdercancer
-
Astellas Pharma US
@AstellasUS
Thank you @IAmBiotech for hosting last week’s virtual fly-in. Our EVP and General Counsel Catherine Levitt had the opportunity to meet virtually with legislators & staff to share our efforts to create a diverse and inclusive workplace that helps enable success for all employees.
-
Astellas Pharma US
@AstellasUS
Today on @TheDoctors our partner @BillRancic and 2019 #c3prize winner @nannyangels will discuss the program and the importance of innovations in cancer care beyond medicine. Find out when #thedoctors airs for you below.
-
Astellas Pharma US
@AstellasUS
Cancer care is complex – and even more so during a pandemic. #c3prize judge and CEO of @Hopelab Margaret Laws discusses with @BillRancic how she hopes this year’s applicants will fuel new ideas that address health disparities. Watch their full interview on @statnews.
-
Astellas Pharma US
@AstellasUS
2019 #c3prize Grand Prize winner Audrey Guth created @nannyangels to provide peace of mind, stability and normalcy for families with cancer. Watch her interview with @BillRancic to learn more about her story and apply for this year’s Prize at c3prize.com.
-
Astellas Pharma US
@AstellasUS
Do you have an idea that could change cancer care? The #c3prize will award up to $200K in total funds for the best non-treatment ideas. Apply today and make a difference: www.astellas.com/us/about/product/c3prize
-
Astellas Pharma US
@AstellasUS
If you have an idea that can make a difference in #cancer care and improve the lives of those impacted by cancer – #c3prize is still accepting applications. Learn more: www.astellas.com/us
-
Astellas Pharma US
@AstellasUS
.@GiulianaRancic & @BillRancic are looking for your great ideas for the #c3prize. Reply & tag someone who has an idea to improve cancer care for patients & their loved ones.
-
Astellas Pharma US
@AstellasUS
We’re now accepting entries for the C3 Prize, which funds the best ideas in cancer care beyond medicine. Our 2019 categories: Cancer Care Journey, Cancer Health Disparities & Cancer Survivorship. Have an idea…or know someone who does? #c3prize www.c3prize.com
-
Astellas Pharma US
@AstellasUS
Yesterday, Mark Reisenauer joined @BillRancic and @joshkampel at #sxsw to discuss challenges in #cancercare and how one big idea can be a catalyst for change. Watch the discussion here, starting at 36:09: www.facebook.com/W2OGroup/videos/798992237130154/.
-
Astellas Pharma US
@AstellasUS
We're hosting a Facebook Live Chat with @BillRancic & our #c3prize Category Winners next week! Tune in at 6:30pm CDT on October 3 to ask questions & hear from our winners: www.facebook.com/events/239906686873401/











































































































































































































































